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ABSTRACT 
 
 
 
Skeletal muscle is a highly adaptive tissue that alters its size and function in response 
to different environmental and physiological challenges such as exercise, neural 
stimulation, growth factors, nutrition, disease and aging. Skeletal muscle growth 
involves the intricate transcriptional regulation by several molecular signalling 
pathways, however our understanding of these molecular processes is neither 
definitive nor complete. Improving our knowledge of how skeletal muscle responds 
to different environmental and physiological challenges may help identify novel 
therapeutic strategies and targets to sustain muscle mass and function during ageing 
and disease.  The striated muscle activator of Rho signalling (STARS) protein is a 
muscle specific actin binding protein that associates with the sarcomere. STARS is 
highly responsive to stress conditions and has the ability to stimulate the SRF 
transcriptional pathway which is known to regulate muscle growth and function. 
Recently the importance of STARS in cardiac muscle development and remodelling 
has emerged. However, very little is known about its role and regulation in skeletal 
muscle and was therefore the focus of this thesis.  
 
Identifying the molecular targets and intracellular signals activated by endurance 
exercise will significantly enhance our understanding of how skeletal muscle adapts 
to increased contractile load and may identify potential therapeutic targets to combat 
diseases characterized by perturbed skeletal muscle metabolism, growth and 
regeneration. The aims of the first study were to establish if STARS, as well as 
members of its downstream signalling pathway, are upregulated following acute 
endurance cycling exercise; and secondly, to determine if STARS is a target of the 
PGC-1α/ ERRα transcriptional complex. The first study showed for the first time that 
an acute bout of single-leg endurance exercise is sufficient to induce an increase in 
STARS mRNA and protein levels.  This response was paralleled by an increase in 
the nuclear protein content of several key members of the STARS signalling 
pathway, MRTF-A and SRF.  In C2C12 myotubes the STARS gene was a target of 
the PGC-1α/ERRα transcriptional complex and it was demonstrated that the presence 
of STARS is required for the PGC-1α regulation of the CPT-1β gene. These findings 
  ii 
demonstrate that STARS expression is upregulated in response to endurance exercise 
and may be involved the regulation of oxidative metabolism. 
 
Skeletal muscle regeneration is dependent on the activation of satellite cells, the 
subsequent proliferation of myoblasts, followed by their myogenic differentiation 
and fusion with existing muscle fibres.  The second study investigated the role of the 
STARS protein in the proliferation and differentiation of C2C12 muscle cells. 
Several novel observations were made. Firstly, STARS overexpression increased 
myoblast proliferation. This was associated with increases in SRF target genes Il-6, 
c-fos, and Junb and decreases in cell cycle regulators Cyclin d1, p21 and p27 mRNA 
levels. Secondly, overexpressing STARS at the onset of myoblast differentiation 
enhanced differentiation, with a paralleled increase in mRNA expression of the 
differentiation markers Ckm and MHC isoforms.  Finally, STARS overexpression 
increased the mRNA levels of several SRF target genes including α-actin and Mhc2b 
and PGC-1α/ERRα target genes including Mhc2a, Cpt-1β and Ckmt2 during 
myogenic differentiation.  These results suggest that STARS maybe a novel 
therapeutic target to enhance skeletal muscle repair and regeneration following 
damage via its activation of muscle cell proliferation and differentiation. 
 
Skeletal muscle growth is a process tightly controlled by signalling pathways 
regulating protein synthesis and protein degradation.  The primary aim of the third 
study was to determine whether STARS directly influences muscle cell growth by 
regulating C2C12 myotube protein synthesis, degradation and AKT phosphorylation.  
STARS overexpression increased actin polymerization, however this did not affect 
protein synthesis, degradation or AKT phosphorylation.  STARS overexpression 
increased PGC-1α and SRF mRNA levels and shifted the muscle cell to a more 
oxidative phenotype as demonstrated by an increase in Ckmt2 and Cpt-1β and the 
slow myosin isoform, Mhc1.  STARS knockdown decreased actin polymerization 
and increased cell death, dead cell protease activity, markers of inflammation, 
including caspase-1, IL-1β and Mcp-1, as well as markers of regeneration such as 
SOCS3 and the embryonic myosin, Myh8. A reduction in the expression of STARS 
also moved the myotubes towards a faster contractile phenotype as indicated by a 
reduction in Mhc1 and increased Mhc2a and Mhc2x. These observations suggest that 
STARS is required for skeletal muscle cell survival and under basal conditions 
  iii 
influences the regulation of genes involved in muscle oxidative metabolism. 
 
The findings of this thesis expand the present knowledge about the regulation of 
STARS expression in skeletal muscle and its potential role in muscle growth and 
function.  STARS is a protein that associates with the sarcomere and its up regulation 
in response to exercise may potentially increase muscle cell sensitivity to muscle 
contraction and enhance activation of intracellular signalling pathways involved 
skeletal muscle growth and regeneration.  For these reasons STARS maybe a future 
therapeutic target for enhancing muscle growth and regeneration for the treatment of 
muscle loss with age and disease. 
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CHAPTER 1 
 
LITERATURE REVIEW 
 
 
A component of this literature review has been accepted for publication in The Frontiers in Striated 
Muscle Physiology as a mini review; Marita A. Wallace, Séverine Lamon, Aaron P. Russell. The 
regulation and function of the striated muscle activator of rho signalling (STARS) protein.  12 
December 2012 doi: 10.3389/fphys.2012.00469. 
 
1.1 Introduction 
Skeletal muscle is the most abundant tissue in the human body comprising about 
40% of total body mass [1]. The primary functions of skeletal muscle include the 
control of body movement, the maintenance posture, as well as playing an important 
role in whole body metabolism [1]. Skeletal muscle is a highly adaptive tissue that 
can alter its size and biochemical makeup in response to many factors [2]. Skeletal 
muscle size and function is tightly regulated by the regenerative capacity of the 
muscle as well as by the balance between the processes controlling muscle protein 
synthesis and protein degradation. Skeletal muscle growth (hypertrophy) is positively 
influenced by increased muscle loading (exercise) and changes in nutrition and 
hormone levels. On the other hand, muscle loss or wasting (atrophy) is observed in 
disease states, disuse and aging [3, 4]. 
 
Muscle atrophy is a strong predictor of morbidity and mortality in cardiovascular, 
musculoskeletal, nervous, renal and respiratory diseases and cancers [3, 5-7]. These 
are some of the top 10 causes of Australian deaths at a cost to our health care system 
of over $20 billion per year [8].  Age related muscle loss (sarcopenia) reduces 
functional independence and quality of life as well as increases the risk of falls and 
fractures [9].  Falls and fractures are a major source of morbidity and mortality in the 
increasing population of the elderly and fall-related acute care for the elderly was 
estimated to be $566 million in Australia in 2003-04 [9, 10].  The maintenance of 
skeletal muscle mass is essential for improving the quality and longevity of life as 
well as reducing the risk of diseases such as cardiovascular disease, diabetes and 
obesity.  Understanding the molecular signalling pathways controlling skeletal 
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muscle growth is essential to the development of therapeutic treatments for the 
treatment of muscle loss and maintenance of muscle mass with age. This will 
significantly enhance the quality of life in our ageing society and reduce the 
economic burden on our health care system. One key protein that may be involved in 
regulating skeletal muscle growth is the striated muscle activator of Rho signalling 
(STARS) protein.  Its role in cardiac muscle is becoming apparent, however our 
knowledge of how this protein may positively influence skeletal muscle growth 
remains limited and is therefore the focus of this thesis. 
 
1.2 Skeletal muscle structure, function and composition 
Skeletal muscle is comprised of bundles of muscle fibres (fascicles), nerves and 
blood vessels, which are enclosed in a connective tissue sheath called the epimysium.  
Each fascicle is surrounded by another connective sheath called the perimysium, 
whist each muscle fibre within the fascicle is tightly packed and separated from other 
fibres by the endomyosium. Muscle fibres are long cylindrical and multinucleated 
cells that lie parallel to each other. The nuclei of muscle fibres are located against the 
inside of the plasma membrane called the sarcolemma. Centrally located within the 
muscle fibres are the myofibrils, which are long contractile protein bundles 
containing myofilaments.  The myofibrils are surrounded by the sarcoplasm, which 
contains important organelles such as the mitochondria (oxidative metabolism), 
sarcoplasmic reticulum (calcium storage for muscle contraction) and the transverse 
tubules (pathway for action potentials). 
 
Myofibrils contain the apparatus that contracts the muscle cell and consists 
predominantly of two types of myofilaments; a thick filament composed of the 
protein myosin and a thin filament composed mainly of the protein actin (Figure 1.1). 
Myosin and actin filaments are organised longitudinally in the smallest contractile 
unit of skeletal muscle, the sarcomere.  It is this alignment that gives skeletal muscle 
its striated muscle appearance.  In addition to actin and myosin, myofibrils also 
contain two other important proteins, troponin and tropomyosin.  These proteins 
associate with actin and are necessary for muscle contraction to occur.  Myosin 
filaments are located primarily within the dark portion of the sarcomere called the A-
band, while the actin filaments occur in the light regions of the sarcomere called the 
I-band.  The H-zone is the region in the centre of the sarcomere where myosin 
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filaments do not overlap with actin and the Z-disk is the thin sheet of structural 
proteins that separates the sarcomeres from each other. 
 
 
Figure 1.1 Skeletal muscle myofibrils. The sarcomere is the contractile unit of muscle and contains 
the thick myosin filaments (red) and thin actin filaments (blue). 
 
 
Skeletal muscle structure is closely linked to its function.  The primary function of 
skeletal muscle is force production for locomotion via muscle contraction.  The 
sliding filament theory best describes the process of muscle contraction.  During 
muscle contraction the actin filaments at each end of the sarcomere slide inward on 
the myosin filaments, pulling the Z-disk toward the centre of the sarcomere and thus 
shortening the fibre.  Muscle contraction is an energy dependent process that requires 
adenosine triphosphate (ATP), and sources within that muscle fibre regenerate ATP 
are creatine phosphate, glycolysis and oxidative phosphorylation.  Muscle 
contraction therefore gives rise to other important functions of skeletal muscle such 
as metabolism and thermoregulation as it requires the breakdown of carbohydrates 
and fats and the production of heat. 
 
Skeletal muscle is composed of a heterogeneous collection of muscle fibre types and 
this allows for the wide variety of capabilities and functions that this organ displays.  
In human skeletal muscle the three most common fibre types are referred to as type I, 
type IIa and type IIx fibres and are named after the respective myosin heavy chain 
(MHC) isoform they contain [11]. In mammalian skeletal muscle, another muscle 
fast glycolytic fibre also exists, type IIb, however, this fibre is not detected in human 
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skeletal muscle. Each muscle fibre type is characterised by specific contractile and 
metabolic properties due to the type of MHC isoform they express and the expression 
of other cellular components such as the mitochondria and glycolytic and oxidative 
enzymes.  The characteristics of each fibre type are presented in Table 1.1.  Due to 
their slow contraction speed, low fatigability and high mitochondrial content and 
oxidative capacity, type I fibres are most adapted for endurance exercise.  In contrast, 
type IIx fibres are more adapted for short and powerful activities due to their fast 
contraction speed, high fatigability and low mitochondrial content and oxidative 
capacity.  Type IIa fibres are both glycolytic and oxidative and have intermediate 
capabilities of the latter two fibres.  
 
Characteristics Type I Type IIa Type IIx 
Properties slow-oxidative oxidative-glycolytic fast-glycolytic 
Contraction speed Slow Medium Fast 
Force generation Low Medium High 
Substrate oxidation Fatty acids Fatty acids & Glucose Glucose 
Fatigability Low Medium High 
Mitochondrial density High Medium Low 
Table 1.1 Characteristics of the three fibre types found in human skeletal muscle.  
 
 
1.3 Embryonic skeletal muscle growth and development 
Muscle development begins early in embryonic development.  During muscle 
development, skeletal muscle precursor cells, called somites, travel to the limb bubs 
and form the early myoblasts [12].  The migration of these somites and formation of 
myoblasts is dependent upon the expression of the tyrosine kinase receptor, c-met, 
which is in turn regulated by the transcription factor, Paired box protein 3 (Pax-3) 
[13].  Following the formation of myoblasts these early muscle cells are stimulated to 
grow and divide (proliferation) by several cell cycle regulatory factors. Myoblast 
proliferation is dependent on the expression of muscle regulatory factors (MRFs), 
myogenic differentiation 1 (MyoD) and myogenic factor 5 (Myf-5) [14-17].  
Following myoblast proliferation, myoblasts exit the cell cycle and begin fuse.  At 
this time the transcription of muscle specific genes becomes apparent.  Myoblast 
fusion (myogenesis) transpires in two distinct phases.  First, during primary 
myogenesis, most of the early mono-nucleated myoblasts fuse to form primary 
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multinucleated myotubes, while some continue to proliferate and become late 
myoblasts [18].  The formation of these primary myotubes requires the involvement 
of another MRFs, called myogenin and the myocyte enhancer factor 2 (MEF2) of 
myogenic transcription factors [19-23].  During secondary myogenesis, the late 
myoblasts fuse and differentiate with the primary myotubes to form mature skeletal 
muscle fibres, while the basal lamina forms around each muscle fibre [18].  The 
expression of MRF4 (also known as Myf6) is required during secondary myogenesis 
and is the prominent MRF expressed in adult skeletal muscle [24-26].  Following the 
completion of myogenesis, mature muscle fibres are formed and contain several 
myofibrils, which have the ability to induce muscle contraction. 
 
1.4 Postnatal changes in skeletal muscle 
Following embryonic development, muscle fibres are terminally differentiated and 
can no longer undergo cell division.  Therefore, postnatal skeletal muscle growth is 
dependent on two main processes; (1) the regulation of protein balance via protein 
synthesis and protein degradation pathways and (2) the proliferation, differentiation 
and fusion of satellite cells with damaged muscle fibres.  Changes in skeletal muscle 
mass and function results from exposure to different environmental and 
physiological challenges such as exercise, neural stimulation, growth factors, 
nutrition, disease and aging. Skeletal muscle growth involves the intricate 
transcriptional regulation by several molecular signalling pathways, however our 
understanding of these molecular processes is neither definitive nor complete. 
Improving our knowledge of how skeletal muscle responds to different 
environmental and physiological challenges may help identify novel therapeutic 
strategies and targets to sustain muscle mass and function during ageing and disease.  
Key signalling molecules and intracellular signalling pathways involved in skeletal 
muscle regeneration, hypertrophy and atrophy and discussed below. 
 
1.4.1 Skeletal muscle regeneration 
Muscle regeneration is a process by which damaged skeletal muscle fibres undergo 
repair to form new muscle.  Lying between the basal (external) lamina and the 
sarcolemma are mononuclear undifferentiated cells, called satellite cells [27-31].  
These skeletal muscle precursor cells can be identified due to the expression of a 
number of distinctive genetic markers such as Pax-3 and Paired box protein 7 (Pax-7) 
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[32, 33].  Skeletal muscle regeneration is dependent on the activation and 
proliferation of satellite cells and their myogenic differentiation and fusion with 
existing muscle fibres [29, 30, 34, 35].  Following muscle damage, the infiltration 
and activities of several molecules involved in inflammation are essential for satellite 
cell activation and muscle regeneration.  At the site of muscle damage there is an 
initial accumulation of leukocytes and macrophages, which aid in the removal of 
cellular debris [36, 37]. Macrophages also play an important role in muscle 
regeneration by the production of pro-inflammatory cytokines which are involved in 
satellite cell activation such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor 
necrosis factor-alpha (TNFα) [38].  Additionally, satellite cells are activated and 
proliferate in response to stimulation by growth factors such as insulin-like growth 
factor-1 (IGF-1), hepatocyte growth factor (HGF), fibroblast growth factor (FGF) 
and leukemia inhibitory factor (LIF) [34, 39].   
 
Upon activation satellite cells re-enter the cell cycle and result in the proliferation of 
skeletal myoblasts (Figure 1.2).  Adult myoblasts then differentiate into myotubes, 
and fuse with the damaged fibres or form new fibres [39].  The regulation of skeletal 
muscle regeneration is under the tight control of many transcription factors. The 
MRFs are involved in the regulation of myogenesis in postnatal skeletal muscle 
regeneration similar to the role played in embryonic muscle development.  MyoD 
and Myf5 are essential for proliferating satellite/myoblasts, while myogenin and 
MRF4 are involved in terminal differentiation [40-42].  A decline in the expression 
of Pax7 also coincides with the onset of differentiation and withdrawal from the cell 
cycle, suggesting a role in satellite/myoblast cell proliferation [32, 43].   
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Figure 1.2 Skeletal muscle regeneration in response to muscle damage. Adult muscle fibres contain 
quiescent satellite cells that upon stimulation become myoblasts, proliferate, differentiate and fuse 
with existing fibres.  Each step of the muscle regeneration process is controlled by many 
transcriptional factors. 
 
 
Muscle wasting may partly be dependent on how the muscle repairs itself after 
damage [44].  With disease and age-related skeletal muscle wasting, a decline in 
satellite cell activity is associated with reduced regenerative capacity [45].  Damaged 
or diseased skeletal muscle over time eventually exhausts the satellite cell population 
and muscle losses its ability to regenerate [46-48].  Therefore, it is proposed that the 
repeated participation of satellite cells in muscle regeneration throughout life results 
in a significant reduction in their collective mitogenic potential. The molecular 
signalling pathways involved in human skeletal muscle growth and regeneration are 
not fully understood.  As the maintenance of muscle mass is a critical component for 
health an increasing of knowledge of signalling mechanisms involved in muscle 
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growth and regeneration may help in the treatment of muscle loss with disease and 
aging [49-51]. 
 
1.4.2 Skeletal muscle hypertrophy 
Skeletal muscle size is tightly regulated by the synergy between anabolic and 
catabolic signalling pathways [3].  Skeletal muscle hypertrophy is characterised by 
an increase in muscle mass and occurs when the rate of protein synthesis exceeds the 
rate of protein degradation.  Several conditions including increases in exercise, 
resistance training, nutrition, hormone treatment and electro-stimulation have been 
shown to be associated with muscle hypertrophy [6, 52-55].  Several signalling 
pathways involved in mediating skeletal muscle hypertrophy and/or protein synthesis 
have been discovered including the IGF-1/PI3K/AKT pathway, the mitogen-
activated protein kinase (MAPK) pathway and the calcineurin/nuclear factor of 
activated T-cells (NFAT) pathway.  The type of stimulus activating these signalling 
pathways vary greatly and evidence also exists that shows a considerable amount of 
cross-talk between these pathways [56-59].  One protein known to be implicated with 
several signalling pathways involved in skeletal muscle hypertrophy is the acute 
transforming retrovirus thymoma (AKT) protein [3, 4, 60, 61]. AKT is 
phosphorylated and activated via upstream signalling involving IGF-1 and 
phosphatidylinositol 3-kinase (PI3K).  Once activated AKT has been shown to 
increase protein synthesis via the mammalian target of rapamycin (mTOR) and 
glycogen synthase kinase- 3β (GSK-3β) [4, 50, 60].  Current understanding of how 
AKT and other signalling proteins regulate skeletal muscle hypertrophy is still 
emerging and further research is required for the identification of therapeutic targets 
to combat the depilating effects of muscle atrophy. 
 
1.4.3 Skeletal muscle atrophy 
Skeletal muscle atrophy is characterised by a loss of muscle mass and occurs when 
the rate of protein degradation exceeds the rate of protein synthesis or is due to an 
increase in muscle cell death [5, 7, 62].  Muscle atrophy observed in neuromuscular 
diseases such as muscular dystrophy and is seen in cases of denervation, 
immobilisation, sepsis, sedentary lifestyles and the aging process [3, 5-7].  Currently, 
the signalling pathways known to regulate muscle atrophy include the autophagic-
lysosomal pathway, the calpain pathway, the caspase/apoptotic protease pathway and 
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the ubiquitin proteasome pathway (UPP) [63-67].  AKT also plays an integral role in 
the regulation of signalling pathways involved in protein degradation [4, 50, 60].  For 
example, when AKT is inactivated it results in the dephosphorylation and activation 
of the Forkhead box (FOXO) transcription factors, FOXO1 and FOXO3a.  These 
FOXO proteins regulate the expression of genes involved in the UPP, such as 
Atrogin-1 and muscle RING-finger protein-1 (MuRF1), and autophagy such as LC3 
and GABA(A) receptor-associated protein like 1 (Gabarapl1) [68].  The activation of 
signalling pathways involved in skeletal muscle atrophy can vary greatly depending 
on the cause of the muscular atrophy.  Therefore, future research is needed to 
identify the underlying intracellular mechanisms responsible for the varying cases of 
muscle atrophy for the development of potential therapeutic treatments. 
 
1.5 Exercise 
One of the most influential stimuli that leads to a change in skeletal muscle mass, 
structure and composition is exercise [27].  The type, duration and intensity of 
exercise performed can also result in different adaptations in the muscle mass, 
composition, contractile activity and metabolic features of the muscle fibres [69].  
Endurance or moderate-intensity exercise typically results in a switch in muscle fibre 
composition towards an increase in Type I fibre isoform proteins, together with an 
enhanced oxidative capacity and mitochondrial content, whilst an increase in muscle 
mass is typically observed with resistance or weight-bearing exercise [70, 71].  The 
effect of exercise on muscle atrophy with aging and disease has been reported to 
improve strength, endurance and functional capacity to perform everyday activities 
[72, 73].  The importance of resistance training in maintaining muscle mass, strength 
and endurance has been highlighted in many investigations [74, 75].  However, there 
are some studies illustrating significant gains of strength and endurance with low and 
moderate intensity exercise [75-77].  
 
As the performance of high intensity exercise may be challenging for some 
individuals, due to a lack of functional strength, the undertaking of low to moderate 
exercise may be more of a suitable option [78, 79]. Therefore, future investigations 
should also focus on the possible effects of endurance exercise on the maintenance or 
promotion of muscle growth. Several studies have illustrated that there are 
significant increases in the transcription of genes encoding proteins involved in 
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muscle structure and function following a single bout of endurance exercise in 
healthy human subjects [80-85].  Expression of muscle specific genes has also been 
demonstrated in rabbits and humans to be increased significantly within the first few 
hours of recovery following a single endurance exercise bout [86, 87].  Research also 
suggests a possible role of endurance exercise in regulating several specific proteins 
involved in skeletal muscle growth, structure and function.  For example, endurance 
training has been shown in humans and horses to increase the gene expression of 
MHC 2a, an important structural and functional muscle protein [88, 89]. Similarly, 
the gene expression of another structural and functional muscle protein, α-actin, was 
observed to increase in the left ventricle of rats following one week of treadmill 
running [90].  Finally, gene expression of IGF-1, a protein involved in muscle 
growth, was augmented in the left ventricle of rats following two or six weeks of 
swimming exercise [91].  Therefore, it is possible in human skeletal muscle that 
moderate-intensity muscle contraction, typical of endurance exercise, may be 
involved in stimulating signalling pathways that regulate muscle structure, growth 
and regeneration. 
 
1.6 Skeletal muscle microstructure and mechanosignal transduction 
The ability of skeletal muscle to rapidly change to physiological requirements such 
as exercise, requires the coordination and activation of intracellular signalling 
pathways that are involved in the regulation of muscle structure, function and 
growth. Recent investigations have identified novel proteins that associate with the 
sarcomere and the actin cytoskeleton; two of the important cellular components 
involved in skeletal muscle structure and function.  These proteins play important 
roles not only in maintaining skeletal muscle structure but also mechanosignal 
transduction by the sensing of external mechanical stimuli (exercise) and subsequent 
activation of intracellular signalling pathways involved in muscle growth and 
function. The role of Z-disk and actin cytoskeleton associating proteins involved in 
mechanosignal transduction in skeletal muscle is discussed below. 
 
1.6.1 Z-disk proteins 
The Z-disk represents the lateral boundary between each sarcomere, as well as the 
key interface between the sarcomere and the actin cytoskeleton where key structural 
proteins, actin, titin and nebulin are anchored [92, 93].  Besides its obvious structural 
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role the Z-disk has emerged as a key player in the mechanical sensing of both muscle 
contraction and stretch. The structure of the Z-disk is modified by the contractile 
state of the muscle fibre and the resulting conformational changes are suggested to 
regulate skeletal muscle signalling and homeostasis [94, 95].  Recently, a large 
number of Z-disk associating proteins have been discovered that display dynamic 
distribution within the muscle cell [93].  These proteins transmit signals by shuttling 
between the Z-disk and other cellular locations such as the actin cytoskeleton and the 
nucleus.  For example, Muscle LIM Protein (MLP) has been shown to associate with 
the Z-disk and display nuclear accumulation in the nucleus following pressure 
overload or passive stretch in cardiomyocytes [96-98]. The sensing of mechanical 
strain by MLP is believed to occur through its interactions with a major component 
of the Z-disk, α-actinin.  This protein is an important actin crosslinking protein that 
binds to specific sites interacts with a variety of proteins involved in skeletal muscle 
structure, contraction and mechanosensing [99-101]. Both α-actinin and MLP 
activate intracellular signalling cascades involved in muscle growth, such as the 
calcineurin/NFAT signalling pathway [102]. These Z-disk proteins are just a couple 
of a large number of proteins that have been discovered.  As mechanical stimuli, 
such as exercise results in positive skeletal muscle adaptations, further understanding 
of the role of Z-disk proteins in skeletal muscle growth may lead to the development 
of novel therapeutic strategies for the maintenance of skeletal muscle mass. 
 
1.6.2 The actin cytoskeleton 
The actin cytoskeleton is a cellular structure that is contained within the cytoplasm of 
all eukaryotic cells and acts to maintain cell shape and stability [103].  The 
cytoskeleton is a dynamic structure composed primarily of the protein actin, which is 
present in either one of two forms, a monomeric or single unit form called G-actin, or 
a polymeric or filament form called F-actin [103-105].  The lowest concentration of 
G-actin required to initiate actin polymerisation is referred to as the critical 
concentration (Cc) [104].  Net polymerisation occurs when the G-actin concentration 
is higher than the Cc, and net depolymerisation takes place when the G-actin 
concentration is lower than the Cc [104].  The equilibrium between the gain and loss 
of G-actin from the F-actin filaments affects the mobility and stability of the cell.  
When G-actin disassembly occurs faster than F-actin filament assembly the cell 
becomes more mobile and unstable.  Conversely, if G-actin is predominately being 
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assembled into the F-actin filaments the cell becomes more rigid and stable.  The 
distribution of actin between its two forms is tightly regulated by numerous actin-
binding proteins that are stimulated in response to extracellular signalling [106].  The 
resultant changes in actin dynamics influences a diverse range of cellular processes, 
most of which require changes in cell shape such as cell motility, contractility, 
mitosis, cytokinesis, axon outgrowth, endocytosis and secretion [103].  The actin 
cytoskeleton also participates in transmembrane signalling systems by forming 
complexes with cell adhesion molecules and receptors [107, 108].   
 
In skeletal muscle, the actin cytoskeleton is essential for maintaining cell structure by 
acting as a structural scaffold between the sarcomere to the cell membrane.  The 
actin cytoskeleton also plays an important role in intracellular signalling pathways 
that regulate gene transcription of proteins involved in skeletal muscle growth, 
structure and contraction [103]. Ras homolog gene family member A (RhoA) 
signalling is one such signalling pathway that has been shown to stimulate gene 
transcription of muscle specific genes via changes in actin dynamics.  RhoA is a 
member of the Rho GTPase family of proteins which are involved in the regulation 
of a broad range of signalling pathways [109, 110]. RhoA is a small G-protein that 
stimulates actin polymerization through its two downstream effector molecules, Rho 
kinase (ROCK) and mammalian homolog of diaphanous (mDia) [111-115].  RhoA 
number regulates a number of cell functions including gene expression, cell growth 
and cell motility by reorganising the actin cytoskeleton in response to extracellular 
signals [116].  Several studies have shown that RhoA signalling is required for the 
differentiation of smooth, cardiac, and skeletal muscle cells [117-124].  RhoA 
signalling stimulates key proteins involved in the regulation of muscle 
differentiation, such as MyoD [125].  Different stimuli have been shown to stimulate 
RhoA signalling, including biomechanical stress and pressure overload in 
cardiomyocytes, and is also required for cardiomyocyte hypertrophy [121, 126-130].  
In skeletal muscle, RhoA protein levels have been shown to increase and decrease 
respectively, following functional overload and hindlimb suspension in rats [51, 131, 
132].  RhoA signalling contribution to muscle remodelling in skeletal muscle is still 
to be fully determined. One possible collaborator of RhoA signalling believed to be 
involved in stimulating the expression of proteins involved muscle growth, structure 
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and function is the muscle specific protein, striated muscle activator of Rho 
signalling (STARS) protein.   
 
 
1.7 STARS 
The striated muscle activator of Rho signalling (STARS) protein, also known as 
Myocyte Stress-1 (MS1) and Actin-binding Rho-activating protein (ABRA), is a 43 
kDa protein, highly enriched in cardiac, skeletal and smooth muscle [133-136]. 
STARS was independently identified in 2002 using differential cDNA screening for 
novel genes expressed in the hearts of mouse embryos [133] and using molecular 
indexing to identify regulated genes following left ventricle (LV) pressure overload 
in the rat [134]. It is highly responsive to stress conditions and its ability to stimulate 
the serum response factor (SRF) [133, 137] transcriptional pathway makes this 
protein an interesting target for understanding physiological and pathophysiological 
muscle development.  
 
STARS, in conjunction with RhoA, enhances actin polymerisation by increasing the 
binding of G-actin to F-actin [133] (Figure 1.3). The reduction in G-actin removes its 
inhibitory effect on the transcriptional co-activator, myocardin-related transcription 
factor-A (MRTF-A), allowing its translocation to the nucleus [133, 137]. Once in the 
nucleus, MRTF-A associates with SRF to promote transcription of its target genes 
[137].  These target genes encode proteins that are important for muscle cell growth, 
structure and muscle contraction [138, 139].  Over-expression or knockdown of 
STARS gene expression has been shown to increase and decrease SRF 
transcriptional activity respectively [133, 137, 140]. The effect of STARS on 
downstream targets has been limited to investigations in transfected COS (monkey 
kidney fibroblast-like cells), 293T (human renal epithelial cells), NIH3T3 (mouse 
embryonic cells) and C2C12 cells and cardiomyocytes [133, 137, 140].  However, 
due to the ability of STARS to act as a muscle-specific transducer of cytoskeletal 
signals that stimulate transcription of SRF target genes, STARS may play a pivotal 
role in skeletal muscle growth and regeneration. 
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Figure 1.3 The STARS signalling pathway.  STARS stimulates SRF transcriptional activity via actin 
polymerisation and MRTF-A nuclear translocation. 
 
 
1.7.1 MRTF-A 
Myocardin and myocardin-related transcription factors (MRTFs) are part of a family 
of transcriptional co-activators that combine with SRF to enhance SRF 
transcriptional activity [141-146].  Myocardin is expressed in smooth and cardiac 
muscle cells and is involved in regulating the transcription of smooth muscle genes 
that are SRF target genes [118, 144, 147, 148].  MRTFs, which include MRTF-A 
(MAL/MKL1/BSAC) and MRTF-B (MKL2) are also expressed in skeletal, cardiac 
and smooth muscle cells, as well as other cells types involved in cell proliferation 
and migration [141, 142, 145, 146, 149, 150].  MRTF-A is contained within the 
cytoplasm of unstimulated cells by binding with unpolymerised G-actin.  Actin 
polymerisation results in the disassociation of G-actin from MRTF-A and 
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consequently MRTF-A translocates to the nucleus to stimulate SRF transcriptional 
activity.  For example, in cultured cells the complex of SRF and MRTF enhanced 
transcription of α-actin [137].  The N-terminal of MRTF-A contains RPEL motifs, 
which have been shown to be sufficient and necessary for the binding of G-actin 
[143, 151].  This association has been shown, in NIH 3T3 cells, to sequester MRTF-
A to the cytoplasm and inhibits its binding with SRF [143].  Serum stimulation and 
STARS/RhoA signalling have both resulted in the depletion of the G-actin pool, the 
nuclear translocation of MRTF-A and the activation of SRF gene transcription in 
smooth muscle cells [118, 143]. 
 
1.7.2 SRF 
SRF is a transcription factor that belongs to the MADS box family and regulates cell 
proliferation, migration, cytoskeletal dynamics and myogenesis, by binding to a 
conserved DNA sequence [CC(A/T)6GG], known as a CArG box or serum response 
element (SRE) [152-154]. The MAPK and STARS/RhoA pathways are two 
signalling cascades that have been identified to stimulate SRF transcriptional activity 
[155-160].  The MAPK pathway involves the phosphorylation of ternary complex 
factors (TCFs), which assists their association with SRF on target genes that contain 
TCF-binding sites adjacent to the CArG box [158].  Depending on which promoter 
SRF binds to, transcriptional activity of specific target genes may be increased or 
decreased [158, 159, 161]. Alternatively, as mentioned earlier, STARS/RhoA 
signalling stimulates the transcriptional activity of SRF through a mechanism 
mediated by changes in actin dynamics. 
 
Several proteins involved in the structure and function of striated muscle, such as α-
actin, a structural protein, and MHC 2b, a protein involved increasing skeletal muscle 
contraction, are transcriptionally regulated by SRF [152, 162-165].  In mice, it has 
been shown that SRF regulates the transcription of interleukin 4 (IL-4) and IGF-1, 
two factors that are involved in skeletal muscle growth and regeneration [139].  
Following 8 weeks of resistance training in humans, an increase in SRF target genes, 
α-actin and IGF-1 was observed together with an increase in SRF nuclear protein 
and gene levels [166].  Gene deletion studies in smooth, cardiac and skeletal muscles 
have shown that SRF is essential for the correct assembly of the myofilaments and 
the generation of contractile force [167-170].  For example, over-expression of either 
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wild-type or dominant-negative SRF in mice results in various forms of heart failure 
due to severe changes in contractile gene expression [171, 172].  The conserved 
DNA sequence of SRF can theoretically bind up to 1,216 versions of the 10-base pair 
DNA sequence [138].  However, the ability of SRF to distinguish between different 
target genes is based on the presence of binding sites for other transcription factors, 
the number of CArG boxes, as well as the association of SRF with a number of cell 
specific and signal responsive transcriptional cofactors [138, 173-176]. 
 
1.8 Localisation and activation of STARS 
In primary cardiomyocytes, STARS locates to the sarcomere where it associates with 
the I-band, predominantly around the Z-disk and to a smaller extent in the M-line 
[133]. When overexpressed, STARS binds actin in rat cardiomyocytes and non-
muscle COS cells [133]. Its function as an actin binding protein has important 
consequences for intracellular signalling that may influence numerous cellular 
processes within muscle tissue.  
 
STARS protein activity is regulated by two actin-binding LIM (ABLIM) protein 
family members, ABLIM-2 and ABLIM-3 [140].  Both ABLIM proteins co-
precipitate with STARS in transfected COS cells, strongly bind to F-actin in C2C12 
cells and localise to the sarcomere in mouse skeletal muscle [140].  The ABLIM 
proteins can also enhance STARS-dependent SRF-activation. It has been suggested 
that the ABLIM proteins regulate STARS activity by assisting its binding to the 
sarcomere [140]. As the sarcomere plays a critical role in sensing biomechanical 
stress and activating signalling pathways in skeletal muscle, STARS could possibly 
act as a link between contractile function and intracellular signalling in muscle cells.  
 
The actin binding of STARS requires two separate but co-dependent regions in the 
C-terminal end of the protein, located between the amino acid sequences 234-279 
and 346-375 [133]. These regions contain two independent F-actin binding domains, 
actin binding domain 1 and 2 (ABD1/ABD2) [177]. ABD1 (fragment 193-296) binds 
with higher affinity to F-actin when compared to ABD2. ABD1 does not adopt a 
well-folded structure until it is bound to F-actin [177], while ABD2 (fragment 294-
375), the most C-terminal fragment, is independently folded [177]. It has been 
hypothesised that ABD1 could completely fulfil the actin-binding function of 
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STARS in muscle, therefore, leaving ABD2 available for other potential functions 
within muscle [177].  While STARS is predominantly cytosolic, its presence has 
been observed in the nucleus of non-muscle COS cells following STARS 
overexpression [133].  It is possible that the nuclear role or function of STARS is 
controlled by ABD2, however this remains to be determined. The functional 
significance of STARS within the nucleus is currently unclear but leaves the 
possibility that STARS itself may act as a transcriptional co-activator or transcription 
factor. 
 
1.9 Transcriptional regulation of STARS  
The STARS promoter contains binding sites for several muscle-enriched 
transcription factors (Figure 1.4). Gene expression of STARS is diminished in the 
heart of Mef2c null mouse embryos. This suggests that Mef2c may be involved in the 
transcriptional regulation of STARS gene expression, at least in cardiac muscle 
[178]. Further analysis confirmed the existence of two regions that synergistically 
mediate MEF2C activation of STARS transcription [178]. Two conserved E-boxes 
have also been identified within the proximal 1.5kbp of the 5' upstream STARS 
promoter sequence [179]. These two sites are required for recruiting MyoD and 
subsequently activating the STARS promoter during myogenic differentiation in 
C2C12 muscle cells. STARS can also regulate its own transcription via a feed-
forward mechanism that requires SRF binding to SRE on the STARS promoter 
[180]. Conversely, STARS is repressed in embryonic, neonatal and adult hearts by 
GATA-binding factor 4 (GATA4) [181]. Depletion of GATA4 allows the 
pathological up regulation of STARS [181]. 
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Figure 1.4 Known and potential transcriptional factors that regulate STARS gene transcription and 
their binding sites on the STARS promoter region. 
 
Analysis of the STARS promoter region shows potential binding sites for other key 
stress responsive, transcriptional factors involved in skeletal muscle growth and 
function, such as estrogen receptor alpha (ERα) and estrogen-related receptor α 
(ERRα). ERα and the closely related orphan ERRα are nuclear receptors, which are 
activated by the sex hormone 17B-estradiol (estrogen) [182].  Interestingly, estrogen 
transcriptionally activates similar genes as those activated during exercise [183]. 
Highly endurance-trained men have a higher skeletal muscle ERα mRNA expression 
than moderately active men [184]. Furthermore, a positive correlation between ERα 
and citrate synthase activity (oxidative capacity) was observed [184]. Thus, 
considering that ERα is involved in the adaptations of skeletal muscle to mechanical 
stress, the question whether STARS gene expression induced by mechanical stress 
can be regulated through upstream induction of ERα and/or ERRα in skeletal muscle 
arises.  
It has been reported that peroxisome proliferator-activated receptor y co-activator 1 
alpha (PGC-1α) is a co-activator of MEF2, ERα- and ERRα- dependent 
transcription [185-189].  Exercise induces the expression of PGC-1α, which 
promotes fibre-type switching from glycolytic towards more oxidative fibres [187]. 
The expression of PGC-1α is markedly decreased during multiple models of rodent 
muscle atrophy [190].  Furthermore, transgenic over-expression of PGC-1α protects 
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against muscle atrophy at least in part by its ability to suppress FOXO-dependent 
transcription of atrophy-associated genes [190].  This protective role of PGC-1α may 
explain how exercise, through increasing the expression of PGC-1α can maintain 
skeletal muscle mass and prevent muscle wasting [191, 192].  Since STARS gene 
expression is also stress responsive and has binding sites for PGC-1α activated 
transcription factors, it is possible that STARS gene expression may occur via the 
binding of PGC-1α to MEF2, ERα and / or ERRα. 
 
1.10 Conditions that influence STARS expression 
1.10.1 Cardiac muscle hypertrophy 
Cardiac hypertrophy is an adaptation of the heart in response to an increased 
workload, stress or injury. This adaptation is initially beneficial but sustained cardiac 
hypertrophy eventually results in impaired cardiac function, partially due to cell 
death caused by apoptosis [193]. STARS is increased in several models of cardiac 
hypertrophy and myopathy. Left ventricle hypertrophy (LVH) in rats, stimulated by 
pressure overload by aortic banding, caused a pronounced early up-regulation of 
STARS within 1 hour and a considerable 3-fold increase in STARS at 4 hours post 
banding [134]. This elevation of STARS mRNA had returned to control levels before 
24 hours post banding. The transient increase in STARS gene expression was 
observed prior to any detectable increase in left ventricle mass which did not occur 
until at least 4 days post banding. This suggests that STARS may detect the initial 
mechanical stress and its activation would signal to mechanisms that directly cause 
the cardiac remodelling response to LVH. Transgenic (Tg) mice expressing 
constitutively active calcineurin, under the control a cardiac-specific α–myosin heavy 
chain (α-MHC) promoter (Cn-Tg mice), also develop cardiac hypertrophy and 
cardiomyopathy [178]. In this model STARS is also 8-9 fold higher in the hearts of 
Cn-Tg mice when compared to wild type littermates [178]. However this cardiac 
hypertrophy only occurs when the mice are subjected to pressure overload. A similar 
observation has been made in humans with STARS mRNA significantly higher in 
human hearts with idiopathic cardiomyopathy when compared to normal control 
hearts [178]. In vitro it has been shown that overexpressing STARS increases the 
size of H2c9 rat myocardial cells [194]. While the mechanisms behind this 
cardiomyocyte hypertrophy was not established, STARS overexpression did not 
affect proliferation, but it did reduce chemically induced apoptosis [194]. STARS 
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may also regulate muscle cell hypertrophy by influencing protein synthesis and 
degradation, however this has not been experimentally determined. These 
observations suggest that STARS is an early marker of cardiac remodelling in 
response to increased mechanical stress. The fact that endogenous STARS is rapidly 
and transiently increased in response to external stress signals suggests that it may 
have a protective and a physiological adaptive role in muscle cells. However, forced 
and uncontrolled up-regulation of STARS may result in maladaptation.  
 
1.10.2 Angiogenesis 
Fluid shear stress (FSS)-induced collateral growth during arteriogenesis is associated 
with an increase in STARS gene expression [136]. This induction of STARS is 
abolished with the nitric oxide (NO) inhibitor L-NAME, suggesting that STARS 
transcription may be controlled by NO. The local intracollateral over expression of 
STARS ameliorates collateral conductance in rabbits following femoral artery 
ligature. In contrast, mice with an ablation of STARS have impaired arteriogenesis 
[136]. These observations extend the role of STARS to arterial structure and 
function. 
 
1.10.3 Exercise, disuse and ageing 
The adaptation of skeletal muscle to changes in mechanical stress, such as muscle 
contraction or immobilization, requires the sensing and the transduction of the 
extracellular stress signals into the cell in order to generate the appropriate 
physiological response. Our group first observed that STARS mRNA levels 
significantly increased in the vastus lateralis muscle following 8 weeks of 
hypertrophy-inducing resistance exercise training in humans [166]. Similarly skeletal 
muscle STARS gene expression is increased [195] in post-menopausal women 
following 12 months of hypertrophy-inducing plyometric power training [196]. 
Whether STARS directly causes skeletal muscle hypertrophy has not been 
established. With respect to acute single-bout exercise, STARS gene expression 
increases 10-fold when measured 3 hours after eccentric exercise [197]. This 
transient increase in STARS following contraction-induced mechanical stress may 
provide a protective mechanism to reduce the risk of contractile damage to the 
sarcomere or be required to activate intracellular signals responsible for muscle 
adaptation to exercise.   It is currently not known if a concurrent increase in STARS 
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protein levels is observed with enhanced STARS gene expression in response to 
mechanical stress.  It is also unknown if low-force contraction that occurs during 
endurance exercise can regulate STARS expression in skeletal muscle.  
 
Limb immobilization drastically reduces the exposure of skeletal muscle to 
mechanical stress factors. Hind limb suspension decreased STARS mRNA 
expression in rat soleus muscle within the first 24 hours and remains elevated for 48 
hours. However a reduction in muscle weight was not observed until 48 hours post 
intervention [198]. Whether the decrease in STARS is a cause or a consequence of 
muscle wasting is yet to be established. In contrast, 20 days of hind limb suspension 
in humans, resulting in a 10% loss in muscle mass, did not reduce STARS mRNA 
levels [199]. We have observed that reducing mechanical stress due to cessation of 
exercise training for 8 weeks results in a loss of muscle mass and a reduction in 
STARS mRNA [166]. 
 
STARS is reduced in skeletal muscle from of aged mice [200] and pigs [135]. As 
STARS binds and stabilizes actin and the sarcomere, it has been suggested that it 
protects against contraction-induced damage [133]. Muscle from older animals is 
more susceptible to contraction-induced damage, partially due to a mechanically 
compromised sarcomeric structure that is less able to withstand stretch [201].  Older 
muscle also repairs less efficiently which is attributed to its reduced capacity to 
promote satellite cell activation, proliferation and differentiation, thereby 
contributing to its impaired regenerative capacity and reduced muscle mass [202, 
203]. The reduction in STARS in older muscle may be a factor contributing to the 
increased susceptibility of contraction-induced muscle damage as well as its 
attenuated muscle cell proliferation and repair. 
 
1.10.4 Insulin resistance 
STARS gene expression is upregulated in skeletal muscle of patients with type 2 
diabetes when compared with healthy family members [204]. In rodents, STARS 
expression is also increased in mice made insulin resistant by high-fat feeding [204] 
as well as in the heart of streptozotocin (STZ)-induced type I diabetic mice and in 
db/db type II diabetic mice [181]. Knockdown of STARS in L6 myotubes enhances 
insulin signalling, as measured by increased insulin stimulated AKT phosphorylation 
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as well as basal and insulin-stimulated glucose uptake [204]. Additionally, the 
reduction in STARS increases plasma membrane glucose transporter type 4 
(GLUT4) localization in basal and insulin stimulated conditions. Presently, it is 
difficult to determine if the increase in STARS in diabetic muscle is a consequence 
of or directly contributes to insulin resistance.  
 
1.11 STARS – Regulation of skeletal muscle regeneration 
STARS is transcriptionally regulated by MEF2, MyoD and SRF, transcription factors 
involved in skeletal muscle cell proliferation and differentiation [178-180, 205-208].  
STARS is expressed in skeletal muscle during early embryonic development and 
continues to increase during post-natal muscle development [133, 135, 180]. STARS 
is also more highly expressed in terminally differentiated skeletal myotubes when 
compared to proliferating myoblasts [179], suggesting that it may play a role in 
skeletal muscle proliferation and differentiation.  Overexpression of STARS in 
porcine smooth muscle cells (SMC) increases proliferation [136]. The ability of 
STARS to enhance SMC proliferation was also observed in the A10 rat vascular 
smooth muscle cell line, but not in porcine aortic endothelial cells [136] or in the 
H9c2 rat cardiac cell line [194]. At present the effect of STARS on skeletal muscle 
cell proliferation has not been investigated. The potential of STARS to promote 
muscle cell proliferation also requires further validation in vivo. Furthermore, 
identification of the downstream molecules activated by STARS that regulate 
proliferation is required. STARS may play an important role in sensing mechanical 
stress and up-regulating important pathways in muscle growth and regeneration. It 
also appears that the biological role/s of STARS may depend on the muscle cell type 
investigated.  
 
Members of the STARS signalling pathway have also been implicated in muscle 
regeneration.  Several studies have shown that RhoA signalling is required for the 
differentiation of smooth, cardiac, and skeletal muscle cells [117-124].  RhoA 
activity is transient, rapidly increasing when cells move from proliferation to 
differentiation, and then decreasing until myoblasts fuse to form multinucleated 
myotubes [209]. In C2C12 skeletal muscle cells dominate-negative RhoA reduces 
myogenic differentiation, whereas activated RhoA enhances myocyte differentiation 
and growth [122, 123]. Additionally, RhoA signalling stimulates key proteins 
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involved in the regulation of muscle differentiation, such as MyoD and myogenin in 
myoblasts [125, 210].  
 
SRF also plays an important role in muscle growth and regeneration.  In mouse cells, 
SRF is essential for myoblast proliferation and myogenic differentiation [211].  SRF 
regulates cell proliferation via its transcription of immediate early genes such as c-
fos, JunB, and early growth response-1 (Egr-1) [138, 212, 213].  Knockdown of SRF 
in embryonic stem cells results in faulty expression of immediate early SRF target 
genes, however, cell proliferation is not effected [214]. SRF enhances muscle 
differentiation and MyoD gene expression C2C12 mouse myotubes, via RhoA 
signalling [215].  Proliferating myoblasts display high RhoA and MRTF-A levels 
which result in enhanced SRF activity and MyoD expression [216]. MyoD 
expression in satellite cells is essential for effective muscle regeneration [217].  In 
response to muscle injury MyoD is induced rapidly and expressed in proliferating 
myoblasts where it plays a role in controlling the proliferation-to-differentiation 
switch, as well as the differentiation process by regulating myogenin, a terminal 
differentiation factor [218].  Inhibition of RhoA, SRF or actin polymerization inhibits 
MyoD expression as well as myoblast proliferation and differentiation [219-221], 
suggesting that the role of RhoA and SRF is dependent upon of the myogenic state of 
the muscle cell.  As STARS stimulates SRF transcriptional activity it’s possible that 
STARS maybe involved in skeletal muscle regeneration and growth via controlling 
both myoblast proliferation and differentiation, however this is still to be 
investigated.  
 
1.12 STARS – Regulation of skeletal muscle mass 
As mentioned previously, STARS gene expression increases in models of 
hypertrophy and declines in conditions of muscle atrophy in skeletal muscle [166, 
195, 200].  As STARS stimulates an intracellular signalling pathway known to 
regulate muscle growth, these observations suggest that STARS may be involved in 
the regulation of skeletal muscle mass.  Recent investigations have shown that 
STARS can induce in hypertrophy in cardiomyocytes and in mice following 
mechanical loading [137, 194], however at present its role in skeletal muscle 
hypertrophy is unknown.  
 
  24 
Members of the STARS signalling pathway have also been implicated in the 
processes of muscular hypertrophy and atrophy.  Different stimuli have been shown 
to stimulate RhoA signalling, including biomechanical stress and pressure overload 
in cardiomyocytes, and are also required for cardiomyocyte hypertrophy [121, 126-
130].  In skeletal muscle, RhoA protein levels have been shown to increase and 
decrease respectively, following functional overload and hindlimb suspension in rats 
[51, 131, 132].  During load-induced hypertrophy, SRF activity and expression was 
enhanced in both rats and roosters [131, 222].  Following eight weeks of resistance 
training RhoA protein and SRF mRNA and protein levels increased significantly in 
human skeletal muscle [166].  These results suggest that RhoA and SRF may play a 
role in human skeletal muscle growth and wasting, however, however the signalling 
mechanisms and whether STARS is involved remains unclear. 
 
SRF regulates the transcription of IGF-1 which is a factor involved in skeletal muscle 
growth and regeneration [139].  IGF-1 is known to increase protein synthesis and 
hypertrophy through its activation of the AKT signalling pathway, a pathway up-
regulated in hypertrophied human muscle [223]. Along similar lines, the activation of 
AKT, actin polymerization, SRF expression and protein synthesis is associated with 
vascular hypertrophy, strengthening the possibility that STARS may be a key 
upstream activator of these processes [224]. With respect to muscle atrophy, IGF-1 
activation of AKT signalling has been shown to attenuate the FOXO induced 
increase in the atrophy genes Atrogin-1 and MuRF1 and attenuate myotube protein 
degradation and myofibre atrophy [49, 225, 226]. Recently, combined 
overexpression of STARS and the SRF transcriptional coactivator, MRTF-A in rat 
primary cardiomyocytes increases AKT phosphorylation.  Therefore, STARS may 
potentially regulate protein synthesis and degradation, possibly via the activation of 
AKT signalling. Establishing the role of STARS in regulating protein synthesis and 
degradation processes involved in skeletal muscle hypertrophy and atrophy is 
required and may provide an alternative therapeutic target for enhancing muscle 
growth and regeneration. 
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1.13 Summary and Significance of Research 
Understanding the signalling mechanisms involved in skeletal muscle regeneration, 
growth, structure and function remains a key objective.  Continual adaptations such 
as growth, repair and maintenance of skeletal muscle are required throughout the 
lifespan for the maintenance of healthy living and longevity. For healthy adaptation 
to occur the muscle cells must be able to detect the extracellular stress signals and 
efficiently transmit them to appropriate intracellular transcriptional programs. The 
STARS protein potentially plays a key role in the detection and transmission of 
adaptive stress signals in muscle cells and maybe a future therapeutic target for 
enhancing muscle growth and regeneration for the treatment of muscle loss with age 
and disease.  However, there are many aspects about the role and regulation of 
STARS in skeletal muscle that remain unclear.  This PhD thesis will expand the 
present knowledge about the regulation of STARS expression in skeletal muscle and 
its potential role in muscle growth and function. 
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1.14 Aims 
 
The specific aims of the thesis are: 
 
1. To investigate whether the expression of STARS and members of its 
downstream signalling pathway are regulated in response to an acute bout of 
endurance exercise and to determine if the STARS gene is regulated via 
PGC-1α/ERRα signalling. 
 
2. To investigate the effect of STARS overexpression on skeletal muscle cell 
proliferation and differentiation in vitro and determine whether altering the 
expression of STARS influences several SRF and PGC-1α/ERRα target genes 
involved in myoblast proliferation and differentiation. 
 
3. To investigate the effect of STARS overexpression and knockdown on 
skeletal muscle cell protein synthesis and degradation and determine whether 
altering the expression of STARS influences several SRF and PGC-1α/ERRα 
target genes involved in muscle cell structure, function and growth.  
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1.15 Hypotheses 
 
It was hypothesised that: 
 
1. STARS and members of its downstream signalling pathway would be 
upregulated following an acute bout of endurance exercise. The STARS gene 
will be identified as a PGC-1α/ ERRα transcriptional target and a gene that 
may be involved the regulation of oxidative metabolism. 
 
2. STARS will enhance skeletal muscle cell proliferation and differentiation in 
vitro. STARS overexpression in skeletal muscle cells will be associated with 
an increase in the expression of several SRF and PGC-1α/ ERRα target genes 
involved in myoblast proliferation and differentiation. 
 
3. STARS overexpression will increase protein synthesis and decrease protein 
degradation and result in cellular hypertrophy of skeletal muscle cells.  
STARS knockdown will increase cell death and protein degradation, while 
attenuating protein synthesis.  SRF and PGC-1α/ ERRα target genes involved 
in muscle cell structure, function and growth will be increased and decrease 
with STARS overexpression and knockdown respectively. 
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CHAPTER 2 
 
STRIATED MUSCLE ACTIVATOR OF RHO SIGNALLING (STARS) IS A 
PGC-1α/ERRα TARGET GENE AND IS UPREGULATED IN HUMAN 
SKELETAL MUSCLE FOLLOWING ENDURANCE EXERCISE 
 
 
This work has been published prior to the completion of this dissertation Wallace MA, Hock B, Hazen 
BC, Kralli A, Snow RJ, Russell AP: Striated muscle activator of Rho signalling (STARS) is a PGC-
1α/ERRα target gene and is upregulated in human skeletal muscle following endurance exercise. The 
Journal of Physiology 2011; 589(8): p. 2027-2039 
 
Abstract 
The striated muscle activator of Rho signalling (STARS) is an actin-binding protein 
specifically expressed in cardiac, skeletal and smooth muscle. STARS has been 
suggested to provide an important link between the transduction of external stress 
signals to intracellular signalling pathways controlling genes involved in the 
maintenance of muscle function. The aims of this study were firstly, to establish if 
STARS, as well as members of its downstream signalling pathway, are upregulated 
following acute endurance cycling exercise; and secondly, to determine if STARS is 
a transcriptional target of peroxisome proliferator-activated receptor gamma 
coactivator 1-α (PGC-1α) and estrogen-related receptor-α (ERRα). When measured 3 
hours post exercise, STARS mRNA and protein levels as well as MRTF-A and SRF 
nuclear protein content, were significantly increased by 140-, 40-, 40- and 40% 
respectively. Known SRF target genes, carnitine palmitoyltransferase-1β (CPT-1β) 
and JUNB, as well as the exercise responsive genes PGC-1α mRNA and ERRα were 
increased by 2.3, 1.8, 4.5 and 2.7-fold, 3 hours post exercise. Infection of C2C12 
myotubes with an adenovirus expressing human PGC-1α resulted in a 3-fold increase 
in Stars mRNA; a response that was abolished following the suppression of 
endogenous ERRα. Over expression of PGC-1α also increased Cpt-1β, Cox4 and 
Vegf mRNA by 6.2, 2.0 and 2.0-fold respectively. Suppression of endogenous 
STARS reduced basal Cpt-1β levels by 8.2-fold and inhibited the PGC-1α-induced 
increase in Cpt-1β mRNA. Our results show for the first time that the STARS 
signalling pathway is upregulated in response to acute endurance exercise. 
Additionally, we show in C2C12 myotubes that the STARS gene is a PGC-1α/ ERRα 
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transcriptional target.  Furthermore, our results suggest a novel role of STARS in the 
co-ordination of PGC-1α-induced up regulation of the fat oxidative gene, CPT-1β. 
 
 
2.1 Introduction 
Skeletal muscle contraction is a catalyst for numerous physiological adaptations 
including enhanced substrate metabolism, growth and regeneration [50, 60, 227, 
228]. For these skeletal muscle adaptations to occur the extracellular signals must be 
detected, then transmitted to the cell [229]. These signals result in the intracellular 
activation of transcriptional co-activators and transcription factors [230] with a 
consequent increase in their target genes that encode proteins mediating metabolic, 
structural and contractile function of skeletal muscle [228, 231]. Understanding the 
molecular targets and intracellular signals activated by exercise is important for 
identifying potential therapeutic targets to combat diseases characterized by 
perturbed skeletal muscle metabolism, growth and regeneration.   
 
The striated muscle activator of Rho signalling (STARS), also known as myocyte 
stress-1 (ms1) [134] and actin-binding rho activating protein (Abra) [136], is an 
actin-binding protein specifically expressed in cardiac, skeletal and smooth muscle 
[133, 134] [136]. STARS, in part collaboration with RhoA, enhances the binding of 
free G-actin to F-actin filaments, resulting in enhanced or stabilized actin 
polymerization [133]. As a consequence there is a reduction in free G-actin, which 
permits the nuclear translocation of the transcriptional co-activator myocardin-
related transcription factor-A (MRTF-A) [160]. MRTF-A is a transcriptional co-
activator of serum response factor (SRF) [143], a transcription factor known to 
regulate genes involved in muscle metabolism and growth [138, 139] STARS gene 
expression is increased in rat heart during pressure overload [134] and its mRNA and 
proteins levels are increased in rabbit smooth muscle following fluid shear stress-
induced arteriogenesis [136]. Forced over expression of STARS causes cardiac 
hypertrophy in mice [178] and increases the proliferation of porcine smooth muscle 
cells [136]. STARS mRNA, as well as several members of the STARS signalling 
pathway, are upregulated in hypertrophied human skeletal muscle following 
increased muscle loading caused by resistance exercise training and downregulated 
following reduced training [166]. STARS has therefore been suggested to provide an 
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important link between the transduction of external stress to intracellular signalling 
pathways and the control of genes involved in the maintenance of muscle function 
[60, 133, 136]. 
 
Moderate intensity skeletal muscle contraction induced by endurance exercise has 
positive health implications for diseases such as diabetes, obesity and cardiovascular 
disease as well as maintaining skeletal function in the elderly [232-234]. It has 
recently been observed that endurance exercise increases the phosphorylation of SRF 
[235], a key downstream target of the STARS signalling pathway [133, 137]. 
Whether endurance exercise increases the levels of STARS, members of the STARS 
signalling pathway and/or downstream transcriptional targets involved in muscle 
metabolism and growth has not been investigated.  
 
The STARS gene has recently been identified as a transcriptional target of MEF2 in 
cardiac muscle [178] as well as MyoD in C2C12 myotubes [179].  Analysis of the 
human STARS promoter reveals also an estrogen-related receptor-α (ERRα) binding 
site, located -150 bp upstream of the transcriptional start site. ERRα, in combination 
with its transcriptional co-activator PGC-1α, is known to regulate genes involved in 
skeletal muscle function [236]. As both ERRα and PGC-1α are upregulated in human 
skeletal muscle following endurance exercise [237, 238], it is possible that STARS is 
a target of the PGC-1α/ERRα transcriptional program. 
 
Therefore the primary aim of the present study was to determine if STARS and 
members of its downstream signalling pathway, including MRTF-A and SRF, as well 
as several SRF target genes including CPT-1β, JUNB, α-actin, IGF-1, are up-
regulated following acute endurance exercise. A secondary aim was to determine if 
the STARS gene is regulated via PGC-1α /ERRα signalling. 
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2.2 Methods 
2.2.1 Subjects  
Nine healthy male subjects participated in the study: age 24 ± 5 years, weight 84 ± 
10 kg, single leg VO2 max 36.6 ± 3.8 ml.kg-1.min-1. The study was approved by the 
Deakin University Human Research Ethics Committee in accordance with the 
Declaration of Helsinki (2000). All participants gave their informed consent and 
agreed to muscle biopsies and physiological testing. 
  
2.2.2 Preliminary Testing 
Subjects were familiarised with the electromagnetically braked cycle ergometer 
(Lode B.V, Groningen, The Netherlands) and single leg cycling on two separate 
occasions prior to a single leg cycling VO2 peak test. The VO2 peak test involved single 
leg cycling at three incremental work rates of 65, 80 and 95 Watts (W) for 3 minutes 
followed by an increase of 15 W.min-1 until exhaustion.  Expired air was collected 
and analysed using zirconia cell O2 and infrared CO2 analysers (Applied 
Electrochemical Instrument, Pittsburgh, PA) that were calibrated against 0.01% 
alpha rated gases (Medgraphics, St Paul, MN). 
 
2.2.3 Experimental Procedure  
Subjects commenced the experimental trial one week after the VO2 peak test and 
abstained from strenuous exercise during this time.  For each testing session the 
subjects were required to report to the laboratory having fasted overnight and 
abstained from caffeine and alcohol consumption for 24 hours. On the first day of the 
trial a resting muscle sample (PRE) was obtained from the non-exercising (NEx) leg 
to avoid the potential influence of a stress response from the biopsy needle.  With the 
exercising (Ex) leg subjects then performed single leg cycling at 65% single leg VO2 
peak (95.9 ± 19.5 W) until exhaustion (1.2 ± 0.2 hours), which was determined by the 
subjects’ choice to cease cycling or by the subjects’ inability to maintain the required 
cadence. Muscle samples were taken from the Ex leg at 3 and 24 hours post exercise. 
 
2.2.4 Muscle Biopsies 
Skeletal muscle samples were obtained under local anaesthesia (1% Xylocaine) from 
the belly of the vastus lateralis muscle using a percutaneous needle biopsy technique 
[239] modified to include suction [240].  Following a small incision through the skin 
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muscle biopsies were taken using a Bergstrom needle, snap frozen and stored in 
liquid nitrogen until required for analysis. 
 
2.2.5 RNA Extraction 
Total RNA was extracted from 5-20 mg skeletal muscle samples using Tri-Reagent® 
Solution (Ambion Inc., Austin TX) according to the manufacturer’s protocol.  First-
strand cDNA was generated from 1 µg RNA in 20 µL reaction buffer using the AMV 
reverse transcriptase (RT) kit (Promega, Madison WI) and Random Hexomer 
primers (500 ng) (Promega, Madison WI) according to manufacturer’s protocol. 
 
2.2.6 Real Time Quantitative PCR 
Real-time PCR was carried out using either a 7500 Real-Time PCR system (Applied 
Biosystems, Forster City CA) or a Stratagene MX3000 PCR system (Agilent 
Technologies, Santa Clara, CA) system to measure mRNA levels of human and 
mouse genes of interest. To compensate for variations in input RNA amounts and 
efficiency of the reverse transcription, data were normalized to cyclophilin mRNA 
levels when assaying muscle biopsies, and ribosomal protein 36B4 (also known as 
RPLPO) RNA levels when assaying C2C12 cells. Details of the human and mouse 
PCR primers are provided in Table 2.1. 
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Table 2.1 Details of human and mouse primers used for RT-PCR analysis. 
 
 
2.2.7 Protein Extraction 
Nuclear and cytosolic proteins were extracted from skeletal muscle using the NE-
PER® Nuclear and Cytoplasmic extraction kit (Pierce Biotechnology, Rockford, IL) 
as performed previously by our group [166].  Exactly 2 µL of inhibitor cocktail, 
containing protease and phosphatase inhibitors (Sigma, St. Louis MO) at a ratio of 
1:1 per 20 mg of muscle sample was added before the extraction of both cytosolic 
and nuclear proteins.  In brief, the muscle samples were homogenised in the CER I 
solution provided in the NE-PER kit using a Polytron PT 1200C (Kinematica AG, 
Luzern, Switzerland).  The following steps were performed in accordance with the 
manufacturer’s protocol.  For myotubes total protein was extracted using 1x RIPA 
buffer (Millipore, North Ryde, NSW) with 1 µL/mL protease inhibitor cocktail 
(Sigma, Castle Hill, NSW) and 10 µL/mL Halt Phosphatase Inhibitor Single-Use 
Cocktail (Thermo Scientific, Rockford, IL). Total protein content was determined 
using the BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL) according to 
the manufacturer’s instructions. 
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2.2.8 Western Blotting 
Electrophoresis and protein transfer were performed using the XCell Surelock Novex 
Mini- Cell (Invitrogen, Carlsbad, CA) system.  Protein lysates were separated by 
SDS-PAGE using pre-cast NuPAGE® Novex 4 to 12% Bis-Tris gels (Invitrogen, 
Carlsbad, CA) and transferred to a PVDF membrane (Millipore, Billerica, MA). 
Membranes were then incubated at room temperature for 1 hour in blocking buffer 
(0.1% Tween 20–Tris-buffered saline (TBST)) supplemented with 5% gelatin.  After 
blocking, membranes were incubated overnight at 4 °C with the following primary 
antibodies diluted 1:1000 in 5% gelatin/TBST (STARS, Institute of Medical and 
Veterinary Science, Adelaide SA; SRF, Santa Cruz (sc-335), Santa Cruz, CA; 
MRTF-A, Santa Cruz (sc-32909), Santa Cruz, CA). Following washing the 
membranes were incubated for 1 hour with horseradish peroxidase-conjugated 
secondary antibody diluted 1:2000 in 5% gelatin/TBST. After washing, the specific 
proteins were revealed using ECL-Plus (GE Healthcare, Buckinghamshire, UK) and 
exposed on a Kodak 2000 mm image station (Eastman Kodak, Rochester, NY). 
Individual protein band optical densities were determined using ImageJ Software 
(National Institutes of Health, Bethesda, MA). Tubulin (cytoplasmic fractions) and 
Lamin A (nuclear fractions) as well as Ponceau staining (0.5% Ponceau-S (w/v), 1% 
acetic acid (v/v)) were used to control for protein loading as published previously by 
our group [166]. A representative blot is shown in supplementary Figure S2.1. 
Validation of our STARS antibody using siRNA knockdown of STARS and 
adenoviral over expression of STARS is shown in supplementary Figure S2.2. 
 
2.2.9 Immunofluorescence 
Immunfluorescence experiments for identifying fibre specific protein levels of 
STARS were performed as reported previously by our group [241, 242]. The 
antibodies raised against STARS, MHC type I and MHC type IIa were diluted 1:200, 
1:10 and 1:10, and visualized using a goat and –rabbit (IgG)- FITC, donkey anti-
mouse (IgM)-TRITC and a goat anti-mouse (IgGγ1)-Alexaflour 320, respectively. 
Negative controls, using only the secondary antibody, were also performed in 
parallel and on the same glass slide as the experimental samples. Sections were 
viewed and photographed using an Olympus IX70 fluorescent microsope and a 
Magna Fire camera with dedicated software.  Due to freezing artifacts only 6 of the 9 
subjects were analyzed. Between 80 and 120 fibres were visualized per subject. 
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2.2.10 Cell Culture - C2C12 myotubes 
C2C12 myoblasts (ATCC) were plated in 12-well or 6-well tissue culture plates in 
complete DMEM (10%FBS). As the cultures approached confluence (~90% 
confluent), media was changed to differentiation medium (DMEM) supplemented 
with 2% horse serum (HS).  Differentiation media was replaced on day 2, day 4, and 
day 6.  
 
2.2.11 Adenoviral infections  
For siERRα experiments, myotubes were infected with MOI 200 siERRα or vector 
control adenovirus on day 4 of differentiation.  On day 6 of differentiation, myotubes 
were infected with an additional dose of MOI 200 siERRα (or vector control) and 
MOI 50 of PGC-1α (tagged with a FLAG epitope) or LacZ (control) expressing 
adenovirus.  Twenty-four hours later, RNA or DNA was harvested for RT-qPCR 
gene expression analysis or ChIP analyses, respectively.  For expression of a 
constitutively active ERRα (VP16-ERRα), day 6 myotubes were infected with MOI 
50 of adenoviruses expressing LacZ (control) or VP16-ERRα [243]. RNA was 
harvested 24 hours later.  
 
2.2.12 siRNA knock down of STARS combined with PGC1α over-expression 
STARS knockdown in C2C12 myotubes was achieved using 100 pmol of Stealth 
RNAi™ siRNA (target sequence; 5′-ACCAGAACGGTTGTCAGCAAGGCTT -3′; 
Invitrogen, Melbourne, Australia) over a 72 hour period. Stealth RNAi™ siRNA 
Negative Control Hi GC (Invitrogen, Melbourne, Australia) was used as the control 
siRNA, which contains the same GC content as the target sequence. siRNA 
transfection of C2C12 myotubes was performed using 5 μl Lipofectamine 2000 
(Invitrogen, Melbourne, Australia).  Twenty-four hours after transfection, the C2C12 
myotubes were infected with either a GFP (control) or PGC-1α adenovirus at a MOI 
of 25 for a further 48 hours.   
 
2.2.13 Chromatin Immunoprecipitation (ChIP) 
ChIP was performed on adenovirus-transduced C2C12 myotubes as described 
previously [238].  Briefly, C2C12 myotubes were crosslinked for 10 minutes at 37º 
in 1% formaldehyde in PBS.  After quenching, sonication to ~500 bp fragments, and 
pre-clearing by treatment with protein A/G sepharose, soluble chromatin was 
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immnuoprecipitated with the following antibodies: anti-GFP (control), anti-FLAG 
(clone M2) for the detection of FLAG-Tagged PGC-1α, or anti-ERRα (a generous 
gift of Dr. V. Giguere [244]).  Genomic DNA (gDNA) from each 
immunoprecipitation was quantified by real-time PCR, using primers 
(TCTCCTCCAAGTGCCAGAGT and AGCTGTATTGAGGGCTACCG) to amplify 
an ERR response element (ERRE) 272 bp upstream of Stars, as well as primers 
specific to the ERR response element -containing region of the Esrra gene (positive 
control) and a region that lacks ERREs, distal to the Esrra promoter (negative 
control) (primers described in [245]).  Data were normalized first against total 
genomic input and then expressed relative to levels of immunoprecipitated DNA 
from the ERRα negative control region [245].  Values shown are the mean and 
standard deviation of three independent experimental replicates. 
 
2.2.14 Statistics 
Differences between time were determined using a one-way ANOVA. Experiments 
combining over expression and knockdown of targets were analysed using a two-way 
ANOVA. The level of significance was set at p < 0.05. Where required a post-hoc 
analysis was performed using either paired or unpaired t-tests with a Bonferroni 
adjustment. 
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2.3 Results 
2.3.1 Expression of STARS pathway members are increase following acute 
endurance exercise 
STARS mRNA (Figure 2.1A) and protein levels (Figure 2.1B) were increased by 
140% and 40% respectively (P<0.05) when measured 3 hours post exercise, with 
both returning to near basal levels 24 hrs post exercise. MRTF-A nuclear protein 
content increased by 34% (P<0.05) 3 hrs post exercise and returned to basal lines 
levels 24 hrs post-exercise (Figure 2.1C). SRF nuclear protein content also increased 
by 39% when measured 3 hrs post exercise (P<0.05), however it remained elevated 
24 hrs post-exercise (P<0.01) (Figure 2.1D).  
 
 
Figure 2.1 Effect of acute endurance exercise on the levels of (A) STARS mRNA, (B) STARS 
protein and (C) MRTF-A and (D) SRF nuclear protein. Pre, before exercise; 3 hrs, 3 hours post 
exercise; 24 hrs, 24 hours post exercise. Significantly different from the other groups, *, P < 0.05; 
significantly different from pre, **, P < 0.01. 
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2.3.2 SRF target genes and PGC-1α and ERRα are up-regulated following acute 
endurance exercise  
Levels of the SRF targets genes, CPT-1β (Figure 2.2A) and JUNB (Figure 2.2B) 
mRNA increased by 2.3 and 1.8-fold (P<0.05) respectively, 3 hrs post exercise and 
returned to baseline levels 24 hrs post exercise. No change in other SRF target genes, 
α-actin (Figure 2.2C) or IGF-1 (Figure 2.2D) mRNA was observed. PGC-1α (Figure 
2.2E) and ERRα (Figure 2.2F) mRNA were also increased 4.5-fold and 2.7-fold, 
respectively 3 hrs post exercise and returned to baseline levels 24 hrs post exercise; a 
response mirroring that of STARS, CPT-1β and JUNB mRNA.  
 
 
Figure 2.2 Effect of acute endurance exercise on CPT-1β, (B) JUNB, (C) α-ACTIN, (D) IGF-1, (E) 
PGC-1α and (F) ERRα mRNA levels. Pre, before exercise; 3 hrs, 3 hours post exercise; 24 hrs, 24 
hours post exercise. Significantly different from the other groups; *, P < 0.05; **, P < 0.01. 
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2.3.3 STARS expression is regulated by PGC-1α/ERRα 
As PGC-1α is known to transcriptionally regulate CPT-1β [246], it was of interest to 
determine if STARS could also be regulated via a PGC-1α/ERRα transcriptional 
program. Infection of C2C12 myotubes with an adenovirus expressing human PGC-
1α resulted in a 3-fold increase in Stars mRNA (P<0.01) (Figure 2.3A). This was 
abolished when the myotubes were infected with PGC-1α as well as an adenovirus 
containing an siRNA sequence against ERRα (Figure 2.3A). Additionally, 
expression of a constitutively active form of ERRα, VP-16 ERRα, resulted in a 7-
fold increase in Stars mRNA (p<0.01) (Figure 2.3B). 
 
 
Figure 2.3 Stars is regulated via the PGC-1α / ERRα transcriptional program in C2C12 myotubes.  
(A) Stars mRNA levels 24 hours after expression of LacZ (control) or PGC-1α, in the absence or 
presence of siRNA against ERRα (siERRα). N = 6 per group (duplicate samples from 3 separate 
experiments). (B) Stars mRNA levels 24 hours after expression of LacZ (control) or the constitutively 
active VP16-ERRα. N=4 per group. Significantly different from the other groups; **,  P < 0.01. 
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2.3.4 ERRα is essential for the recruitment of the PGC-1α to the STARS promoter 
To test if ERRα and PGC-1α act directly at the Stars gene to induce its expression, 
we asked whether ERRα and PGC-1α interact physically with the Stars promoter. 
Analysis of the Stars genomic sequence indicated a putative ERRα binding site 
matching the known 9 bp ERRE consensus 5’-TNAAGGTCA-3’ [244] and 
conserved across species (Figure 4A). To determine binding of endogenous ERRα 
and exogenous adenovirally-expressed PGC-1α at this region, we 
immunoprecipitated crosslinked chromatin with antibodies against either GFP 
(control antibody measuring background), FLAG-tagged PGC-1α or ERRα, and 
measured the enrichment of the Stars locus DNA in the immunoprecipitated 
material. Both PGC-1α and ERRα were detected at the Stars ERRE (Figure 4B), as 
well as at the previously defined ERRE of the Esrra gene that was used as positive 
control (Figure 4C). ERRα was detected at the Stars locus only when PGC-1α was 
expressed, i.e. when endogenous ERRα levels were induced [238].  Knockdown of 
endogenous ERRα expression by siERRα ablated binding of PGC-1α to the Stars 
ERRE (Figure 4B), demonstrating a critical role for ERRα in recruitment of the 
PGC-1α coactivator to the Stars promoter. 
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Figure 2.4 PGC-1α and ERRα bind an ERRE upstream of Stars in C2C12 myotubes.  (A), a 
University of California, Santa Cruz (UCSC) genome browser screenshot depicting the presence of an 
ERRE (at 272 bp 5’ of the Stars transcription site and its conservation across species. Occupancy of 
PGC-1α and ERRα at the Stars (B) and Esrra (positive control) (C) ERREs, as determined by ChIP 
assays in C2C12 myotubes expressing LacZ (control) or PGC-1α, in the absence (Super) or presence 
of siRNA for ERRα (siErrα). Data are expressed relative to a region devoid of ERREs and are the 
mean ± SD of triplicates. **, P < 0.01, significantly different from all treatments within the group. 
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2.3.5 STARS is predominately expressed in type I and type IIa fibres 
In human skeletal muscle we have previously shown that PGC-1α protein levels are 
greater in oxidative type I and oxidative-glycolytic type IIa fibres, than in glycolytic 
type IIx fibres [192]. Using immunofluorescence staining we observed that STARS 
protein levels are also predominately expressed in oxidative type I and oxidative-
glycolytic type IIa fibres when compared with glycolytic type IIx fibres (Figure 5A 
and B). STARS was also expressed in the myonuclei as shown via its co-localization 
with the DAPI stain (Figure 5C-E). Due to limited nuclear protein extracts STARS 
nuclear protein content could only be measured in 6 of the 9 subjects. Following 
exercise 5 of 6 subjects showed an increase in STARS nuclear protein levels. 
Although the increase was by 60% this did not reach statistical significance (Figure 
5F).  
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Figure 2.5 The STARS protein is more abundantly expressed in oxidative type I and oxidative-
glycolytic type IIa fibres, than in glycolytic type IIx fibres and is also found in the nucleus. 
Immunofluorescence staining of the (A) STARS protein and (B) MHCI (Red; oxidative type I) and 
MHCIIa (Blue; oxidative-glycolytic type IIa ) and MHCIIx (Not stained; glycolytic type IIx). The 
same fibres to the marks of I, IIa or IIx in figures A and B. (C), DAPI stain, (D) STARS stain and (E) 
their co-localization, respectively, is shown in the section. Arrows represent colocalization of the 
nuclei and STARS. (F), Western blot showing the STARS protein levels in nuclear protein fraction 
before, 3hrs after and 24 hrs post exercise. 
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2.3.6 STARS knockdown reduces PGC-1α up-regulation of Cpt-1β 
As PGC-1α is known to regulate genes involved in mitochondrial biogenesis, 
angiogenesis and oxidative phosphorylation it was of interest to see if knock-down of 
STARS could ablate this response. In C2C12 myotubes PGC-1α over expression 
resulted in a 2.0-fold increase in Cox4 and Vegf mRNA; an effect not influenced by 
the knockdown of STARS. PGC-1α over expression also increased Cpt-1β mRNA by 
6.6-fold. However, the endogenous knockdown of STARS significantly reduced the 
basal levels of Cpt-1β mRNA levels by 8.2-fold and ablated the PGC-1α-induced 
increase in Cpt-1β mRNA (Figure 6). 
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Figure 2.6 Regulation of (A) Cox4,  (B) Cpt-1β  and (C) Vegf mRNA  by  PGC-1α with and without 
STARS knockdown in C2C12 myotubes.  N = 6 per group (duplicate samples from 3 separate 
experiments). Significantly different from the other groups; **,  P < 0.01. 
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2.4 Discussion 
Identifying the molecular targets and intracellular signals activated by endurance 
exercise will significantly enhance our understanding of how skeletal muscle adapts 
to increased contractile load and may identify potential therapeutic targets to combat 
diseases characterized by perturbed skeletal muscle metabolism, growth and 
regeneration.  The present study demonstrates several new and important findings, 
which are summarized in Figure 2.7. Firstly, we show for the first time that an acute 
bout of single-leg endurance exercise is sufficient to induce an increase in STARS 
mRNA and protein levels; secondly, the response of STARS is paralleled by an 
increase in the nuclear protein content of several key members of the STARS 
signaling pathway, MRTF-A and SRF; thirdly, in C2C12 myotubes the STARS gene 
is a target of the PGC-1α/ERRα transcriptional complex; and finally, the presence 
STARS appears to be required for the PGC-1α regulation of the CPT-1β gene in 
C2C12 myotubes. 
 
 
Figure 2.7 A diagram summarizing the main findings from the study. STARS is transcriptional target 
of PGC-1α / ERRα signaling. Acute endurance exercise increase STARS mRNA and protein levels as 
well as the nuclear translocation of the transcriptional co-activator MRTF-A and its target 
transcription factor SRF. Increased nuclear abundance of MRTF-A and SRF should increase the 
potential for SRF target transcription. 
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STARS, an actin-binding protein, is considered to communicate mechanical stress 
signals to downstream transcriptional regulators, such as MRTF-A and SRF, via its 
influence on actin dynamics [133, 137]. SRF is known to regulate genes involved in 
muscle structure, function and growth such as α-actin, MHC, IGF and JUNB [138, 
139, 247] as well as fat metabolism, such as CPT-1β [248]. Therefore, STARS may 
be an upstream regulator of signals controlling the expression of genes which encode 
proteins involved in muscle function, growth and metabolism.  In support of this 
notion forced over expression of STARS in vivo [178] and in vitro [194] results in 
hypertrophy of cardiac tissue and protects against apoptosis. Additionally, we have 
recently shown that the STARS signalling pathway is increased in hypertrophied 
human skeletal muscle following resistance exercise [166]. In contrast, STARS and 
several members of its signalling pathway are reduced in skeletal muscle of 
sarcopenic mice [200] and after 1 day of limb immobilization in rats [198]. However, 
after 20 days of limb immobilization in humans there were no observed changes in 
STARS [199]. The results from the present study show that acute moderate-intensity 
exercise results not only in increased levels of STARS mRNA but also the STARS 
protein. Combined, these observations suggests that the regulation of STARS is rapid 
and transient which is a logical regulatory response for a protein believed to be 
responsible for the sensing and transmission of extracellular stress signals. It should 
be noted that this is the first measurement of endogenous STARS protein levels and 
shows, at least in the present experimental model, that the regulation of STARS 
mRNA is closely mirrored by the regulation of its protein. 
     
In parallel with the increase in STARS, we show for the first time that both MRTF-A 
and its transcriptional target SRF have enhanced nuclear abundance following 
endurance exercise; a response consistent with enhanced STARS activity [137]. 
These results support our previous observation following high-intensity resistance 
training [166].  Along similar lines, endurance exercise training has also been shown 
to increase SRF activity, as shown by enhanced phosphorylation levels, in human 
skeletal muscle [235].  In the present study, we also observed an increase in the SRF 
target genes CPT-1β, a regulator of long-chain fatty acid β-oxidation and JUNB, a 
cell-cycle and growth regulator, but not the expression levels of α-actin and IGF-1, 
genes involved in structure and growth. While these results suggest that both 
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moderate and intense exercise elicits stress signals that can be detected by STARS 
and transmitted downstream to its effector targets, such as MRTF-A and SRF, their 
transcriptional control might be dependent on the exercise intensity. For example, 
SRF is known to regulate over 200 genes, many of which are involved in muscle 
structure, function, growth and regeneration [138, 139] but not all are regulated at the 
same time. The selective regulation of certain SRF target genes might be attributed to 
their sensitivity to the stress signals initiated by the acute nature of the endurance 
exercise protocol.  
 
While we show here that endurance exercise, and previously that resistance exercise 
[166], regulates STARS transcription and translation, the exact stress signals 
initiating this are unknown. During exercise, numerous stress signals are initiated by 
changes in motor nerve activation and calcium concentrations, mechanical and 
contractile stress, increased muscle blood flow and shear stress, hormonal and 
metabolic stress, which are known to activate intracellular signalling pathways 
controlling skeletal muscle gene transcription and translation [60, 61, 249-251]. 
Identifying the primary stressor/s activated by endurance exercise which regulate 
STARS, and consequently its downstream signalling pathway, is beyond the scope of 
this study, however, this should be an area investigated in the future.  
 
Our observation that STARS is increased in response to moderate intensity 
endurance exercise suggests that the STARS signalling pathway may also play a role 
in skeletal muscle adaptations associated with endurance exercise such as substrate 
oxidation, capillary function and mitochondrial biogenesis; factors often perturbed in 
metabolic diseases [252]. Indeed SRF, a downstream target of STARS signalling, has 
also been shown to control the transcription of CPT-1β [248], a regulator of fat 
metabolism, as well as vascular endothelial growth factor (VEGF), a regulator of 
angiogenesis [253]. Another commonalty between CPT-1β and VEGF is that they 
can also be regulated by the transcriptional co-activator PGC-1α [246, 254].  PGC-1α 
is upregulated in human skeletal muscle in response to both moderate and high 
intensity endurance exercise [192, 237, 238]. PGC-1α co-activates several 
transcription factors that regulate genes involved in skeletal muscle substrate 
oxidation and mitochondrial biogenesis [236, 255]. We identified that one of these 
transcription factors, ERRα, has a binding site on the STARS promoter. Therefore, 
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we performed in vitro experiments using C2C12 myotubes whereby we manipulated 
PGC-1α and ERRα levels using adenoviral infection. Our results demonstrate that 
STARS is a transcriptional target of the PGC-1α/ERRα transcriptional program.  
 
Previous work by our group has shown that in human skeletal muscle PGC-1α 
protein levels are greater in oxidative type I and oxidative-glycolytic type IIa fibres, 
than in glycolytic type IIx fibres [192]. In the present study, we also observed a 
similar fibre type expression for the STARS protein. In addition to this, we observed 
that the STARS protein was also localized to the nucleus, which supports 
observations made in transiently transfected COS cells [133] and in rat endothelial 
cells [136]. The PGC-1α regulation of STARS, their similar fibre type expression 
profile, as well as the localization of STARS in the nucleus, suggested to us that a 
PGC-1α/STARS transcriptional relationship may exist. Our observation that the 
knock-down of endogenous STARS reduces CPT-1β mRNA and attenuates the 
PGC-1α upregulation of CPT-1β mRNA supports this possibility. However, it 
remains to be determined whether STARS has the capacity to directly bind DNA or 
whether it’s down regulation impacts indirectly on transcriptional signalling 
pathways; potentially through SRF. These in vitro results, combined with our 
observation of increases in PGC-1α and ERRα mRNA following acute endurance 
exercise, suggests that a possible feed-forward loop involving SRF, PGC-1α, ERRα 
and STARS may exist during moderate-intensity muscle contraction which controls 
oxidative metabolism and muscle function. In contrast to the increase in these genes 
following exercise, skeletal muscle SRF, PGC-1α and STARS are all reduced in 
conditions such as ageing [200, 256, 257] and limb immobilization [198, 258]; 
situations that present reduced skeletal muscle mass, function and attenuated 
metabolism. The possible existence of this novel transcriptional pathway requires 
further investigation. 
 
In conclusion, we show for the first time that STARS mRNA and protein as well as 
MRTF-A and SRF nuclear content are increased following endurance exercise. 
Additionally, we have identified the STARS gene as a PGC-1α/ ERRα 
transcriptional target and a gene which may be involved the regulation of oxidative 
metabolism. Future investigations should focus on STARS and its downstream 
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signalling pathway on the regulation of skeletal muscle oxidative function, 
potentially via its influence on actin polymerization. 
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2.5 Supplementary Figures 
 
Figure S2.1 Comparison of protein loading using (A) Ponceau staining and LaminA for nuclear 
protein extracts and (B) Ponceau staining and Tubulin for cytoplasmic protein extracts. 
 
 
 
Figure S2.2 Validation of the STARS antibody. (A), C2C12 myotubes were transfected with a control 
siRNA scramble sequence or a siRNA STARS sequence which reduced the amount of STARS protein 
as determined by western blot. C2C12 myotubes were also infected with a control adenovirus 
containing LACZ or an adenovirus containing STARS which increased the amount of STARS protein 
as determined by western blot. Tubulin is shown as a normalizing protein indicating equal protein 
loading. (B), Western blot showing that our STARS antibody recognizes the STARS protein in human 
and mouse skeletal muscle as well as in human primary myotubes and C2C12 mouse myotubes. 
Protein extraction, quantification, normalization and Western blotting was performed as mentioned in 
the methods section. 
 
 
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2.6 Supplementary Methods 
2.6.1 Preparation of human primary myotubes 
A human primary muscle culture was used in the validation of our STARS antibody. 
A muscle biopsy sample ( ~150 mg; as mentioned in the methods) from a healthy 
young male was used to prepare a primary human muscle culture, as published by 
our group previously [259] but with minor modifications. In brief, the excised 
muscle was immersed, extensively washed then minced in ice-cold Hams F-10 
medium. The minced tissue was then digested in 25 ml of 0.05% Trypsin/EDTA at 
37°C with agitation for 20 min to release the myoblasts. The supernatant containing 
the myoblasts was then collected. This process was repeated a further two times to 
breakdown any remaining tissue, followed by the addition of 10% HS. Connective 
tissue was removed by filtering the supernatant through a pre-wet 74 µm (15 mm 
diameter) filter followed by centrifugation for 10 min at 1600 rpm. The cell pellet 
was re-suspended in Hams F-10 medium containing 20% FBS, 25 ng/ml bFGF, 
0.05% pen/strep and 0.05% amphoterecin (human growth media). The cells were 
then seeded on to an uncoated 25 cm2 flask and incubated at 37°C for 30 min to 
induce fibroblast attachment, leaving myoblasts suspended in the medium. The 
medium was aspirated and this process was repeated for another 30 min. The 
medium was then aspirated and seeded on to 25 cm2 flask coated with an 
extracellular matrix (ECM). The resulting primary cell cultures were maintained in 
the human growth media in humidified air at 37°C and 5% CO2.  At 70% confluence 
differentiation was induced by the Hams F-10 medium with 2% HS for 7-10 days. 
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CHAPTER 3 
 
STARS INCREASES SKELETAL MUSCLE CELL PROLIFERATION AND 
DIFFERENTIATION 
 
 
This work is currently in preparation for submission to the Journal of Molecular and Cell Biology 
 
Abstract 
Skeletal muscle regeneration is dependent on the activation of satellite cells, the 
subsequent proliferation of myoblasts, followed by their myogenic differentiation 
and fusion with existing muscle fibres.  Skeletal muscle cell proliferation and 
differentiation is controlled and coordinated by multiple signalling pathways and 
transcription factors.  The striated muscle activator of rho signalling (STARS), a 
muscle specific actin binding protein, stimulates actin polymerization and influences 
SRF and PGC-1α transcription of genes involved in muscle cell growth, structure 
and function. The role of STARS in skeletal muscle cells is not well understood. 
Therefore, this study determined whether STARS regulated muscle cell proliferation 
and differentiation. The influence of STARS on SRF, PGC-1α and ERRα target 
genes involved in muscle cell growth, contraction and metabolism was also 
investigated. STARS overexpression enhanced myoblast proliferation and was 
associated with increases in SRF target genes Il-6, c-fos, and Junb and decreases in 
cell cycle regulators, Cyclin d1, p21 and p27. STARS overexpression also enhanced 
myogenic differentiation and increased the mRNA expression of differentiation 
markers, Ckm and myosin heavy chain. STARS overexpression increased the mRNA 
levels of several SRF target genes including α-actin and Mhc2b and the PGC-
1α/ERRα target genes including Mhc2a, Cpt-1β and Ckmt2 during myoblast 
differentiation. As STARS is a muscle specific protein that activates skeletal muscle 
cell proliferation and differentiation, it maybe a future therapeutic target to enhance 
skeletal muscle repair and regeneration following damage. 
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3.1 Introduction 
Pre and post natal skeletal muscle development, as well as regeneration of mature 
adult skeletal muscle, requires the coordinated control of myoblast proliferation and 
differentiation [260, 261]. Myogenic regulatory factors (MRFs) are basic helix-loop-
helix (bHLH) E-box binding proteins [262]. They consist of Myf5 and MyoD that 
control myoblast proliferation and specification [16, 263], and MRF4 and myogenin 
that control terminal differentiation [25, 263]. Two MADS box proteins, myocyte 
enhancer factor 2 (MEF2) and serum response factor (SRF), interact with MRFs to 
further enhance myoblast proliferation and differentiation [212, 262, 264].  SRF 
regulates cytoskeletal dynamics, myogenic expression, cell proliferation and 
differentiation via its transcription of immediate early genes such as c-fos, junB, and 
Egr-1, as well as muscle specific genes such as actin and myosin [138, 212, 213].  
Attenuating SRF activity disrupts myoblast proliferation and differentiation [211] 
while SRF knockdown impairs skeletal muscle development in vivo [168, 172]. 
Understanding the molecular factors that may regulate SRF activity is important for 
understanding skeletal muscle development and regeneration. 
 
Striated muscle activator of Rho signalling (STARS) (also known as ms1, and Abra), 
is a muscle specific actin binding protein that associates with the I-band, Z-disk and 
M-line of the sarcomere [133]. STARS increases actin polymerization resulting in 
the nuclear translocation of the SRF transcriptional co-activator myocardin-related 
transcription factor-A (MRTF-A) and enhanced SRF transcriptional activity [133, 
137].  STARS is up-regulated in rodent cardiac muscle in response to pressure 
overload and in rabbit smooth muscle following fluid shear-induced arteriogenesis 
[134, 136, 178]. In human skeletal muscle, we and others have shown that STARS is 
increased in response to resistance exercise training and acute endurance and 
eccentric exercise [166, 197, 205].  These studies suggest that STARS may act as a 
sensor to transduce extracellular mechanical stress signals to activate the molecular 
pathways regulating skeletal muscle development, growth and regeneration. 
 
STARS is transcriptionally regulated by MEF2, MyoD, PGC-1α/ERRα and SRF, 
transcription factors involved in skeletal muscle cell proliferation and differentiation 
[178-180, 205-208]. STARS overexpression also results in its auto-regulation via a 
feed-forward mechanism that requires SRF binding to the serum response element 
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(SRE) on the STARS promoter [180]. As there are functional SRE binding sites on 
the PGC-1α promoter [265] STARS overexpression may result in an SRF-mediated 
upregulation of PGC1α and ERRα, factors involved in myotube differentiation and 
myosin heavy chain regulations [185, 187, 243, 266, 267], however this has not been 
investigated. STARS is expressed in skeletal muscle during early embryonic 
development and continues to increase during post-natal muscle development [133, 
135, 180]. STARS is also more highly expressed in terminally differentiated skeletal 
myotubes when compared to proliferating myoblasts [179], suggesting that it may 
play a role in skeletal muscle proliferation and differentiation. Overexpression of 
STARS in porcine smooth muscle cells and in the A10 rat vascular smooth muscle 
cell line increases proliferation [136]. However, STARS does not increase 
proliferation of porcine aortic endothelial cells [136] or the H9c2 rat cardiac cell line 
[194]. These results suggest that the role of STARS may be dependent on muscle cell 
type.  Presently, the role of STARS in skeletal muscle cell proliferation and 
differentiation has not been investigated.  
 
Therefore, the aim of the present study is to examine the effect of STARS 
overexpression on skeletal muscle cell proliferation and differentiation in vitro. A 
secondary aim is to determine whether increasing STARS influences several SRF 
target genes involved in myoblast proliferation and differentiation, including c-fos, 
JunB, α–actin, and myosin heavy chain isoforms. Finally, it was of interest to 
determine if STARS overexpression also increases PGC-1α and ERRα target genes. 
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3.2 Methods 
3.2.1 Construction of pFLAG-mSTARS expression vector 
The cDNA for mouse STARS was subcloned into the pFLAG-CMV4 (Sigma-
Aldrich, Castle Hill, NSW) mammalian expression plasmid and was designated 
pFLAG-mSTARS. The DNA template used to produce the mouse STARS DNA 
fragment was the pBluescript-mouseSTARS plasmid, which was previously cloned 
by our group. Polymerase chain reaction (PCR) using specifically designed primers 
(Geneworks, Hindmarsh, SA) was performed to amplify the mouse STARS DNA 
sequence and incorporate the desired restriction enzyme sites, EcoRI and BamHI. 
PCR products were separated on a 1.0% agarose gel and the ~1000 base mouse 
STARS DNA fragment was extracted and purified using a QIAquick Gel extraction 
Kit (QIAGEN, Doncaster, Vic). The mouse STARS DNA fragment and pFLAG-
CMV4 plasmid were digested using the EcoRI and BamHI restriction enzymes 
(NEB, Ipswich, MA) and subsequently ligated to produce the pFLAG-mSTARS 
plasmid. Amplification of pFLAG-mSTARS was achieved by transformation into 5-
α Competent E. coli (High Efficiency) cells (NEB, Ipswich, MA) and plasmid DNA 
extraction and purification was performed using a QIAGEN plasmid kit (QIAGEN, 
Doncaster, VIC). Finally, automated sequencing (Applied Genetic Diagnostics, 
Parkville, VIC) was performed and no mutations were observed. A full explanation 
of cloning methods is provided in the supplementary methods section. 
 
3.2.2 Transient Transfection with pFLAG-mSTARS 
C2C12 myoblasts were plated onto 6-well plates or 35mm µ-Dishes (ibidi, Munich, 
Germany) at a density of 1.5-2.0 x 104 cells per well in complete DMEM (10% FBS) 
and were allowed to attach overnight.  Myoblasts were transiently transfected with 
pFLAG-mSTARS or pFLAG-CMV4 (Sigma-Aldrich, Castle Hill, NSW) plasmid 
using Lipofectamine 2000 (Life Technologies, Mulgrave, VIC).  Briefly, 2 µg of 
plasmid and 4 µL Lipofectamine 2000 was used to transfect each well or dish. 
Myoblasts were exposed to transfection reagents for 24 hours, following this 
myoblasts were incubated in complete DMEM (10% FBS) for 48 hours. Cell 
proliferation was determined by immunofluorescence analysis, RNA and protein was 
harvested for RT-PCR gene expression and western blot analysis. 
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3.2.3 Immunofluorescence 
To determine myoblast proliferation C2C12 myoblasts were incubated with 0.1 
μg/ml 4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich, 
Castle Hill, NSW) stain for 10 minutes at room temperature. Cell images were 
obtained using the Olympus Fluoview FV10i confocal laser scanning microscope 
with dedicated software at a 10x magnification. A minimum of 10 images per group 
were analysed using ImageJ Software (National Institutes of Health, Bethesda, MA) 
to quantify the number of nuclei per image.  
 
3.2.4 Adenoviral Infection with ADV-STARS 
Adenoviral constructs containing mouse STARS (ADV-STARS) or control gene 
LacZ (ADV-LacZ) were a generous gifts from Eric N. Olson, The University of 
Texas Southwestern Medical Center.  Details of adenoviral amplification, 
purification and titration are provided in the supplementary method section. C2C12 
myoblasts (ATCC) were plated in 6-well tissue culture plates in complete DMEM 
(10%FBS) and allowed to reach ~90% confluence.  Cells were infected with MOI 
100 ADV-STARS or vector control adenovirus (ADV-LacZ) in differentiation 
medium (DMEM) supplemented with 2% horse serum (HS). Cells were allowed to 
differentiate for 5 days and media was replaced every 48 hours. RNA and protein 
were harvested each day of the differentiation process (D1 to D5) for RT-PCR gene 
expression and western blot analysis.  Cell images were captured with an Olympus 
Color View III camera on an Olympus IX51 microscope using dedicated software. 
 
3.2.5 RNA Extraction 
Total RNA was extracted using Tri-Reagent® Solution (Ambion Inc., Austin TX) 
according to the manufacturer’s protocol.  First-strand cDNA was generated from 1-
2 µg RNA in 20 µL reaction buffer using High Capacity RNA-to-cDNA kit (Applied 
Biosystems, Forster City, CA) according to manufacturer’s protocol. Before diluting 
cDNA, 1 µL ribonuclease H (RNase H) (Life Technolgies, Mulgrave, VIC) was 
added to each sample and incubated at 37 °C for 30 minutes. Following this, cDNA 
was diluted in NFW to 5 ng/µL and stored at -20 °C until further analysis. 
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3.2.6 Real time quantitative PCR 
Real-time PCR was carried out using the Stratagene MX3000 PCR system (Agilent 
Technologies, Santa Clara, CA) to measure mRNA levels of genes of interest. To 
compensate for variations in input RNA amounts and efficiency of the reverse 
transcription, data was normalized to ribosomal protein 36B4 (also known as 
RPLPO) mRNA levels or single-stranded DNA (ssDNA) content that was 
determined using the Quanti-iT OliGreen ssDNA Assay Kit (Molecular Probes, 
Eugene, OR). PCR primer details for the mouse genes are provided in Table 3.1. 
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Table 3.1 Details of mouse primers used for RT-PCR analysis. 
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3.2.7 Protein Extraction 
Total protein was extracted using 1x RIPA buffer (Millipore, North Ryde, NSW) 
with 1 µL/mL protease inhibitor cocktail (Sigma-Aldrich, Castle Hill, NSW) and 10 
µL/mL Halt Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific, 
Rockford, IL). Total protein content was determined using the BCA Protein Assay 
Kit (Pierce Biotechnology, Rockford, IL) according to the manufacturer’s 
instructions. 
 
3.2.8 Western blotting 
Electrophoresis and protein transfer were performed using the XCell Surelock Novex 
Mini- Cell (Invitrogen, Carlsbad, CA) system.  Protein lysates were separated by 
SDS-PAGE using pre-cast NuPAGE® Novex 4 to 12% Bis-Tris gels (Invitrogen, 
Carlsbad, CA) and transferred to a PVDF membrane (Millipore, Billerica, MA). 
Membranes were then incubated at room temperature for 1 hour in blocking buffer 
supplemented with 5% BSA/PBS.  After blocking, membranes were incubated 
overnight at 4 °C with the following primary antibodies diluted 1:1000 in 5% 
BSA/PBS (STARS, Institute of Medical and Veterinary Science, Adelaide SA; 
Myosin heavy chain (A4.1025), Developmental Studies Hybridoma Bank, Iowa City 
IA). Following washing the membranes were incubated for 1 hour with infrared dye-
conjugated secondary antibodies (Thermo Fisher Scientific, Inc, Rockford, IL). After 
washing, the specific proteins were revealed using Odyssey Imaging System (LI-
COR, Lincoln, NE, USA). GAPDH was used to control for protein loading and 
individual protein band optical densities were determined using ImageJ Software 
(National Institutes of Health, Bethesda, MA).  
 
3.2.9 Statistics 
Differences in STARS expression during myoblast differentiation were determined 
using a one-way ANOVA. Overexpression experiments in proliferating C2C12 
myoblasts were analysed using a two-tailed unpaired t-Test, whilst overexpression 
experiments during myoblast differentiation were analysed using a two-way 
ANOVA. The level of significance was set at p < 0.05. Where required a post-hoc 
analysis was performed using unpaired t-tests with a Bonferroni adjustment. 
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3.3 Results 
3.3.1 STARS expression is increased during myogenic differentiation 
Stars mRNA (Figure 3.1A) levels were increased by 53% in confluent C2C12 
myoblasts (D0) when compared to sub-confluent myoblasts (MB), however no 
differences were observed in STARS protein levels (Figure 3.1B).  Stars mRNA 
levels continued to increase during 5 days of differentiation (Figure 3.1C). By D1 
Stars mRNA levels increased by 7.6-fold when compared to D0. Each sequential day 
saw a doubling of Stars mRNA levels and at D5 was increased by 80-fold when 
compared to D0.  STARS protein levels were significantly augmented at D2 when 
compared to D0 (Figure 3.1D).  By D3 STARS protein had increased 3-fold and 
started to decline at D4 and D5 following differentiation, but still remained higher 
than D0. 
 
 
Figure 3.1 Analysis of STARS expression during myogenic proliferation and differentiation of 
C2C12 cells. (A) Stars mRNA and (B) STARS protein expression in sub-confluent myoblasts (MB) 
and confluent myoblasts (D0). *, P<0.05, significantly different from MB; N=6 per group. (C) Stars 
mRNA and (D) STARS protein levels in confluent myoblasts (D0) and at day 1 to 5 (D1 to D5) 
following C2C12 myoblast differentiation.  *, P<0.05, significantly different from D0; N = 6 per 
group (triplicate samples from 2 separate experiments).  
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3.3.2 STARS overexpression in proliferating C2C12 myoblasts 
STARS was overexpressed in proliferating C2C12 myoblasts by transfection with a 
pFLAG-mSTARS (STARS) mammalian expression plasmid for 48 hours; pFLAG-
CMV4 was used as the transfection control.   This resulted in a 4.5 and 1.6-fold 
increase in Stars mRNA (Figure 3.2A) and STARS protein (Figure 3.2B) levels, 
respectively. 
 
 
Figure 3.2 STARS overexpression in proliferating C2C12 myoblasts.  (A) Stars mRNA and (B) 
STARS protein levels 48 hours after transfection with pFLAG-CMV4 (Control) or pFLAG-mSTARS 
(STARS). N = 6 per group (triplicate samples from 2 separate experiments). * P<0.05, significantly 
different from Control. 
 
 
3.3.3 STARS increases C2C12 myoblast proliferation 
To investigate whether STARS overexpression triggered an increase in the 
proliferation of C2C12 myoblasts cell number was counted following DAPI staining 
of the nuclei. Forty-eight hours after transfection of the pFLAG-mSTARS expression 
plasmid an increase in the number of C2C12 myoblasts was observed (Figure 3.3A). 
Quantification of the number of nuclei per visual field revealed a 1.8-fold increase in 
the number of DAPI stained nuclei in the myoblasts transfected with the pFLAG-
mSTARS expression plasmid when compared to the control group (Figure 3.3B).  
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Figure 3.3 STARS increases C2C12 myoblast proliferation. (A) DAPI stain (nuclei) and phase 
contrast images of C2C12 myoblasts 48 hours after transfection with pFLAG-CMV4 (Control) or 
pFLAG-mSTARS (STARS). (B) Quantification of the number of nuclei per visual field by DAPI 
staining of C2C12 myoblasts. Images from a minimum of 10 visual fields were obtained per group at 
a 10x magnification and repeated in 3 separate experiments. *, P<0.05, significantly different from 
Control. 
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3.3.4 SRF target genes, c-fos, Junb and Il-6, are up-regulated following STARS 
overexpression in C2C12 myoblasts 
As STARS overexpression increased C2C12 myoblast proliferation it was of interest 
to investigate the regulation of SRF targets genes that promote myoblast proliferation 
and as well as cell cycle regulators. SRF target gene Il-6 (Figure 3.4A) increased by 
6-fold, whilst Igf-1 (Figure 3.4B) and Lif mRNA (Figure 3.4C) decreased by 41% 
and 37% respectively, in C2C12 myoblasts overexpressing STARS when compared 
to the control cells..  Immediate early genes that are transcriptionally regulated by 
SRF, c-fos (Figure 3.4D) and Junb (Figure 3.4E) increased by 2.6-fold and 1.5-fold 
respectively, whilst Egr-1 mRNA (Figure 3.4F) did not change.  STARS 
overexpression reduced the mRNA levels of cell cycle regulators, Cyclin d1 (Figure 
3.4G), p21 (Figure 3.4H) and p27 (Figure 3.4I) by 26%, 54% and 27% respectfully 
when compared to control cells. 
 
 
Figure 3.4 mRNA levels of SRF target genes and cell cycle regulators following STARS 
overexpression in C2C12 myoblasts. (A) Il-6, (B) Igf-1, (C) Lif, (D) c-fos, (E) Junb, (F) Egr-1, (G) 
Cyclin d1, (H) p21 and (I) p27 mRNA levels in C2C12 myoblasts measured 48 hours after 
transfection with pFLAG-CMV4 (Control) or pFLAG-mSTARS (STARS). N = 6 per group (triplicate 
samples from 2 separate experiments).  * P<0.05, significantly different from Control. 
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3.3.5 STARS overexpression in differentiating C2C12 myoblasts 
STARS was overexpressed in differentiating C2C12 myoblast by infection for the 
first 48 hours of differentiation with an adenovirus expressing mouse STARS (ADV-
STARS); ADV-LacZ was used as the infection control. This resulted in an increase 
in Stars mRNA (Figure 3.5A) and STARS protein (Figure 3.5B) levels during the 5 
days of differentiation. An 11-fold increase in Stars mRNA levels was observed by 
D1 and it continued to increase with each day of differentiation (Figure 3.5A). By D5 
there was a 61-fold increase in ADV-STARS infected cells.  STARS protein levels 
were increased by 46% with ADV-STARS infection at D1 and by 2-fold from D2 to 
D5 when compared to control cells (Figure 3.5B). 
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Figure 3.5 STARS overexpression in differentiating C2C12 myoblasts.  (A) Stars mRNA and (B) 
STARS protein levels at day 1 to 5 (D1 to D5) of C2C12 myoblast differentiation following 
adenoviral infection with ADV-LacZ (LacZ) or ADV-STARS (STARS). N = 6 per group (triplicate 
samples from 2 separate experiments).  * P<0.05, significantly different from LacZ at the same day of 
differentiation. 
 
3.3.6 STARS increases C2C12 myoblast differentiation 
Serum depletion initiates myoblast differentiation, where myoblasts elongate and 
fuse to form multinucleated myotubes. To investigate whether STARS 
overexpression enhances C2C12 myoblast differentiation, phase contrast images 
were taken each day following adenoviral infection to observe visual cell changes 
during differentiation (Figure 3.6).  No differences in myoblast differentiation were 
observed 2 days after adenoviral infection with ADV-STARS. By day 3 there was a 
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visual distinction in the appearance of the cells, with an increased number of formed 
myotubes with STARS overexpression.  Following 5 days of differentiation, STARS 
overexpression resulted in both an increase in the number of formed myotubes and a 
reduction in the number of undifferentiated myoblasts when compare to LacZ 
control. 
 
Figure 3.6 STARS overexpression increases C2C12 myoblast differentiation. Phase contrast images 
of differentiating C2C12 myoblasts following adenoviral infection with ADV-LacZ (LacZ) or ADV-
STARS (STARS).  Images presented are a typical representation of a minimum of 10 images obtained 
at each day of the differentiation process (Day 1 to Day 5) for both groups at a 10x magnification. 
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3.3.7 Regulation of myogenic differentiation markers with STARS overexpression 
To confirm the visual observations, the mRNA expression of myogenic 
differentiation markers was investigated; creatine kinase muscle (CKM), MyoD and 
myogenin.  STARS overexpression increased Ckm mRNA levels from D2 to D5 with 
the greatest increase observed at D3 (2.3-fold) (Figure 3.7A).  Myod mRNA levels 
were significantly decreased at D2, D4 and D5 following STARS overexpression by 
14%, 21% and 16%, respectively (Figure 3.7B).  STARS overexpression decreased 
Myogenin mRNA levels at D2 by 42%, at D3 and D4 by ~25%, and by 44% at D5 
when compared to LacZ control (Figure 3.7C). 
 
 
Figure 3.7 mRNA levels of myogenic differentiation markers following STARS overexpression in 
differentiating C2C12 myoblasts. (A) Ckm, (B) Myod and (C) Myogenin mRNA levels at day 1 to 5 
(D1 to D5) of C2C12 myoblast differentiation following adenoviral infection with ADV-LacZ (LacZ) 
or ADV-STARS (STARS). N = 6 per group (triplicate samples from 2 separate experiments). * 
P<0.05, significantly different from LacZ at the same day of differentiation. 
  70 
3.3.8 Regulation of myosin heavy chain with STARS overexpression during 
myogenic differentiation 
STARS overexpression during C2C12 myoblast differentiation resulted in an 
alteration in the gene expression of MHC isoforms. Mhc1 mRNA levels were 
decreased by ~30% following STARS overexpression from D2 to D5 when 
compared to LacZ control (Figure 3.8A).  In contrast, Mhc2a (Figure 3.8B) and 
Mhc2b (Figure 3.8C) mRNA levels were increased following STARS overexpression 
from D2 to D5.  The greatest difference was observed at D3 with a 2.2-fold and 5-
fold increase in Mhc2a and Mhc2b mRNA levels respectfully. No differences were 
observed in Mhc2x mRNA levels between ADV-STARS infected cells and control 
LacZ cells during differentiation (Figure 3.8D).  Due to the changes in MHC isoform 
mRNA levels with STARS overexpression we then investigated total myosin heavy 
chain protein expression during differentiation.  MHC protein was not detectable 
until D2 of differentiation, with no difference observed between ADV-LacZ and 
ADV-STARS infected cells (Figure 3.8E).  STARS overexpression increased MHC 
protein levels at D3 and D4 by 30% and 19% respectfully, when compared to LacZ 
controls.  On the last day of differentiation there was no difference in MHC protein 
levels between ADV-LacZ and ADV-STARS infected cells. 
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Figure 3.8 Myosin heavy chain expression following STARS overexpression in differentiating 
C2C12 myoblasts. (A) Mhc1, (B) Mhc2a, (C) Mhc2b, (D) Mhc2x mRNA and (E) MHC protein levels 
at day 1 to 5 (D1 to D5) of C2C12 myoblast differentiation following adenoviral infection with ADV-
LacZ (LacZ) or ADV-STARS (STARS). N = 6 per group (triplicate samples from 2 separate 
experiments). * P<0.05, significantly different from LacZ at the same day of differentiation. 
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3.3.9 Regulation of SRF, PGC-1α and ERRα target genes with STARS 
overexpression during myogenic differentiation 
As STARS overexpression increased C2C12 myoblast differentiation it was of 
interest to investigate the regulation of SRF, PGC-1α and ERRα targets genes that 
promote myoblast differentiation. No differences in α-Actin mRNA levels were 
observed by D2, however was increased by ~38% from D3 to D5 with STARS 
overexpression (Figure 3.9A).  In contrast, Igf-1 mRNA levels were decreased in 
ADV-STARS infected cells from D3 to D5 when compared to ADV-LacZ control 
(Figure 3.9B). On the final day of differentiation Igf-1 mRNA levels were decreased 
by 45% following STARS overexpression. Cpt-1β (Figure 3.9C) and Ckmt2 (Figure 
3.9D) mRNA levels were both increased at D2 by 1.5-fold and 3.1-fold respectively. 
Each sequential day saw a further increase in mRNA levels and by D5 Cpt-1β and 
Ckmt2 mRNA levels increased by 2.1-fold and 8.6-fold respectively, in ADV-
STARS infected cells when compared to ADV-LacZ control. 
  
 
Figure 3.9 Regulation of SRF, PGC-1α and ERRα target genes following STARS overexpression in 
differentiating C2C12 myoblasts. (A) α-Actin, (B) Igf-1, (C) Cpt-1β and (D) Ckmt2 mRNA levels at 
day 1 to 5 (D1 to D5) of C2C12 myoblast differentiation following adenoviral infection with ADV-
LacZ (LacZ) or ADV-STARS (STARS). N = 6 per group (triplicate samples from 2 separate 
experiments). * P<0.05, significantly different from LacZ at the same day of differentiation. 
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3.4 Discussion 
Skeletal muscle growth and regeneration is controlled by intracellular signals 
regulating myoblast proliferation and their differentiation into mature multinucleated 
myotubes [268].  Understanding the signalling proteins that are involved in myoblast 
proliferation and differentiation may identify potential therapeutic targets to improve 
skeletal muscle repair, growth and function. The present study investigated the role 
of the STARS protein in the proliferation and differentiation of C2C12 muscle cells 
and has observed several novel findings. Firstly, STARS overexpression increased 
myoblast proliferation. This was associated with increases in Il-6, c-fos, and Junb 
and decreases in Igf-1, Lif, Cyclin d1, p21 and p27 mRNA levels. Secondly, 
overexpressing STARS at the onset of myoblast differentiation increased the rate of 
differentiation, with a paralleled increase in mRNA expression of Ckm and several 
myosin heavy chain isoforms.  Finally STARS overexpression increased the mRNA 
levels of several SRF target genes including α-actin and Mhc2b and PGC-1α/ERRα 
target genes including Mhc2a, Cpt-1β and Ckmt2 during myoblast differentiation into 
myotubes. 
 
STARS is expressed during early embryonic development of skeletal muscle and 
continues to increase during post-natal muscle development [133, 135, 180]. STARS 
mRNA is also more highly expressed in differentiating skeletal myotubes when 
compared to proliferating myoblasts [179].  In the present study, both STARS 
mRNA and protein were detected in proliferating skeletal myoblasts. Stars mRNA 
levels were increased by 53% in confluent C2C12 myoblasts when compared to sub-
confluent myoblasts, however STARS protein levels remained unchanged during 
myoblast proliferation. Endogenous levels of Stars mRNA increased by 30-fold at 
day 3 of differentiation, supporting previous observations made in C2C12 cells 
[179]. Stars mRNA levels continued to increase up to day 5 of differentiation. In the 
present study, these observations were extended to the STARS protein, which 
continued to increase until day 3 of differentiation. These observations suggest that 
STARS may play a role in myoblast proliferation and differentiation.  
 
Skeletal muscle regeneration is dependent on the activation of satellite cells and the 
subsequent proliferation of myoblasts and their myogenic differentiation and fusion 
with existing muscle fibres [29, 30, 34, 35].  STARS is a muscle specific actin 
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binding protein that increases actin polymerization, MRTF-A nuclear translocation 
and SRF reporter activity [133, 137].  SRF regulates the gene expression of several 
proteins involved in the activation and proliferation of satellite cells such IL-6, IGF-1 
and LIF [138, 212, 213]. Impairment of SRF activity disrupts myoblast proliferation 
[211] while SRF knockdown impairs skeletal muscle development in vivo [168, 172]. 
In the present study, STARS overexpression increased the proliferation of skeletal 
myoblasts.  STARS overexpression also increased myoblast proliferation in porcine 
smooth muscle cells and in the A10 rat vascular smooth muscle cell line [136].  
However, this proliferative effect of STARS was not observed in porcine aortic 
endothelial cells [136] or the H9c2 rat cardiac cell line [194]. These findings suggest 
that the role of STARS in muscle cell proliferation is dependent on muscle cell type. 
 
STARS overexpression in skeletal myoblasts also increased the mRNA expression of 
the SRF target gene, Il-6, but a decrease in the expression of other SRF target genes, 
Igf-1 and Lif.  IL-6 increases myoblast proliferation by stimulating macrophage 
infiltration and expression of cytokines and chemokines; molecules involved in the 
inflammation and muscle regeneration response following injury [269, 270].  SRF 
controls satellite cell proliferation by modulating IL-6 expression levels [271].  The 
increase in Il-6 mRNA following STARS overexpression may potentially influence 
the decrease IGF-1 gene expression. For example, whole body overexpression of IL-
6 reduces both serum levels of IGF-1 and hepatic IGF-1 mRNA, while in C2C12 
cells IL-6 treatment inhibits IGF-1 activity [272, 273].  The exact mechanism by 
which STARS overexpression results in the regulation of these genes remains 
unknown.  
 
SRF regulates cell proliferation via its transcription of immediate early genes such as 
c-fos, JunB, and Egr-1 [138, 212, 213].  Increased skeletal myoblast proliferation 
following STARS overexpression was associated with an increased gene expression 
of c-fos and Junb but had no effect of Egr-1 mRNA levels.  In L6 and C2C12 cells, 
c-fos and JunB enhance myoblast proliferation, respectively [274, 275]. These results 
suggest that STARS potentially increases myoblast proliferation by stimulating SRF 
immediate early gene transcription of c-fos and JunB. STARS overexpression 
decreased the mRNA levels of proteins involved in the regulation of the cell cycle 
such as, Cyclin d1, p21 and p27. Cyclin D1 activates cyclin dependent kinase 4 
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(CDK4) and 6 (CDK6); kinases that stimulate the transition of cells from the Gap 1 
(G1) to the synthesis (S1) phase of the cell cycle [276].  Conversely, the cyclin 
dependent kinase inhibitors p21 and p27, block the activity of cyclin dependent 
kinase 2 (CDK2) and CDK4 [277, 278]. This prevents cell cycle progression to G1 
and S1 and results in cell cycle arrest [277, 278].  As STARS increases myoblast 
proliferation, the reduction in Cyclin d1 gene expression does not appear to block 
cell cycle progression.  This maybe due, in part, to reduced inhibition of CDK2 and 
CDK4 activity as a result of decreased p21 and p27 gene expression. Whether this is 
a direct or in-direct of STARS is unknown. 
 
STARS, in conjunction with RhoA, stimulates SRF transcriptional activity via 
changes in actin dynamics [133].  RhoA signalling is required for the differentiation 
of smooth, cardiac, and skeletal muscle cells [117-124].  In C2C12 skeletal muscle 
cells dominate-negative RhoA reduces myogenic differentiation, whereas activated 
RhoA enhances myocyte differentiation and growth [122, 123]. RhoA signalling also 
stimulates key proteins involved in the regulation of muscle differentiation, such as 
MyoD and myogenin in myoblasts [125, 210]. Additionally, SRF physically interacts 
with myogenin and MyoD and activates gene transcription [279].  In the present 
study, overexpressing STARS at the onset of myoblast differentiation enhanced 
myogenic differentiation in skeletal muscle cells by increasing the number of formed 
myotubes and a reducing the number of undifferentiated myoblasts.  In mammals, an 
increase in CKM and MHC gene expression occurs during the differentiation from 
myoblast to myotubes and is used as a marker of myogenic differentiation [280, 
281]. STARS overexpression in differentiating skeletal myoblast increased Ckm 
mRNA levels across all days of the differentiation process whilst an increase in 
Mhc2a and Mhc2b and a decreased Mhc1 mRNA levels was observed from day 2 to 
day 5 of myogenic differentiation.  The increased gene expression of these MHC 
isoforms also resulted in an earlier rise in total MHC protein at day 3 and 4 of 
differentiation.  To fully understand the potential effects of STARS on MHC isoform 
expression we first need to consider the MHC expression in the cell line examined. 
Using immunofluorescence Millar (1990) showed MHC1 was more highly expressed 
in C2C12 cells, however the validity of these results is questionable as the antibodies 
used were not specific to individual isoforms [282]. More recently, Brown and 
colleagues (2011) showed type I isoforms were upregulated earlier during 
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differentiation whilst type II isoforms were upregulated later during differentiation in 
C2C12 cells [281].  Taking these observations into consideration, the decrease in 
Mhc1 mRNA expression with STARS overexpression maybe an indication of an 
accelerated differentiation process, whilst the increase in Mhc2a and Mhc2b suggest 
there is a switch to a faster MHC isoform.  However, extrapolation of these results to 
potential in vivo changes is restricted and further validation of MHC changes is 
required. 
 
MyoD and myogenin are two important members of the MRF family of transcription 
factors that regulate myogenic differentiation [41, 42].  MyoD is required for skeletal 
muscle cell determination and early myoblast differentiation, while myogenin is 
essential for terminal differentiation and normal biochemical and morphological 
characteristics of skeletal muscle [41, 42].  In the present study, STARS 
overexpression decreased Myod and Myogenin mRNA levels in differentiating 
skeletal muscle cells.  STARS is a transcriptional target of MyoD, and both MyoD 
and myogenin physically interact with SRF to potentially promote muscle-specific 
gene expression [179, 279]. The reasons for the reduction in Myod and Myogenin 
gene expression following STARS overexpression are currently unknown. However, 
as STARS appears to increase skeletal muscle cell differentiation an earlier decline 
in MyoD and myogenin expression maybe the result of an accelerated differentiation 
process. 
 
STARS overexpression results in its auto-regulation via a feed-forward mechanism 
that requires SRF binding to the SRE on the STARS promoter [180]. STARS 
overexpression in H9c2 rat cardiomyocytes increases several SRF target genes 
involved in cardiac cell growth [194].  In the present study, it was shown for the first 
time in differentiating skeletal muscle cells that STARS overexpression increases the 
gene expression of SRF target genes involved in skeletal muscle structure and 
contraction such as α-actin and Mhc2b.  STARS overexpression also decreased the 
gene expression of Igf-1 in differentiating skeletal muscle cells as was observed in 
proliferating myoblasts. As shown in Chapter 2, STARS gene transcription can be 
regulated by PGC-1α/ERRα; transcriptional partners involved in skeletal muscle cell 
differentiation and mitochondrial biogenesis [205-208].  It was also shown in 
Chapter 2 that STARS knockdown in C2C12 myotubes prevented PGC-1α 
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stimulated gene transcription of Cpt-1β.  In the present study, STARS overexpression 
during myogenic differentiation increased several PGC-1α/ERRα target genes 
involved in muscle contraction, mitochondrial biogenesis and oxidative metabolism 
such as Mhc2a, Ckmt2 and Cpt-1β, however decreased Mhc1 gene expression.  
Similarly, ERRα overexpression in differentiating C2C12 muscle cells increases both 
Ckmt2 and Mhc2a [208], while mice overexpressing PGC1α have an increased 
percentage of type I and type IIa muscle fibres [187].  Therefore, during myogenic 
differentiation STARS may enhance, or be necessary for complete transcriptional 
activation of certain PGC-1α/ERRα target genes such as Mhc2a, Ckmt2 and Cpt-1β.  
The reasons for the decrease in Mhc1 gene expression is unknown, however as MHC 
isoform expression is regulated by multiple signalling pathways and transcription 
factors, down regulation of Mhc1 mRNA is potentially an indirect effect of STARS 
overexpression.  Together these observations show for the first time that a forced up 
regulation of STARS during myoblast differentiation greatly impacts transcriptional 
pathways involved in muscle growth, contractile function, mitochondrial biogenesis 
and oxidative metabolism. 
 
While the present study demonstrates several novel and important findings, there are 
limitations to these observations. Firstly, C2C12 mouse cells were used for all 
experiments as they are commonly used as an in vitro model for skeletal muscle 
research.  These cells spontaneously differentiate in culture after serum removal and 
display many similar characteristics to muscle fibres in human skeletal muscle. 
However, despite being a robust model, extrapolation of results in vitro to in vivo 
models is limited and can only really form the basis for further research in animal 
models.  Secondly, the comparison between STARS overexpression and knockdown 
on C2C12 myoblast proliferation and differentiation would have been an important 
addition.  It should be noted that attempts were made to knockdown STARS in 
C2C12 myoblasts with no initial success using siRNA sequences and due to time 
constraints the knockdown of STARS using short hairpin RNA (shRNA) was not 
possible.  Lastly, since STARS has been shown to increase actin polymerisation and 
subsequently SRF transcriptional activity the addition of a measure of actin 
polymerisation would have strengthened the increase mRNA levels of SRF target 
genes with STARS overexpression in this study, however, again due to time 
constraints this was not possible. 
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In conclusion, we show for the first time in C2C12 skeletal muscle cells that STARS 
overexpression increases myoblast proliferation and myogenic differentiation. 
Overexpression of STARS in proliferating myoblasts was associated with increased 
expression of SRF target genes involved in muscle cell proliferation. On the other 
hand, STARS overexpression in differentiating muscle cells was associated with 
increased expression of SRF and PGC-1α/ERRα target genes involved in muscle cell 
structure, contraction, mitochondrial biogenesis and oxidative metabolism. STARS 
maybe a novel therapeutic target to enhance skeletal muscle repair and regeneration 
following damage via its activation of muscle cell proliferation and differentiation. 
Maintaining the levels of STARS may also help to stimulate or maintain oxidative 
metabolism. 
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3.5 Supplementary Methods 
3.5.1 Polymerase Chain Reaction (PCR) for mouse STARS DNA 
PCR using specifically designed primers (Geneworks, Hindmarsh, SA) was 
performed to amplify the mouse STARS DNA sequence and incorporate the desired 
restriction enzyme sites (EcoRI and BamHI) to insert into the pFLAG-CMV4 
(Sigma-Aldrich, Castle Hill, NSW) mammalian expression plasmid. PCR’s were 
performed using 50 ng of template DNA,  0.2 mM dNTPs (dATP, dCTP, dGTP, 
dTTP), 0.2 µM primer(s), 0.5 units of Phusion Hot Start High-Fidelity DNA 
Polymerase (Thermo Scientific, Rockford, IL) in 1x Phusion HF Buffer (Thermo 
Scientific, Rockford, IL), in a 50 µL reaction volume. The PCR reaction was 
performed using a TaKaRa PCR Thermal Cycler Dice™ (Takara Bio Inc., Shiga, 
Japan) and involved an initial denaturation at 98°C for 30 seconds; 30 cycles of 
denaturation at 98°C for 10 seconds, annealing at 66°C for 30 seconds, and extension 
at 72°C for 45 seconds, then a final extension at 72°C for 4 minutes.  PCR products 
were separated on a 1.0% agarose gel and a ~1000 base DNA fragment was extracted 
from the gel using a QIAquick Gel extraction Kit (QIAGEN, Doncaster, Vic). 
 
3.5.2 Agarose Gel Electrophoresis 
Agarose gels containing 0.1 µL/ml of SYBR® Safe DNA Gel Stain (Life 
Technolgies, Mulgrave, VIC) were prepared by using 10 mg/mL (1% w/v) DNA 
Grade Agarose (Life Technolgies, Mulgrave, VIC) in 1x Tris-acetate-EDTA (TAE) 
buffer and gels were immersed in a tank containing 1 x TAE buffer.  DNA samples 
were mixed to a final 1x concentration with the Gel Loading Dye, Orange (6X) (New 
England Biolabs (NEB), Ipswich, MA) and loaded into the wells alongside a 1 Kb 
Plus DNA Ladder (Life Technolgies, Mulgrave, VIC). Electrophoresis was 
performed at 100V for an appropriate time and bands were visualized using a UV 
transilluminator (Vilber Lourmat, France).  
 
3.5.3 DNA Isolation from Agarose Gels 
The required DNA fragments were extracted from the gel and purifired using a 
QIAquick Gel extraction Kit, according to manufacturer’s instructions. Briefly, with 
a clean, sharp scalpel the DNA fragment was excised from the agarose gel, mixed 
with Buffer QG (300 μl per 100 mg of gel) and incubated at 50°C for 10 minutes 
with occasional vortexing. Once gels were dissolved, isopropanol (100 μl per 100 mg 
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of gel) was mixed into the samples, pipetted on to the QIAquick columns, and 
centrifuged for 1 minute at 13,000 rpm. To remove all traces of agarose, 500 μl of 
Buffer QG was added to the QIAquick columns and centrifuged for 1 minute at 
13,000 rpm. To wash, 750 μl of Buffer PE was added to the QIAquick columns and 
centrifuge for 1 minute at 13,000 rpm. Finally, to elute DNA, 30 μl of nuclease free 
water (NFW) (Life Technolgies, Mulgrave, VIC) was added to the center of the 
QIAquick membranes, allowed to stand for 1 minute, and then centrifuged for 1 min 
at 13,000 rpm. 
 
3.5.4 Restriction Enzyme Digestion of DNA 
The PCR product (mouse STARS DNA), as well as the pFLAG-CMV4 plasmid, 
were digested using the EcoRI and BamHI restriction enzymes (NEB, Ipswich, MA) 
in 1 x EcoRI buffer (NEB, Ipswich, MA) with 1 x Bovine Serum Albumin (BSA) 
(NEB, Ipswich, MA). Reactions were digested at 37°C for 6 hours, and then heat 
inactivated at 65°C for 20 minutes. The digested inserts and plasmid were then run 
on a 1% (w/v) agarose/TAE gel, extracted and purified using the QIAquick Gel 
extraction Kit.  
 
3.5.5 Plasmid DNA Ligation 
The digested mouse STARS DNA and pFLAG-CMV4 fragments were run on a 1% 
(w/v) agarose/TAE gel alongside the 1 kb DNA Ladder (NEB, Ipswich, MA) to 
determine the concentration of these fragments. The mouse STARS DNA insert was 
ligated into the digested pFLAG-CMV4 plasmid at a ratio of 3:1 insert to vector 
ratio. The amount of insert required for 100 ng of vector was calculated using the 
following equation: 
 
DNA/100 ng vector = (100 x size of insert (kb))/(size of vector (kb)) x insert: vector 
ratio 
 
The ligation reaction consisted of the digested mouse STARS insert and the pFLAG-
CMV4 plasmid, 3 units of T4 DNA ligase (Promega, Madison WI) in a 1 x T4 ligase 
buffer, and was incubated overnight at 16°C. The ligated product (pFLAG-
mSTARS) was transformed into 5-α Competent E. coli (High Efficiency) cells 
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(NEB, Ipswich, MA) and the QIAprep Spin MiniPrep Kit (QIAGEN, Doncaster, 
Vic) was used to obtain subsequent bacterial colonies. 
 
3.5.6 Transformation of Competent Bacterial Cells 
To transform plasmid DNA, the DNA was incubated with 50 µL 5-α Competent E. 
coli (High Efficiency) cells on ice for 20 minutes. The cells were heat shocked for 60 
seconds in a 42°C water bath, and then immediately placed on ice for a further 2 
minutes. Following this, 1 mL of SOC media (0.5% yeast extract, 2% tryptone, 10 
nM NaCl, 2.5 nM KCl, 10 mM MgCl2, 20 mM MgSO4, 20 mM glucose) was added 
to the cells, and incubated at 37°C for 1 hour on an orbital shaker. The transformed 
cells were then spread on Luria-Bertani (LB) media agar plates with 1 µg/mL 
ampicillin, and incubated overnight at 37°C. 
 
3.5.7 Plasmid DNA Extraction from Bacterial Cultures 
Following plasmid DNA transformation into competent cells, colonies were picked 
and cultures were grown overnight at 30°C in LB media, containing 1 µg/mL 
ampicillin. Plasmid DNA was extracted and purified using either the QIAprep Spin 
MiniPrep Kit or the QIAGEN Plasmid Mega Kit (QIAGEN, Doncaster, VIC) as per 
manufacturer’s protocol. QIAprep Spin Miniprep kits were used to purify ligated 
plasmid colonies and following this, were sent with the appropriate sequencing 
primers for automated sequencing (Applied Genetic Diagnostics, Parkville, VIC).  
Once the correct DNA sequence was confirmed, the QIAGEN Plasmid Mega Kit was 
used to amplify the pFLAG-CMV4 and the cloned pFLAG-mSTARS plasmids. 
 
3.5.8 Adenoviral Amplification 
For each adenovirus, CRE8 cells were trypsinized and plated at a density of 1.46 x 
107 into five 150 mm dishes and 3-5 µL of stock adenovirus was added to each dish. 
After mixing, cells were incubated for 3-5 days, until 50% of the cytopathic effect 
(CPE) was complete. The CPE refers to the morphological changes that the cells 
undergo after infection. Cells typically round up and detach, and 50% CPE resembles 
50% of these cells being detached. Cells were then pelleted by centrifugation at 1500 
rpm for 10 minutes, and resuspended in 5 mL of growth media. 
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3.5.9 Adenoviral Purification 
The cells were lysed by 3 consecutive freeze/thaw cycles in a dry ice/ethanol bath 
and 37°C water bath respectively. The adenovirus was then purified using the 
Adeno-X™ Maxi Purification Kit (Clontech, Mountain View, CA), according to 
manufacturer’s instructions. Briefly, after thawing for the final time, the lysate was 
centrifuged at 3,000 rpm for 5 minutes to pellet the debris. The supernatant was 
collected and 5 µL of Benzonase® Nuclease (Clontech, Mountain View, CA) was 
added to the lysate and incubated for 30 minutes at 37°C. An equal volume 
(approximately 5 mL) of 1x Dilution Buffer was added to the lysate and then filtered 
through the 0.45 mm Syringe-tip Pre-filter to clarify the lysate. Following 
equilibration of the Purification Filter the adenovirus was loaded onto the filter.  The 
filter was then washed with 20 mL 1x Wash Buffer and then finally the adenovirus 
was eluted with 3 mL 1x Elution Buffer. 
 
3.5.10 Adenoviral Titration 
Adenoviruses were titrated using the Adeno-X™ Rapid Titer Kit (Clontech, 
Mountain View, CA). Briefly, serial dilutions of the adenoviruses were added to 2.5 
x 105 AD293 cells and plated in a 24-well plate for 48 hours. Cells were then fixed 
and treated with an anti-hexon (principle protein of adenovirus) protein-specific 
antibody, followed by an HRP-conjugate antibody and staining with a DAB 
substrate. Infected cells turn brown and are visualised with an Olympus IX-51 light 
microscope (Olympus, North Ryde, NSW). Dilutions containing fewer than 10% 
stained cells are used to count 10 optic fields with a 20x objective. The mean number 
of infected cells is used to determine the infectious units (IFU) per mL, which is 
calculated by: 
 
IFU/mL = (mean no. of infected cells per field x fields per well (313)) / (volume of 
virus x dilution factor) 
 
The amount of virus to use for experiments is calculated using the multiplicity of 
infection (MOI), which is the desired amount of viral particles per cell: 
 
Virus (µL) = ((no. of cells to infect) x (desired MOI) / (IFU/mL) x 1000). 
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CHAPTER 4 
 
STARS IS NECESSARY FOR MYOTUBE SURVIVAL BUT DOES NOT 
INFLUENCE BASAL PROTEIN SYNTHESIS OR DEGRADATION 
 
 
This work is currently under review by the American Journal of Physiology – Cell Physiology. 
 
Abstract 
Skeletal muscle mass is regulated by sensing and transmitting extracellular 
mechanical stress signals to intracellular signalling pathways controlling protein 
synthesis and protein degradation. The striated muscle activator of rho signalling 
(STARS), a muscle specific actin binding protein, is sensitive to extracellular stress 
signals. STARS stimulates actin polymerization and influences SRF and PGC-1α 
transcription of genes involved in muscle growth, structure and contraction. The role 
of STARS in skeletal muscle cells is not well understood. Therefore, this study 
determined whether STARS influenced muscle cell growth by regulating protein 
synthesis, protein degradation and AKT phosphorylation. The influence of STARS 
on the expression of SRF, PGC-1α and ERRα, as well as several of their downstream 
targets involved in muscle cell growth, contraction and metabolism was also 
investigated. STARS overexpression in C2C12 myotubes increased actin 
polymerization, however this did not affect protein synthesis, degradation or AKT 
phosphorylation. STARS increased Pgc-1α, Srf, Ckmt2, Cpt-1β and Mhc1 mRNA. 
STARS knockdown increased cell death, dead cell protease activity and markers of 
inflammation, Caspase-1, Il-1β and Mcp-1, regeneration, Socs3 and Myh8 and 
increased Mhc2a and Mhc2x mRNA. We show for the first time that under non-
stressed conditions, STARS overexpression increases actin polymerization and shifts 
the muscle cell to a more oxidative phenotype, potentially via up regulating PGC-1α. 
Under basal conditions, the suppression of STARS causes cell death and increases 
markers of necrosis, inflammation and regeneration. As STARS levels are 
suppressed in clinical models associated with increased necrosis, and inflammation 
such as aging and limb immobilization, rescuing STARS maybe a future therapeutic 
strategy to maintain skeletal muscle function and attenuate contraction-induce 
muscle damage. 
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4.1 Introduction 
Skeletal muscle growth is a process tightly controlled by signalling pathways 
regulating protein synthesis and protein degradation [4, 60, 283]. When protein 
synthesis is greater than protein degradation there is a net increase in protein 
accretion and skeletal muscle hypertrophy; a response associated with increased 
mechanical loading such as resistance exercise [284-286]. When protein degradation 
occurs faster than protein synthesis there is a net loss is muscle protein resulting in 
skeletal muscle atrophy; a response observed following muscle disuse, un-loading 
and in numerous chronic diseases [4, 60, 283]. The activation of signalling pathways 
controlling muscle cell protein synthesis and degradation is dependent upon the 
detection and transmission of extracellular stress signals [287-290]. Once activated, 
intracellular signalling cascades stimulate transcription factors that influence skeletal 
muscle remodelling through changes in gene expression [250]. Identifying molecular 
targets that are sensitive to extracellular stress signals for the control of skeletal 
muscle hypertrophy and atrophy may present as potential therapeutic targets to 
combat muscle wasting diseases and disorders. 
 
The striated muscle activator of rho signalling (STARS) (also known as Abra and 
ms1) is a muscle specific actin binding protein [133-136]. STARS is sensitive to 
extracellular stress signals and when activated localises to the sarcomere and 
stimulates actin polymerization [133]. This has been shown to increase the nuclear 
translocation of the serum response factor (SRF) transcriptional co-activator, 
myocardin-related transcription factor-A (MRTF-A) [133, 137], followed by 
enhanced SRF activity [133, 137]. SRF can transcribe genes that encode for proteins 
involved in muscle growth, structure and contraction such as IGF-1, actin and 
myosin [138, 139]. Combined overexpression of STARS and MRTF-A in rat primary 
cardiomyocytes increases AKT phosphorylation [291]; the latter a key kinase known 
to positively regulate muscle growth and attenuate muscle wasting [4, 60]. As 
demonstrated in Chapter 2 STARS is a transcriptional target of PGC-1α/ERRα 
signalling [205], a pathway regulating genes involved in muscle protein translation, 
structure and contraction as well as substrate metabolism and angiogenesis [187, 243, 
246, 254, 255, 267, 292-295]. Furthermore, as shown in Chapter 2, the down-
regulation of STARS inhibits the transcription of certain PGC-1α/ERRα target genes 
[205]. These observations suggest that STARS is required for effective PGC-
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1α/ERRα transcriptional control of certain genes; genes potentially involved in 
muscle protein translation, structure and function. 
 
Few studies have investigated the ability of STARS to directly regulate muscle size. 
Forced overexpression of STARS results in hypertrophy of H2c9 rat cardiomyocytes 
[194]. Additionally controlled overexpression of STARS in mouse cardiac tissue 
results in an exaggerated hypertrophic response, but only when combined with 
pressure overload [178]. An increase in STARS gene expression is associated with 
skeletal muscle hypertrophy in humans following 8 weeks of resistance training 
[166]. With respect to conditions of muscle atrophy, STARS gene expression is 
reduced in skeletal muscle of ageing mice and pigs [135, 200], following atrophy-
inducing de-training in humans [166] and after hind limb suspension in rats, but not 
humans [198, 199]. However, the causality of these in vivo observations in skeletal 
muscle has yet to be established.  
 
Combined, these observations suggest that STARS may play a direct role in 
regulating skeletal muscle growth, however, this is yet to be investigated. Therefore, 
the primary aim of the present study was to determine whether STARS directly 
influences muscle cell growth by regulating C2C12 myotube protein synthesis and 
degradation as well as AKT phosphorylation. A secondary aim was to determine if 
STARS expression regulates SRF and PGC-1α/ERRα target genes.  
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4.2 Methods 
4.2.1 Cell culture 
C2C12 myoblasts (ATCC, Manassas, VA) were plated in 6-well tissue culture plates 
in complete DMEM (10%FBS) (Life Technologies, Melbourne, Australia). As the 
cultures approached confluence (~90% confluent), media was changed to 
differentiation medium (DMEM) supplemented with 2% horse serum (HS) (Life 
Technologies, Melbourne, Australia).  Differentiation media was replaced every 48 
hours.   
 
4.2.2 Adenoviral infection 
Adenoviral constructs containing mouse STARS (ADV-STARS) or control gene 
LacZ (ADV-LacZ) were generous gifts from Eric N. Olson, The University of Texas 
Southwestern Medical Center. C2C12 myotubes were infected with an adenovirus 
expressing STARS (ADV-STARS) at an MOI 100 or a vector control adenovirus 
(ADV-LACZ) on day 4 of differentiation. Following 48 hours of infection, protein 
synthesis, protein degradation and immunofluorescence analysis of actin 
polymerisation was performed.  RNA and protein were also harvested for RT-PCR 
gene expression and western blot analysis. 
 
4.2.3 siRNA transfection  
STARS knockdown in C2C12 myotubes was achieved using 100pmol of Stealth 
RNAi™ siRNA (target sequence; 5′-TCCAGTCCCAGAAGCTCAATCCCTT-3′; 
Life Technologies, Melbourne, Australia) over a 72 hr period as presented in Chapter 
2.  Stealth RNAi™ siRNA Negative Control Hi GC (Life Technologies, Melbourne, 
Australia) was used as the control siRNA, which contains the same GC content as the 
target sequence. siRNA transfection of C2C12 myotubes was performed using 5 μl 
Lipofectamine 2000 (Life Technologies, Melbourne, Australia).    
 
4.2.4 Protein Synthesis 
Protein synthesis was determined by measuring the incorporation of radio-labelled 
[3H]-tyrosine (GE Healthcare, Sydney, NSW) into the myotubes (modified from 
[296]). After adenoviral infection, C2C12 myotubes were treated for 24 hours with 
or without 10 µM dexamethasone (DEX) (Sigma-Aldrich, St. Louis, MO) to induce 
catabolic stress or 100 nM insulin (INS) to induce anabolic stress. Also during this 
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24 hour period, 1 µCi/ml of radio-labelled [3H]-tyrosine and 2 mM L-tyrosine 
(Sigma-Aldrich, St. Louis, MO) were added to the myotubes.  The use of excess non-
radioactive tyrosine in the medium gives an accurate indication of protein synthesis 
rates without alterations in the free intracellular tyrosine pool [297].  Following this, 
myotubes were washed twice with cold phosphate buffered saline (PBS), and then 1 
ml of cold 10% trichloroacetic acid (TCA) (Sigma-Aldrich, St. Louis, MO) was 
added to each well. After scraping, myotubes sat on ice for 1 hour to precipitate the 
protein, followed by centrifugation at 20,000 x g for 10 minutes. The supernatant 
was removed, and the precipitates were dissolved in 0.1 M NaOH with 1% Triton X-
100 (TX-100) (Sigma-Aldrich, St. Louis, MO) overnight at room temperature. 
Following this, 400 µl of the sample was mixed with 4 ml of Ultima Gold 
scintillation liquid (Perkin Elmer, Boston, MA) and radioactivity was measured 
using a Wallac 1409 DSA liquid scintillation counter (Perkin Elmer, Boston, MA) 
and expressed as counts per minute (CPM). Protein synthesis counts were normalised 
to total genomic DNA [296] in the myotubes. Genomic DNA was extracted using the 
Allprep DNA/RNA mini kit (Qiagen, Melbourne, Australia) as per manufacturer’s 
instructions. DNA was quantified using the NanoDrop 2000 (NanoDrop products, 
Wilmington, DE). 
 
4.2.5 Protein Degradation 
Protein degradation was determined by measuring the release of radio-labelled [3H]-
tyrosine from the myotubes into the media. Following adenoviral infection, C2C12 
myotubes were washed in serum free high glucose DMEM, and then labelled with 2 
µCi/ml of [3H]-tyrosine for 24 hours. Myotubes were washed again in serum free 
high glucose DMEM then incubated in 2mM of L-tyrosine for 2 hours. After 
washing again, myotubes were incubated in serum free DMEM with 2 mM 
unlabelled tyrosine with or without 10 µM DEX or 100 nM INS for 24 hours, to 
measure protein degradation under basal, catabolic and anabolic conditions. 
Following this, 450 µl of the medium was added to 50 µl of TCA and left to 
precipitate on ice for 1 hour. After centrifugation at 13,000 rpm for 5 minutes, 400 µl 
of the supernatant is added to 4 ml of Ultima Gold scintillation liquid and TCA 
soluble radioactivity was measured on the Wallac 1409 DSA liquid scintillation 
counter (reading A). Remaining media from this sample was removed, and the pellet 
was solubilised in 500 µl of 0.5 M NaOH with 0.1% Triton X-100 for 2 hours at 
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37°C. Subsequently, 400 µl of this was added to 4 ml of scintillation liquid and TCA 
insoluble radioactivity was measured (reading B). The remaining media from the 
culture plates was removed and the myotubes were washed twice with cold PBS, 
followed by the addition of 500 µl of 0.5 M NaOH and 0.1% Triton X-100 for 2 
hours at 37°C. Another 500 µl of 10% TCA was added to this overnight at 4°C to 
precipitate the protein in the myotubes. The following day, 400 µl was added to 4 ml 
of scintillation liquid to measure myotube radioactivity (reading C). Proteolytic rate 
was defined as TCA-soluble radioactivity (A), divided by the sum of TCA-soluble 
radioactivity (A), TCA-insoluble radioactivity (B) and myotube radioactivity (C), 
then multiplied by 100. All radioactivity measurements were expressed as counts per 
minute (CPM). 
 
4.2.6 Immunofluorescence  
C2C12 myotubes were prepared on 35 mm µ-Dishes (ibidi, Munich, Germany) for 
immunofluorescence analysis of F-actin expression using Phalloidin staining (Morel 
et al., 2009). Cells were fixed for 10 minutes with 4.0% paraformaldehyde 
(PFA)/PBS (Sigma-Aldrich, St. Louis, MO), permeabilised with 0.1% TX-100/PBS 
for 5 minutes and then blocked in 1.0% BSA/PBS for 1 hour at room temperature. 
Antibody staining required incubating myotubes at room temperature for 20 minutes 
with 5 units/mL Alexa Fluor® 546 Phalloidin (Life Technologies, Melbourne, VIC) 
to label F-actin, 9 µg/ml Alexa Fluor® 488 Deoxyribonuclease I (DNAse I) (Life 
Technologies, Melbourne, VIC) to label G-actin and 0.1 μg/ml 4',6-diamidino-2-
phenylindole (DAPI) (Sigma-Aldrich, St. Louis, MO) in 1% BSA/PBS. All images 
were obtained using the Olympus Fluoveiw FV10i-W (Olympus, Melbourne, 
Australia). The amount of red fluorescent staining following the incubation with the 
Phalloidin antibody was measured using Image J. An average of 10 myotubes were 
analysed from 10 different fields of view for each treatment and all measurements 
were normalised to myotube number. 
 
4.2.7 Cytotoxicity analysis 
To determine the cytotoxic effect of STARS knockdown in C2C12 myotubes, the 
CytoTox-Fluor™ Cytotoxicity Assay (Promega, Madison, WI) was used according 
to manufacturer’s instructions to measure the relative number of dead cells per well.  
The cytotoxicity assay measures dead cell protease activity by measuring the release 
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of a fluorogenic peptide substrate that is released from cells that have lost membrane 
integrity.  Briefly, 100µl of the bis-AAF-R110 Substrate was mixed with 10ml Assay 
Buffer and 100µl of this reagent was added to the 100 µl each well of a 96-well plate 
in equal volume to the cell media. The plate was mixed briefly by orbital shaking and 
then incubated for 30 minutes at 37°C. Resulting fluorescence was measured using 
the BioTek Synergy 2 Multi-mode microplate reader (BioTek, Winooski, VT) with 
filters set at 485nm excitation and 520nm emission.  Serum starved myotubes were 
used as the positive control while empty wells (no cells) were used as the negative 
control. 
 
4.2.8 Apoptotic DNA laddering analysis 
Seventy-two hours following transfection with the siRNA sequences, DNA was 
extracted from the myotubes using the Apoptotic DNA-Ladder Kit according to 
manufacturer’s protocol. DNA samples were run on a 1% (w/v) agarose/TAE gel and 
electrophoresis was performed in 1x TAE buffer at 100V for an appropriate time. 
DNA samples were run alongside a 1 Kb Plus DNA Ladder and the apoptotic 
positive control (lyophilized apoptotic U937 cells). Gel images were obtained using 
the Kodak Gel Logic 112 imaging system (Kodak Scientific Imaging Systems, 
Rochester, NY) and a UV transilluminator (Vilber Lourmat, Marne la Vallée, 
France). 
 
4.2.9 RNA Extraction 
Total RNA was extracted using Tri-Reagent® Solution (Ambion Inc., Austin TX) 
according to the manufacturer’s protocol.  First-strand cDNA was generated from 1-
2µg RNA in 20µL reaction buffer using High Capacity RNA-to-cDNA kit (Applied 
Biosystems, Forster City, CA) according to manufacturer’s protocol. Before diluting 
cDNA, 1 µL ribonuclease H (RNase H) (Life Technolgies, Melbourne, Australia) 
was added to each sample and incubated at 37°C for 30 minutes. Following this, 
cDNA was diluted in NFW to 5 ng/µL and stored at -20°C until further analysis. 
 
4.2.10 Real time quantitative PCR 
Real-time PCR was carried out using the Stratagene MX3000 PCR system (Agilent 
Technologies, Santa Clara, CA) to measure mRNA levels of genes of interest.  To 
compensate for variations in input RNA amounts and efficiency of the reverse 
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transcription, data was normalized to ribosomal protein 36B4 (also known as 
RPLPO) mRNA levels or single-stranded DNA (ssDNA) concentration that was 
quantified using the Quanti-iT OliGreen ssDNA Assay Kit (Molecular Probes, 
Eugene, OR). PCR primer details for the genes are provided in Table 4.1. 
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Table 4.1 Details of mouse primers used for RT-PCR analysis. 
 
 
4.2.11 Protein Extraction 
Total protein was extracted using 1x RIPA buffer (Millipore, Sydney, Australia) with 
1 µL/mL protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and 10 µL/mL 
Halt Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific, Rockford, IL). 
Total protein content was determined using the BCA Protein Assay Kit (Pierce 
Biotechnology, Rockford, IL) according to the manufacturer’s instructions. 
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4.2.12 Western blotting 
Electrophoresis and protein transfer were performed using the XCell Surelock Novex 
Mini- Cell (Life Technolgies, Melbourne, Australia) system.  Protein lysates were 
separated by SDS-PAGE using pre-cast NuPAGE® Novex 4 to 12% Bis-Tris gels 
(Life Technolgies, Melbourne, Australia) and transferred to a PVDF membrane 
(Millipore, Billerica, MA). Membranes were then incubated at room temperature for 
1 hour in blocking buffer supplemented with 5% BSA/PBS.  After blocking, 
membranes were incubated overnight at 4°C with the following primary antibodies 
diluted 1:1000 in 5% BSA/PBS (STARS, Institute of Medical and Veterinary 
Science, Adelaide Australia; Pro and active Caspase 3 (IMG-144A), Imgenex, San 
Diego CA; Poly(ADP-ribose)polymerase (PARP), Roche Applied Science, Sydney 
Australia). Following washing the membranes were incubated for 1 hour with 
incubated with infrared dye-conjugated secondary antibodies (Thermo Fisher 
Scientific, Rockford, IL). After washing, the specific proteins were revealed using 
Odyssey Imaging System (LI-COR, Lincoln, NE). GAPDH was used to control for 
protein loading and individual protein band optical densities were determined using 
ImageJ Software (National Institutes of Health, Bethesda, MA). 
 
4.2.13 Statistics 
Protein synthesis and protein degradation experiments were analysed using a two-
way ANOVA. Where required a post-hoc analysis was performed using unpaired t-
tests with a Bonferroni adjustment. All other data from overexpression and 
knockdown experiments were analysed using a two-tailed unpaired t-Test. The level 
of significance was set at p < 0.05. 
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4.3 Results 
4.3.1 STARS overexpression in C2C12 myotubes 
STARS was overexpressed in C2C12 myotubes by infection with an adenovirus 
expressing mouse STARS; ADV-LacZ was used as the infection control. This 
resulted in a 13-fold and 2.9-fold increase in Stars mRNA (Figure 4.1A) and STARS 
protein (Figure 4.1B) levels, respectively. 
 
 
Figure 4.1 STARS overexpression in C2C12 myotubes. (A) Stars mRNA and (B) STARS protein 
levels in C2C12 myotubes when measured 48 hours after infection with ADV-LacZ (LacZ) or ADV-
STARS (STARS). N = 6 per group (triplicate samples from 2 separate experiments). * P<0.05, 
significantly different from LacZ. 
 
 
4.3.2 STARS overexpression increases actin polymerisation 
STARS overexpression resulted in no change in C2C12 myotube length or diameter 
when compared to LacZ control (Figure 4.2A). To determine whether STARS 
overexpression regulated actin polymerization F-actin expression was measured by 
phalloidin staining. A 60% increase in actin polymerisation was observed in C2C12 
myotubes overexpressing STARS when compared to LacZ (Figure 1B and 1C). 
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Figure 4.2 STARS overexpression increases F-actin polymerisation. (A) Phase contrast (cell image) 
and (B) Phalloidin (F-actin) stain images of C2C12 myotubes 48 hours after infection with ADV-
LacZ (LacZ) or ADV-STARS (STARS). Images from a minimum of 10 visual fields were obtained 
per group at a 10x magnification. This was repeated in 3 separate experiments.  (C) Quantification of 
actin polymerization was determined by measuring Phalloidin staining using Image J. An average of 
10 myotubes were analysed from 10 different fields of view for each treatment group. * P<0.05, 
significantly different from LacZ. 
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4.3.3 STARS overexpression does not influence protein balance and AKT 
activation 
To investigate the effect of STARS overexpression on protein synthesis and protein 
degradation we measured the incorporation and release respectively, of radioactive 
H3-Tyrosine from C2C12 myotubes. STARS overexpression did not alter protein 
synthesis (Figure 4.3A) or protein degradation (Figure 4.3B) levels under basal 
conditions in C2C12 myotubes. No differences were observed in total protein content 
(Figure 4.3C) in C2C12 myotubes following adenoviral infection with ADV-STARS 
when compared to ADV-LacZ. Dexamethasone (DEX) treatment decreased protein 
synthesis by 18% and insulin (INS) treatment increased protein synthesis by 34%. 
The combination of STARS with DEX or INS did not influence protein synthesis 
levels. DEX treatment increased protein degradation by 17% whilst INS treatment 
decreased protein degradation by 23%. Again, the combination of STARS with DEX 
or INS did not affect protein degradation levels. Phosphorylation of AKT (pAKT), a 
key kinase in protein synthesis, was also unchanged with STARS overexpression 
(Figure 4.3D). 
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Figure 4.3 STARS overexpression does not influence protein balance and AKT activation in C2C12 
myotubes. (A) Protein synthesis and (B) protein degradation levels levels in C2C12 myotubes when 
measured 48 hours after infection with ADV-LacZ (LacZ) or ADV-STARS (STARS). Myotubes were 
exposed to differentiation media (Basal) with or without 10 µM dexamethasone (DEX) or 100 nM 
insulin (INS) during the last 24 hour of adenoviral infection. N=12 per group N = 12 per group (6 
samples from 2 separate experiments).  * P<0.05, significantly different from Basal. (C) Total protein 
content and (D) pAKT protein levels levels in C2C12 myotubes when measured 48 hours after 
infection with ADV-LacZ (LacZ) or ADV-STARS (STARS). N = 6 per group (triplicate samples 
from 2 separate experiments). 
 
 
4.3.4 STARS overexpression up-regulates PGC-1α and SRF 
The STARS gene is a PGC-1α/ERRα and SRF transcriptional target. The gene 
expression of this transcriptional co-activator and transcription factors can also be 
auto regulated by their own downstream gene targets. Therefore it was of interest to 
investigate whether a possible feedback loop exists between STARS and its 
transcriptional regulators. STARS overexpression increased Pgc-1α mRNA levels 
(Figure 4.4A) by 34%, Srf mRNA levels (Figure 4.4C) by 35% while Errα mRNA 
levels (Figure 4.4B) remained unchanged.  
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Figure 4.4 STARS increases Pgc-1α and Srf gene expression. (A) Pgc-1α, (B) Errα and (C) Srf 
mRNA levels in C2C12 myotubes when measured 48 hours after infection with ADV-LacZ (LacZ) or 
ADV-STARS (STARS). N = 6 per group (triplicate samples from 2 separate experiments). * P<0.05, 
significantly different from LacZ. 
 
 
4.3.5 STARS overexpression increases PGC-1α/ERRα target genes 
In Chapter 3 STARS overexpression in differentiating C2C12 myoblasts increased 
the expression of several PGC-1α, ERRα and SRF target genes.  Therefore 
expression of these genes was measured following STARS overexpression in fully 
differentiated myotubes. Ckmt2 (Figure 4.5A) and Cpt-1β (Figure 4.5B) mRNA 
levels were increased by 105% and 45% respectively. There were no differences in 
α-actin (Figure 4.5C) or Igf-1 (Figure 4.5D) mRNA. 
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Figure 4.5 STARS increases PGC-1α target gene expression. (A) Ckmt2, (B) Cpt-1β, (C) α-actin and 
(D) Igf-1 mRNA levels in C2C12 myotubes when measured 48 hours after infection with ADV-LacZ 
(LacZ) or ADV-STARS (STARS). N = 6 per group (triplicate samples from 2 separate experiments). 
* P<0.05, significantly different from LacZ. 
 
 
4.3.6 Regulation of myosin heavy chain with STARS overexpression 
In Chapter 3 STARS overexpression during C2C12 myoblast differentiation 
increased gene expression of myosin heavy chain isoforms type 2a and 2b. 
Therefore, we chose to investigate whether STARS overexpression in fully 
differentiated myotubes influences myosin heavy chain isoform expression.  Mhc1 
mRNA levels (Figure 4.6A) increased by 31% following STARS overexpression.  
No changes in Mhc2a (Figure 4.6B), Mhc2b (Figure 4.6C) or Mhc2x (Figure 4.6D) 
mRNA levels were observed. 
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Figure 4.6 Myosin heavy chain isoform mRNA levels following STARS overexpression. (A) Mhc1, 
(B) Mhc2a, (C) Mhc2b and (D) Mhc2x mRNA levels in C2C12 myotubes when measured 48 hours 
after infection with ADV-LacZ (LacZ) or ADV-STARS (STARS). N = 6 per group (triplicate samples 
from 2 separate experiments). * P<0.05, significantly different from LacZ. 
 
 
4.3.7 STARS knockdown in C2C12 myotubes 
STARS was knockdown in C2C12 myotubes by transfection with a siRNA against 
mouse STARS for 72 hours. siRNA Negative Control (siCON) was used as the 
transfection control.   This transfection resulted in an 80% and 47% decrease in Stars 
mRNA (Figure 4.7A) and STARS protein (Figure 4.7B) levels, respectively. 
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Figure 4.7 STARS knockdown in C2C12 myotubes. (A) Stars mRNA and (B) STARS protein levels 
72 hours after transfection with siRNA negative control (siCON) or siRNA against STARS 
(siSTARS). N = 6 per group (triplicate samples from 2 separate experiments). * P<0.05, significantly 
different from siCON. 
 
 
4.3.8 STARS knockdown increases myotube loss and damage 
Several visual observations were noted following the knockdown of STARS in 
C2C12 myotubes.  Firstly, there was an increase in the amount of debris floating in 
the wells of myotubes transfected with siRNA against STARS. This was not 
observed in the wells of myotubes transfected with the siCON demonstrating that 
this was not an artefact of the transfection reagents. After removing the debris and 
washing the cells a reduction in the number of myotubes was observed following 
STARS knockdown (Figure 4.8A).  There was also a 32% reduction in actin 
polymerisation in the myotubes (Figure 4B and 4C).   STARS knockdown also 
resulted in an increased presence of myotubes that appeared to be rounding up and/or 
displaying blebs on the cell membrane, both an indication of increased cell death and 
damage (indicated by arrows in Figure 4B, 4C and 4D).  
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Figure 4.8 STARS knockdown increases cell rounding. (A) Phase contrast (cell image) and (B) 
Phalloidin (F-actin) stain images of C2C12 myotubes 72 hours after transfection with siRNA negative 
control (siCON) or siRNA against STARS (siSTARS). Images from a minimum of 10 visual fields 
were obtained per group at a 10x magnification and repeated in 3 separate experiments. Arrows 
indicate rounding or membrane blebbing of myotubes.  (C) Quantification of actin polymerization was 
determined by measuring Phalloidin staining using Image J. An average of 10 myotubes were 
analysed from 10 different fields of view for each treatment group and normalised to myotube 
number. * P<0.05, significantly different from siCON. (D) Membrane blebs are seen in C2C12 
myotubes following STARS knockdown; F-Actin staining using Phalloidin, G-Actin staining using 
DNAse I and nuclei staining using DAPI. Arrow indicates membrane blebbing. 
  103 
4.3.9 STARS knockdown increases myotube cell death and protein loss 
To confirm these visual observations dead cell protease activity was measured using 
a cytotoxicity kit.  A 13% increase in dead cell protease activity (Figure 4.9A) and an 
18% decrease in total protein content (Figure 4.9B) were measured following 
STARS knockdown.  It was of interest to establish if STARS knockdown regulated 
myotube protein synthesis and degradation. However, due to the increase in cell 
death following STARS knockdown, the accuracy in measuring protein synthesis and 
degradation in vitro is compromised. For example, the protein degradation assay 
involves the pre-labelling of proteins with a radioactive amino acid (H3-Tyrosine) 
prior to the treatment of interest. Protein degradation levels are calculated by 
dividing TCA-soluble radioactivity by the radioactivity in pre-labelled proteins. As 
cell death would result in the loss of pre-labelled proteins, the calculation of protein 
degradation levels is inaccurate. 
 
 
Figure 4.9 STARS knockdown increases myotube cell death and protein loss. (A) Dead cell protease 
activity and (B) total protein content in C2C12 myotubes 72 hours after transfection with siRNA 
negative control (siCON) or siRNA against STARS (siSTARS). N = 18 per group (9 samples from 2 
separate experiments) for dead cell protease activity and N = 6 per group (triplicate samples from 2 
separate experiments) for total protein content.  * P<0.05, significantly different from siCON.  
 
 
4.3.10 STARS knockdown does not increase apoptotic cell death 
The presence of cell membrane blebbing is an indication of both necrotic and 
apoptotic cell death. As STARS knockdown increases cell death and membrane 
blebbing typical apoptotic markers were measured to determine whether cell death 
was via apoptotic pathways. Apoptosis increases DNA fragmentation, however no 
differences were observed when comparing siSTARS to siCON transfected 
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myotubes (Figure 4.10A).  No differences were also seen in cleaved Caspase 3 and 
cleaved PARP protein levels following STARS knockdown (Figure 4.10B). 
 
 
Figure 4.10 STARS knockdown does not increase apoptotic cell death. (A) DNA fragmentation of 
extracts from C2C12 myotubes 72 hours after transfection with siRNA negative control (siCON) or 
siRNA against STARS (siSTARS). Lane 1 – DNA ladder; lane 2 – Apoptotic positive control; lane 3 
– siCON; lane 4 – siSTARS. (B) Cleaved Caspase 3 and PARP protein levels 72 hours after 
transfection with siRNA negative control (siCON) or siRNA against STARS (siSTARS). N = 6 per 
group (triplicate samples from 2 separate experiments). 
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4.3.11 STARS knockdown increases gene expression of inflammation and 
regeneration markers 
Necrotic death results in membrane disruption, release of cellular contents into the 
extracellular environment and a strong inflammatory response in surrounding cells. 
To determine if cell death was due to necrosis, gene expression of necrotic and 
inflammation markers were measured, STARS knockdown increased Caspase-1 
(Figure 4.11A), Il-1β (Figure 4.11B) and Mcp-1 (Figure 4.11C) mRNA levels by 2.3-
fold, 10.7-fold and 1.5-fold, respectively. No differences were observed in Tnfα 
mRNA levels (Figure 4.11D). Markers of myotube regeneration were also measured 
to investigate whether the increase in inflammation following STARS knockdown 
was associated with myotube regeneration. Socs3 (Figure 4.11E) and Myh8 (Figure 
4.11F) mRNA levels increased by 90% and 61% following STARS knockdown.  
 
 
Figure 4.11 STARS knockdown increases gene expression of inflammation and regeneration markers. 
(A) Caspase 1, (B) Il-1β, (C) Mcp-1, (D) Tnfα, (E) Socs3 and (F) Myh8 mRNA levels 72 hours after 
transfection with siRNA negative control (siCON) or siRNA against STARS (siSTARS). N = 6 per 
group (triplicate samples from 2 separate experiments).  * P<0.05, significantly different from siCON. 
 
 
4.3.12 Regulation of sarcomeric proteins with STARS knockdown 
STARS knockdown resulted in varying changes in myosin heavy chain isoform 
expression. Mhc1 (Figure 4.12A) mRNA levels decreased by 29%, while Mhc2a 
(Figure 4.12B) and Mhc2x (Figure 4.12C) mRNA levels increased by 7.8-fold and 
1.7-fold respectively. No difference in Mhc2b (Figure 4.12D) mRNA levels was 
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observed. The SRF target gene α-actin (Figure 4.12E) increased by 37%, and finally 
there was a 2.2-fold increase in the sarcomeric Z-disk associating protein, α-actinin2 
(Figure 4.12F). 
 
 
Figure 4.12 Sarcomeric protein mRNA levels following STARS knockdown. (A) Mhc1, (B) Mhc2a, 
(C) Mhc2b, (D) Mhc2x, (E) α-actin and (F) α-actinin2 mRNA levels in C2C12 myotubes 72 hours 
after transfection with siRNA negative control (siCON) or siRNA against STARS (siSTARS). N = 6 
per group (triplicate samples from 2 separate experiments). * P<0.05, significantly different from 
siCON. 
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4.3.13 STARS knockdown decreases PGC-1α/ERRα target genes 
Consistent with previous findings, STARS knockdown reduced Cpt-1β mRNA levels 
by 47% (Figure 4.13A) and also decreased Ckmt2 by 71% (Figure 4.13B) when 
compared to control cells.  
 
 
Figure 4.13 STARS knockdown decreases PGC-1α target genes. (A) Cpt-1β and (B) Ckmt2 mRNA 
levels in C2C12 myotubes 72 hours after transfection with siRNA negative control (siCON) or siRNA 
against STARS (siSTARS). N = 6 per group (triplicate samples from 2 separate experiments). * 
P<0.05, significantly different from siCON. 
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4.4 Discussion 
Identifying the molecular targets that influence protein synthesis and degradation 
will significantly enhance our understanding of how skeletal muscle mass is 
regulated and may identify potential therapeutic targets to combat diseases 
characterized by perturbations in skeletal muscle growth. The present study 
demonstrates several novel and important findings in C2C12 myotubes. Firstly, over 
expression of STARS increases actin polymerization, however this did not affect 
protein synthesis, protein degradation or AKT phosphorylation. Secondly, over 
expression of STARS increased the mRNA levels of PGC-1α and SRF as well as 
several PGC-1α /ERRα target genes such as Ckmt2 and Cpt-1β and the slow myosin 
isoform, Mhc1.  Thirdly, knockdown of STARS decreased actin polymerization and 
increased cell death, dead cell protease activity, markers of inflammation, including 
caspase-1, IL-1β and Mcp-1 as well as markers of regeneration such as SOCS3 and 
the embryonic myosin, Myh8. Finally, STARS knockdown moved the myotubes 
towards a faster contractile phenotype as indicated by a reduction in Mhc1 and 
increased Mhc2a and Mhc2x. There was also an increase in α-actin and α-actinin2. 
 
STARS, an actin binding protein that localizes to the sarcomere [133], has been 
shown to activate MRTF-A/SRF intracellular signalling in non-muscle (COS, 
NIH3T3, 293T), rat cardiomyocytes and differentiated C2C12 cells via increasing 
actin polymerization [133, 137]. SRF transcriptionally regulates genes involved in 
muscle structure, function and growth [138, 139, 247] as well as oxidative 
metabolism [248]. The overexpression of STARS in rat cardiomyocytes is associated 
with an increased expression of several SRF target genes and muscle cell 
hypertrophy [194]. Therefore STARS maybe an important upstream mediator of 
muscle growth and function. The results from the present study show that the 
overexpression of STARS in differentiated mouse C2C12 myotubes also increases 
actin-polymerization. However this did not alter myotube protein synthesis, 
degradation or AKT phosphorylation; therefore there was no change in myotube size. 
In vivo, forced overexpression of STARS in the heart amplifies the hypertrophic 
response, but only after the addition of a mechanical loading stress [178]. This 
suggests that the over expression of STARS alone is not sufficient to cause a 
hypertrophic response. However, an elevated level of STARS does increase the 
sensitivity of the cell to extracellular mechanical stress signals resulting in enhanced 
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growth. The present study also provided catabolic and anabolic stress via treating 
myotubes with DEX and INS, respectively. However, this stress did not result in a 
STARS-dependent change in muscle cell protein synthesis or degradation. This 
demonstrates that over expression of STARS does not increase the sensitivity of the 
cell to intracellular catabolic or anabolic stress signals. STARS overexpression in rat 
primary cardiomyocytes only increases p-AKT levels in the presence of over 
expressed MRTF-A [291]. These observations further support the notion that STARS 
expression alone does not directly influence muscle hypertrophy signalling pathways 
in C2C12 muscle cells. Therefore, the observation that STARS is upregulated in 
hypertrophied skeletal muscle [166, 195] is most likely a consequence and not a 
cause of skeletal muscle hypertrophy.  
 
STARS is a transcriptional target of PGC-1α/ERRα signalling [205] and it can also 
regulate its own transcription via a feed-forward mechanism requiring SRF binding 
to the serum response element (SRE) on the STARS promoter [180]. In the present 
study it was observed for the first time that STARS overexpression increases both 
Pgc-1α and Srf mRNA levels in skeletal muscle cells. In addition, STARS over 
expression also upregulated several PGC-1α/ERRα target genes, such as Ckmt2 [185, 
267] and Cpt-1β [246, 298]. Although STARS increased SRF gene expression, there 
was no change in SRF target genes involved in muscle growth, such as Igf-1, or 
contractile function such as α-actin and Mhc2b. These observations suggest that a 
forced up regulation in STARS, at least under basal, non-mechanically stressed 
conditions, has a greater impact on transcriptional pathways involved in muscle 
oxidative metabolism rather than growth and contractile function. 
 
STARS expression is reduced in conditions associated with reduced physical 
activity, mechanical loading and muscle atrophy, such as ageing, de-training and 
hind limb suspension [135, 198, 200]; conditions associated with increased 
inflammation, necrosis, apoptosis and a loss of muscle mass [299-307]. In the present 
study the knockdown of STARS in myotubes resulted in an increase in cell death, 
dead cell protease activity, cellular debris and membrane blebbing. There was also a 
decrease in the number of myotubes and total protein content. Membrane blebbing, 
loss of membrane integrity and inflammation are typical signs of necrotic death [308-
311]. Membrane blebbing, DNA fragmentation and cleavage of PARP following 
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Caspase 3 activation are also signs of cells undergoing apoptotic death [308-310]. 
STARS knockdown increased the mRNA expression of several proteins involved in 
inflammation such as, Caspase 1, IL-1β and MCP-1, however, no change in DNA 
fragmentation or protein levels of cleaved Caspase 3 and PARP was observed.  
Caspase-1, a key inflammatory enzyme, cleaves and activates inflammatory 
cytokines such as IL-1β [312]. Caspase 1 and IL-1β are part of the inflammasome 
pathway and have been associated with inflammation following muscle damage and 
necrotic death [313]. Caspase-1 is also more highly expressed in necrotic cell lines 
[314]. Therefore, the cell death following STARS knockdown is more than likely 
caused by necrosis rather than apoptosis.  A hallmark of necrotic death is the loss of 
membrane integrity [308-311].   As STARS binds and stabilizes the sarcomere and 
the actin cytoskeleton [133], an increase in necrosis following STARS knockdown 
would potentially result in a loss in membrane structural integrity. This may have 
direct clinical relevance as muscle from older animals has a decrease in STARS 
[135, 200] and an increased susceptibility to contraction-induced damage, partly due 
to compromised sarcomeric structure [201]. Rescuing STARS in the elderly may be 
therapeutic strategy to reduce contraction-induced muscle damage and maintain 
muscle mass and function.  
 
Inflammation plays an essential role in skeletal muscle regeneration following 
damage or injury [36].  In the present study, an increase gene expression of the 
perinatal myosin heavy chain isoform MYH8 as well as SOCS3, a cytokine-
inducible negative regulator of cytokine signalling, was observed following STARS 
knockdown. Increased gene expression of both MYH8 and SOCS3 has been 
observed many models of muscle regeneration such as exercise, cardiotoxin 
treatment, hindlimb ischemia, and Duchene’s muscular dystrophy (DMD) [195, 315-
320].  Additionally, the expression of MCP-1 is also essential for proper 
inflammatory response and muscle regeneration following injury [321]. These 
findings suggest that STARS knockdown activates signals promoting myotube death 
and damage as well as signals for muscle regeneration.  
 
The knockdown in STARS altered the myosin heavy chain isoform profile. There 
was a reduction in the slow oxidative Mhc1 isoform and increases in the fast-
oxidative Mhc2a and fast-glycolytic Mhc2x isoforms. Additionally, there was a 
  111 
reduction in Cpt-1 and Ckmt2. Combined these changes in gene expression   
suggest a shift from a slow to fast switch muscle fibre phenotype. Interestingly, a 
slow to fast isoform conversion is observed in both human and rodents following 
skeletal muscle unloading [11, 322, 323]; models that also present decreases in 
STARS [166, 198]. Additionally, this switch in MHC isoform expression is also 
observed in patients with chronic heart failure (CHF); a condition characterized by 
systemic inflammation [324, 325].  It is currently unknown if changes in MHC 
isoform are a direct effect of STARS, occur indirectly due to the inflammation 
response following STARS knockdown, or a reduced capacity of the muscle to sense 
mechanical loading.  
 
STARS knockdown in both C2C12 myotubes and primary neonatal rat ventricular 
myocytes decreases SRF activity [137]. In the present study STARS knockdown 
decreased actin polymerisation; a cellular process required to increase SRF activity 
by STARS [133].  However, this result was associated with an increased gene 
expression of the SRF target gene α-actin. This increase in α-actin may be due to the 
SOCS3 activation of SRF. It has previously been shown that SOCS3 stimulates SRF 
transcriptional activity and directly increases α-actin gene expression in 
differentiating C2C12 myotubes [315].  Therefore, a potential loss in SRF 
transcriptional activity following STARS knockdown in muscle cells may be 
compensated by the up-regulation of other proteins, such as SOCS3, in an attempt to 
maintain SRF target gene transcription and muscle contractile function. Additionally, 
in the current study STARS knockdown upregulated α-actinin-2, a protein that plays 
an important structural role by cross-linking actin at the Z-disc of the sarcomere [99-
101]. α-actinin-2 interacts with a variety of proteins involved in skeletal muscle 
structure, contraction, mechanosensing and intracellular signalling pathways 
involved in muscle hypertrophy [99-101] and therefore, like STARS, is seen as an 
important link between muscle function and muscle adaptation.  As STARS and α-
actinin-2 seem to have similar localization, binding characteristics and potential 
functions in skeletal muscle, it is plausible that the increase in α-actinin-2 expression 
following STARS knockdown is an attempt to maintain muscle structure and 
function. 
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In conclusion, we show for the first time in C2C12 myotubes that STARS 
overexpression increases actin polymerization without a paralleled increase in 
muscle cell growth. STARS increases PGC-1α and SRF mRNA levels as well as the 
mRNA levels of proteins expressed more in an oxidative fibres, which suggests that 
STARS may shifts the muscle cell to a more oxidative phenotype. The suppression 
of STARS results in cell death and increases markers of necrosis, inflammation and 
regeneration. As STARS levels are suppressed in clinical models associated with 
increased necrosis, and inflammation such as aging and limb immobilization, 
rescuing STARS maybe a future therapeutic strategy to maintain skeletal muscle 
function and attenuate contraction-induce muscle damage. 
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CHAPTER 5 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
5.1 Introduction 
Skeletal muscle is a highly adaptive tissue that can alter its size and biochemical 
makeup in response to many factors. Skeletal muscle size and function is tightly 
regulated by the regenerative capacity of the muscle as well as by the balance 
between the processes controlling muscle protein synthesis and protein degradation.  
Skeletal muscle atrophy is characteristic of many disease states and aging and results 
in a loss of functional independence and an increase in morbidity and mortality. 
Therefore, the maintenance of skeletal muscle mass is essential for improving the 
quality and longevity of life as well as reducing the risk of disease.  Understanding 
the molecular signalling pathways controlling skeletal muscle growth and 
regeneration is essential to the development of therapeutic strategies for the treatment 
of muscle loss and maintenance of muscle mass with disease and age.  Proteins 
involved in the sensing and transduction of mechanical stimuli such as exercise, are 
important intermediary components linking contractile function to intracellular 
signalling pathways that stimulate muscle growth and regeneration.  It is currently 
still largely unknown which intracellular signalling pathways are activated in 
response to different stimuli and how the activation of these pathways result in 
changes to the structural, functional and metabolic phenotype of skeletal muscle. 
 
Recent studies have identified STARS as a muscle specific actin binding protein that 
is responsive to mechanical stress and that stimulates an intracellular signalling 
pathway involved in muscle growth and remodelling.  In vitro, STARS is involved in 
smooth muscle proliferation and cardiomyocyte hypertrophy. In vivo, STARS 
induces an exaggerated cardiac hypertrophy when under mechanical load.  Little is 
known about the types of mechanical stimuli and transcription factors that regulate 
the expression of STARS or the potential roles that STARS has in skeletal muscle.   
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The specific aims of this thesis were: 
 
1. To investigate whether the expression of STARS and members of its 
downstream signalling pathway are regulated in response to an acute bout of 
endurance exercise and to determine if the STARS gene is regulated via 
PGC-1α/ERRα signalling. 
 
2. To investigate the effect of STARS overexpression on skeletal muscle cell 
proliferation and differentiation in vitro and determine whether altering the 
expression of STARS influences several SRF and PGC-1α/ERRα target genes 
involved in myoblast proliferation and differentiation. 
 
3. To investigate the effect of STARS overexpression and knockdown on 
skeletal muscle cell protein synthesis and degradation and determine whether 
altering the expression of STARS influences several SRF and PGC-1α/ERRα 
target genes involved in muscle cell structure, function and growth.  
 
 
5.2 Summary of major findings 
The broad aims of this thesis were to investigate the role and regulation of STARS in 
skeletal muscle.  The present findings show that endogenous STARS mRNA and 
protein levels are sensitive to the mechanical stress induced by endurance exercise. 
They also identify STARS as a positive regulator of myogenesis and an essential 
component for myotube survival. 
 
In Chapter 2 it was shown for the first time that an acute bout of single-leg endurance 
exercise is sufficient to induce an increase in STARS mRNA and protein levels.  
This result was also associated with an increased nuclear protein content of 
downstream transcription factors, MRTF-A and SRF.  In C2C12 myotubes the 
STARS gene was identified as a target of the PGC-1α/ERRα transcriptional 
complex. STARS is also required for the PGC-1α regulation of the Cpt-1β gene in 
C2C12 myotubes. These results show that STARS and members of its signalling 
pathway are regulated by endurance exercise, and that STARS possibly plays a role 
in PGC-1α regulation of oxidative metabolism. 
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In Chapter 3, STARS overexpression in C2C12 myoblasts increased myoblast 
proliferation.  This finding was associated with an increase in SRF target genes 
known to be involved in cell proliferation such as, Il-6, c-fos, and Junb. Additionally, 
the gene expression of two proteins involved in cell cycle exit, p21 and p27 were 
suppressed following STARS overexpression in C2C12 myoblasts.  These results 
suggest that STARS potentially increases myoblast proliferation by stimulating the 
transcriptional activity of its downstream target, SRF and also by regulating the gene 
expression of proteins involved in the cell cycle.  Overexpressing STARS in C2C12 
myoblasts, at the onset of differentiation, enhanced myogenic differentiation by 
increasing the number of formed myotubes. This result was associated with an 
increased gene expression of Ckm and several MHC isoforms; markers of 
differentiation. Finally, STARS overexpression increased the expression of SRF 
target genes α-actin and Mhc2b and also PGC-1α/ERRα target genes including 
Mhc2a, Cpt-1β and Ckmt2; genes collectively known to be involved in muscle cell 
structure, contraction, mitochondrial biogenesis and oxidative metabolism.  These 
results suggest that STARS potentially enhances muscle cell differentiation by 
stimulating the transcriptional activity of both SRF and PGC-1α/ERRα, and highlight 
a novel role in regulating muscle growth, mitochondrial biogenesis and oxidative 
metabolism in developing skeletal muscle cells. 
 
In Chapter 4 the potential role of STARS in regulating muscle cell size via 
alterations in protein synthesis and protein degradation rates was investigated by 
overexpressing and knocking down STARS in C2C12 myotubes.  Overexpression of 
STARS in C2C12 myotubes increases actin polymerization, however this did not 
affect protein synthesis, protein degradation or AKT phosphorylation.  Interestingly, 
overexpression of STARS increased the gene expression of PGC-1α and SRF as well 
as several PGC-1α /ERRα target genes such as Ckmt2 and Cpt-1β and the slow 
myosin isoform, Mhc1.  These results suggest that under non-stressed conditions, 
STARS overexpression does not affect skeletal muscle cell size or protein balance. 
However, it does increases actin polymerization and shifts the muscle cell to a more 
oxidative phenotype, potentially via up regulation of PGC-1α. Knockdown of 
STARS in C2C12 myotubes reduced actin polymerization and increased cell death, 
dead cell protease activity, markers of necrosis and inflammation, including caspase-
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1, IL-1β and Mcp-1 as well as markers of regeneration such as SOCS3 and the 
embryonic myosin, Myh8. Finally, STARS knockdown moved the myotubes towards 
a faster contractile phenotype as indicated by a reduction in Mhc1 and increased 
Mhc2a and Mhc2x gene expression.  These results suggest that STARS is an 
essential protein for maintaining normal muscle cell structure and function as well as 
cell survival.  
 
5.3 Future directions 
This thesis identifies STARS as an exercise induced protein that potentially mediates 
skeletal muscle growth and regeneration.  STARS is a protein that associates with the 
sarcomere and its up regulation in response to exercise may potentially increase 
muscle cell sensitivity to muscle contraction and enhance activation of intracellular 
signalling pathways involved skeletal muscle growth and regeneration.  This thesis 
also identifies STARS as an essential component of skeletal muscle that is required 
for muscle cell survival.  Whilst these studies have helped to identify potential roles 
and regulation of STARS in skeletal muscle, our understanding about its function 
and downstream signalling effects remains limited.   Future in vivo studies using 
either STARS knockout or overexpression mouse models are required to validate the 
roles identified in vitro and may lead to the identification of other functions within 
skeletal muscle.  
 
5.3.1 The role of STARS in skeletal muscle regeneration following muscle injury 
in vivo 
 
Rationale 
STARS is an actin binding protein that associates with the sarcomere and is 
transiently up regulated in response to mechanical stress such as pressure overload 
and exercise.  In Chapter 3, STARS overexpression increased skeletal muscle cell 
proliferation and differentiation and was associated with increased expression of SRF 
and PGC-1α/ERRα target genes.  Together these findings suggest that STARS is 
potentially involved in the sensing of mechanical stress and stimulates intercellular 
signalling pathways involved in skeletal muscle regeneration; however this has not 
been investigated in vivo. 
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Aims 
To investigate the effects on skeletal muscle regeneration in response to muscle 
injury with STARS overexpression and knockout in vivo. 
 
Key methods 
STARS knockdown and overexpression in vivo would be achieved using STARS 
knockout (KO) mice and infecting mice with a recombinant adeno-associated virus 
(rAAV) containing the mouse STARS gene, respectively.  AAV are small single 
stranded DNA that are currently seen as an attractive gene therapy tool as they 
induce long term gene expression without to date any associated disease or pathology 
[326].  Presently, AAV are being used in several clinical trials for the treatment of 
muscular dystrophies [327].  Hindlimb unloading/reloading and crush injury are two 
models which have been used previously to cause skeletal muscle injury in mice 
[328, 329].  These models would be used to cause muscle injury to mice 
overexpressing STARS, STARS KO mice and appropriate wildtype (WT) controls.  
The assessment of muscle injury and regeneration would be determined by 
microscopic examination of muscle sections to quantify normal fibres, regenerating 
and degenerating muscle fibres as well as fat cell infiltration and fibrotic tissue.  
RNA and protein analysis will be used to confirm and extend on the gene and protein 
expression changes observed from the in vitro observations in Chapter 3.  To 
complement these in vivo experiments, in vitro proof of concept analysis may shed 
light on the potential downstream signalling effects of STARS on muscle cell 
proliferation and differentiation.  For instance, in Chapter 3 STARS overexpression 
during myogenic differentiation increases the mRNA expression of SRF target gene, 
α-actin.  To identify whether the increase in α-actin mRNA following STARS 
overexpression was via SRF, forced overexpression of STARS in differentiating 
C2C12 muscle cells would be followed by SRF knockdown to confirm whether 
STARS induced increase in α-actin mRNA requires SRF. Finally, an electromobility 
mobility shift assay (EMSA) would be used to confirm an increase in SRF binding to 
the α-actin promoter region in muscle nuclear extracts from mice overexpressing 
STARS.   
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Significance 
STARS enhances skeletal muscle cell proliferation and differentiation in vitro; two 
essential processes involved in muscle regeneration.  Whether STARS stimulates a 
similar response in an animal model and enhances skeletal muscle regeneration 
following injury has not been investigated.  Additionally, the direct downstream 
targets of STARS that potentially influence muscle cell proliferation and 
differentiation are still to be identified.  This investigation would increase our 
understanding of the potential role of STARS in skeletal muscle regeneration and 
may identify it as a future therapeutic target to enhance skeletal muscle repair and 
regeneration following damage. 
 
5.3.2 The effect of STARS on skeletal muscle structure, function and phenotype in 
vivo. 
 
Rationale 
In Chapter 4, STARS overexpression in skeletal myotubes increased PGC-1α and 
SRF mRNA levels and shifts the muscle cell to a more oxidative phenotype. On the 
other hand STARS knockdown resulted in cell death and increases markers of 
necrosis, inflammation and regeneration. Together these findings suggest that 
altering STARS expression changes several structural, functional and phenotype 
characteristics of skeletal muscle; however this is still to be observed in an in vivo 
model.  
 
Aims 
To investigate the changes in skeletal muscle structure, function and phenotype in 
response to STARS overexpression and knockout in vivo. A secondary aim would be 
to determine if STARS overexpression or knockout alters survival rates. 
 
Key methods 
STARS knockdown and overexpression in vivo would be achieved using STARS KO 
mice and infecting mice with a rAAV containing the mouse STARS gene, 
respectively.  Mice would be housed under normal conditions, exposed to a standard 
diet and normal cage activity and sacrificed at different stages of the life span. 
Microscopic examination of muscle sections will be used to quantify normal fibres, 
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regenerating and degenerating muscle fibres as well as non-muscle areas.  
Immunofluorescent staining would be used to identify type I, type IIa and type IIb 
muscle fibres [267].  To investigate muscle strength and fatigability, mice would be 
subjected to functional tests such as grip strength test and treadmill running until 
exhaustion [267].  RNA and protein analysis will be used to confirm and extend on 
the gene and protein expression changes observed from the in vitro observations in 
Chapter 4.  To complement these in vivo experiments, as mentioned above in vitro 
proof of concept analysis may potentially identify downstream signalling targets of 
STARS involved in muscle cell growth, structure and function.   
 
Significance 
The suppression of STARS in skeletal muscle cells in vitro results in cell death and 
increases markers of necrosis, inflammation and regeneration.  The proposed study is 
required to confirm whether similar observations occur in vivo and will extend our 
knowledge of the potential role of STARS in skeletal muscle maintenance. As 
STARS levels are suppressed in clinical models associated with increased necrosis, 
and inflammation such as aging and limb immobilization, rescuing STARS maybe a 
future therapeutic strategy to maintain skeletal muscle function with age and disuse.   
Forced chronic overexpression of STARS appears to make cardiac muscle 
hypersensitive to adaptive external stress and may result in a maladaptive response in 
this tissue. Therefore, this proposed study is essential to the identification of any 
potential harmful side effects resulting from uncontrolled STARS overexpression in 
skeletal muscle. 
 
5.3.3 Skeletal muscle adaptations to exercise following STARS overexpression in 
vivo 
 
Rationale 
In Chapter 4 the overexpression of STARS in differentiated mouse C2C12 myotubes, 
did not alter myotube protein synthesis and degradation and subsequently did not 
change myotube size. In vivo, forced overexpression of STARS in the heart under 
normal conditions does not alter cardiac muscle mass however results in an amplified 
hypertrophic response after the addition of a mechanical loading stress [178]. These 
findings suggests that the over expression of STARS in muscle alone is not sufficient 
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to cause a hypertrophic response. However, an elevated level of STARS in skeletal 
muscle may increase the sensitivity of the cell to extracellular mechanical stress 
signals, such as exercise, resulting in enhanced growth; however this has not been 
investigated in an in vivo model. 
 
Aims 
To investigate the potential role of STARS in the regulation of skeletal muscle mass 
in response to exercise in vivo. 
 
Key methods 
STARS overexpression in vivo would be achieved by infecting mice with a rAAV 
containing the mouse STARS gene.  Mice would be subjected to an 8-week training 
protocol involving treadmill running, which has previously been shown to invoke a 
hypertrophic response in skeletal muscle [330].  Hind limb muscles will be extracted 
and weighed to compare muscle mass differences between mice overexpressing 
STARS and control mice.  Microscopic examination of muscle sections will be used 
to quantify normal fibres, regenerated, and degenerated muscle fibres as well as non-
muscle areas.  Immunofluorescent staining would be used to identify type I, type IIa 
and type IIb muscle fibres [267].  To investigate muscle strength and fatigability, 
mice would be subjected to functional tests such as grip strength test and treadmill 
running until exhaustion [267].  RNA and protein analysis will be used to examine 
the expression of key proteins involved in protein synthesis and protein degradation 
pathways, as well as examination of SRF and PGC-1α/ERRα target genes. 
 
Significance 
Due to its sarcomeric localization and upregulation in response to exercise, STARS 
maybe a key link between contractile function and intracellular pathways that 
regulate skeletal muscle growth.  The proposed study will enhance our understanding 
the intracellular signalling pathways that regulate skeletal muscle adaptation to 
exercise may lead to the development of future therapeutic targets for the treatment 
of muscle wasting conditions. 
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These proposed studies are only a small part of the many studies that are possible and 
required to gain a further understanding of the role of STARS in skeletal muscle 
adaptation, growth and regeneration.  STARS and its downstream signalling pathway 
are just one part of the large and complex intracellular signalling web that may 
impact on skeletal muscle growth and function. The STARS protein appears to be a 
key player in the detection and transmission of adaptive stress signals in muscle 
cells. However, forced chronic overexpression of STARS appears to make the 
muscle cells hypersensitive to adaptive external stress and may result in a 
maladaptive response. These observations suggest that if STARS was to be 
considered a therapeutic target to enhance skeletal muscle growth and repair then it 
would require a precise and conditional method of induction or suppression. 
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5.4 Conclusions 
In summary the main findings of this thesis are: 
 
• STARS and members of its downstream signalling pathway are upregulated 
in response to an acute bout of endurance exercise in humans. 
 
• STARS is a transcriptional target of PGC-1α/ERRα and possibly plays a role 
in PGC-1α regulation of oxidative metabolism in C2C12 myotubes. 
 
• STARS overexpression in C2C12 myoblasts increases myoblast proliferation 
in C2C12 cells, potentially via the upregulation of SRF target genes involved 
in cell proliferation. 
 
• STARS overexpression at the onset of myoblast differentiation in C2C12 
cells enhances myogenic differentiation potentially via the upregulation of 
SRF and PGC-1α/ERRα target genes involved in muscle cell structure, 
contraction, mitochondrial biogenesis and oxidative metabolism. 
 
• STARS overexpression does not affect skeletal muscle cell size or protein 
balance, however, shifts the muscle cell to a more oxidative phenotype, 
potentially via up regulation of PGC-1α. 
 
• Knockdown of STARS in C2C12 myotubes increased cell death, dead cell 
protease activity, markers of necrosis and inflammation and shifts the 
myotubes towards a faster contractile phenotype. 
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Striated muscle activator of Rho signalling (STARS) is a
PGC-1α/oestrogen-related receptor-α target gene and is
upregulated in human skeletal muscle after endurance
exercise
Marita A. Wallace1, M. Benjamin Hock2, Bethany C. Hazen2, Anastasia Kralli2, Rod J. Snow1
and Aaron P. Russell1
1Centre for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Burwood 3125, Australia
2Department of Chemical Physiology, The Scripps Research Institute, La Jolla, USA
Non-technical summary Exercise improves the ability of skeletal muscle to metabolise fats and
sugars. For these improvements to occur the muscle detects a signal caused by exercise, resulting
in changes in genes and proteins that control metabolism. We show that endurance exercise
increases the amount of a protein called striated muscle activator of Rho signalling (STARS) as
well as several other proteins influenced by STARS. We also show that the amount of STARS can
be increased by signals directed from proteins called peroxisome proliferator-activated receptor
gamma co-activator 1-α (PGC-1α) and oestrogen-related receptor-α (ERRα). We also observed
that when we reduce the amount of STARS in muscle cells, we block the ability of PGC-1α/ERRα
to increase a gene called carnitine palmitoyltransferase-1β (CPT-1β), which is important for fat
metabolism. Our study has shown that the STARS pathway is regulated by endurance exercise.
STARS may also play a role in fat metabolism in muscle.
Abstract The striated muscle activator of Rho signalling (STARS) is an actin-binding protein
specifically expressed in cardiac, skeletal and smoothmuscle. STARShas been suggested to provide
an important link between the transduction of external stress signals to intracellular signalling
pathways controlling genes involved in the maintenance of muscle function. The aims of this
study were firstly, to establish if STARS, as well as members of its downstream signalling pathway,
are upregulated following acute endurance cycling exercise; and secondly, to determine if STARS
is a transcriptional target of peroxisome proliferator-activated receptor gamma co-activator 1-α
(PGC-1α) and oestrogen-related receptor-α (ERRα). When measured 3 h post-exercise, STARS
mRNA and protein levels as well as MRTF-A and serum response factor (SRF) nuclear protein
content, were significantly increased by 140, 40, 40 and 40%, respectively. Known SRF target
genes, carnitine palmitoyltransferase-1β (CPT-1β) and jun B proto-oncogene (JUNB), as well as
the exercise-responsive genes PGC-1α mRNA and ERRα were increased by 2.3-, 1.8-, 4.5- and
2.7-fold, 3 h post-exercise. Infection of C2C12 myotubes with an adenovirus-expressing human
PGC-1α resulted in a 3-fold increase in Stars mRNA, a response that was abolished following the
suppression of endogenous ERRα. Over-expression of PGC-1α also increased Cpt-1β, Cox4 and
Vegf mRNA by 6.2-, 2.0- and 2.0-fold, respectively. Suppression of endogenous STARS reduced
basal Cpt-1β levels by 8.2-fold and inhibited the PGC-1α-induced increase in Cpt-1β mRNA.
Our results show for the first time that the STARS signalling pathway is upregulated in response
to acute endurance exercise. Additionally, we show in C2C12 myotubes that the STARS gene is a
PGC-1α/ERRα transcriptional target. Furthermore, our results suggest a novel role of STARS in
the co-ordination of PGC-1α-induced upregulation of the fat oxidative gene, CPT-1β.
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Abbreviations Abra, actin-binding rho activating protein; CPT-1β, carnitine palmitoyltransferase 1β; COX4, cyto-
chrome c oxidase subunit IV; DAPI, 4,6-diamidino-2-phenylindole; ERRα, oestrogen-related receptor-α; IGF-1,
insulin-like growth factor-1; JUNB, jun B proto-oncogene; MRTF-A, myocardin-related transcription factor-A;
ms1, myocyte stress-1; MHCI, myosin heavy chain I; MHCIIa, myosin heavy chain IIa; PGC-1α, peroxisome
proliferator-activated receptor gamma co-activator-1α; SRF, serum response factor; STARS, striated muscle activator of
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Introduction
Skeletal muscle contraction is a catalyst for numerous
physiological adaptations including enhanced substrate
metabolism, growth and regeneration (Hawke, 2005;
Hawley et al. 2006; Leger et al. 2006a; Russell, 2010). For
these skeletalmuscle adaptations to occur the extracellular
signals must be detected, then transmitted to the cell
(Schiaffino et al. 2007). These signals result in the
intracellular activation of transcriptional co-activators
and transcription factors (McGee et al. 2006) with a
consequent increase in their target genes that encode
proteins mediating metabolic, structural and contra-
ctile function of skeletal muscle (Hawley et al. 2006;
Hood, 2009). Understanding the molecular targets and
intracellular signals activated by exercise is important
for identifying potential therapeutic targets to combat
diseases characterized by perturbed skeletal muscle
metabolism, growth and regeneration.
The striatedmuscle activatorofRho signalling (STARS),
also known as myocyte stress-1 (ms1) (Mahadeva et al.
2002) and actin-binding rho activating protein (Abra)
(Troidl et al. 2009), is an actin-binding protein specifically
expressed in cardiac, skeletal and smooth muscle (Arai
et al.2002;Mahadeva et al.2002;Troidl et al.2009). STARS,
in part in collaboration with RhoA, enhances the binding
of free G-actin to F-actin filaments, resulting in enhanced
or stabilized actin polymerization (Arai et al. 2002).
As a consequence there is a reduction in free G-actin,
which permits the nuclear translocation of the trans-
criptional co-activator myocardin-related transcription
factor-A (MRTF-A) (Sotiropoulos et al. 1999).MRTF-A is
a transcriptional co-activator of SRF (Miralles et al. 2003),
a transcription factor known to regulate genes involved
in muscle metabolism and growth (Charvet et al. 2006;
Miano et al. 2007). STARS gene expression is increased
in rat heart during pressure overload (Mahadeva et al.
2002) and its mRNA and proteins levels are increased in
rabbit smoothmuscle following fluid shear stress-induced
arteriogenesis (Troidl et al. 2009). Forced over-expression
of STARS causes cardiac hypertrophy in mice (Kuwahara
et al. 2007) and increases the proliferation of porcine
smoothmuscle cells (Troidl et al. 2009). STARSmRNA, as
well as several members of the STARS signalling pathway,
are upregulated in hypertrophied human skeletal muscle
following increased muscle loading caused by resistance
exercise training and downregulated following reduced
training (Lamon et al. 2009). STARS has therefore been
suggested to provide an important link between the
transduction of external stress to intracellular signalling
pathways and the control of genes involved in the
maintenance of muscle function (Arai et al. 2002; Troidl
et al. 2009; Russell, 2010).
Moderate-intensity skeletalmuscle contraction induced
by endurance exercise has positive health implications
for diseases such as diabetes, obesity and cardiovascular
disease as well as maintaining skeletal function in the
elderly (Booth et al. 2002; Ventura-Clapier et al. 2007;
Koutroumpi et al. 2008). It has recently been observed
that endurance exercise increases the phosphorylation of
SRF (Rose et al. 2007), a key downstream target of the
STARS signalling pathway (Arai et al. 2002;Kuwahara et al.
2005). Whether endurance exercise increases the levels of
STARS, members of the STARS signalling pathway and/or
downstream transcriptional targets involved in muscle
metabolism and growth has not been investigated.
The STARS gene has recently been identified as a trans-
criptional target of MEF2 in cardiac muscle (Kuwahara
et al. 2007) as well asMyoD in C2C12myotubes (Ounzain
et al.2008).Analysis of thehumanSTARSpromoter reveals
also an oestrogen-related receptor-α (ERRα) binding site,
located 150 bp upstream of the transcriptional start site.
ERRα, in combinationwith its transcriptional co-activator
PGC-1α, is known to regulate genes involved in skeletal
muscle function (Hock & Kralli, 2009). As both ERRα
and PGC-1α are upregulated in human skeletal muscle
following endurance exercise (Cartoni et al. 2005; Russell
et al. 2005), it is possible that STARS is a target of the
PGC-1α/ERRα transcriptional program.
Therefore the primary aim of the present study was
to determine if STARS and members of its downstream
signalling pathway, including MRTF-A and SRF, as well as
several SRF target genes including CPT-1β, JUNB, α-actin
and insulin-like growth factor-1 (IGF-1), are upregulated
C© 2011 The Authors. Journal compilation C© 2011 The Physiological Society
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following acute endurance exercise. A secondary aim
was to determine if the STARS gene is regulated via
PGC-1α/ERRα signalling.
Methods
Subjects
Nine healthy male subjects participated in the study:
age 24 ± 5 years, weight 84 ± 10 kg, single leg V˙O2max
36.6 ± 3.8 ml kg−1 min−1. The study was approved by the
Deakin University Human Research Ethics Committee in
accordance with the Declaration of Helsinki (2000). All
participants gave their informed consent and agreed to
muscle biopsies and physiological testing.
Preliminary testing
Subjects were familiarised with the electromagnetically
braked cycle ergometer (Lode B.V, Groningen, The
Netherlands) and single leg cycling on two separate
occasions prior to a single leg cycling V˙O2peak test. The
V˙O2peak test involved single leg cycling at three incremental
work rates of 65, 80 and 95W for 3min followed by
an increase of 15Wmin−1 until exhaustion. Expired
air was collected and analysed using zirconia cell O2
and infrared CO2 analysers (Applied Electrochemical
Instrument, Pittsburgh, PA, USA) that were calibrated
against 0.01% alpha-rated gases (Medgraphics, St Paul,
MN, USA).
Experimental procedure
Subjects commenced the experimental trial 1 week after
the V˙O2peak test and abstained from strenuous exercise
during this time. For each testing session the sub-
jects were required to report to the laboratory having
fasted overnight, and abstained from caffeine and alcohol
consumption for 24 h. On the first day of the trial a resting
muscle sample (pre)was obtained from thenon-exercising
(NEx) leg to avoid the potential influence of a stress
response from the biopsy needle. With the exercising
(Ex) leg subjects then performed single leg cycling at
65% single leg V˙O2peak (95.9 ± 19.5W) until exhaustion
(1.2 ± 0.2 h),whichwasdeterminedby the subjects’ choice
to cease cycling or by the subjects’ inability to maintain
the required cadence. Muscle samples were taken from the
Ex leg at 3 and 24 h post-exercise.
Muscle biopsies
Skeletal muscle samples were obtained under local
anaesthesia (1% Xylocaine) from the belly of the vastus
lateralis muscle using a percutaneous needle biopsy
technique (Bergstrom, 1962) modified to include suction
(Evans et al. 1982). Following a small incision through the
skin,muscle biopsies were taken using a Bergstromneedle,
snap frozen and stored in liquid nitrogen until required
for analysis.
RNA extraction
Total RNA was extracted from 5–20mg skeletal muscle
samples using Tri-Reagent Solution (Ambion Inc., Austin,
TX, USA) according to the manufacturer’s protocol.
First-strand cDNAwas generated from 1 μg RNA in 20 μl
reaction buffer using the AMV reverse transcriptase (RT)
kit (Promega, Madison, WI, USA) and RandomHexomer
primers (500 ng) (Promega) according to manufacturer’s
protocol.
Real-time quantitative PCR
Real-time PCR was carried out using either a 7500
Real-Time PCR system (Applied Biosystems, Forster City,
CA, USA) or a Stratagene MX3000 PCR system (Agilent
Technologies, Santa Clara, CA, USA) to measure mRNA
levels of STARS, α-actin, IGF-1, PGC-1α, ERRα, CPT-1β,
cytochrome c oxidase subunit IV (COX4) and JUNB.
To compensate for variations in input RNA amounts
and efficiency of the reverse transcription, data were
normalized to cyclophilin mRNA levels when assaying
muscle biopsies, and ribosomal protein 36B4 (also known
as RPLPO) RNA levels when assaying C2C12 cells. PCR
primers for the mouse genes are as follows; Stars, forward
TCA AACGCCCCT TGC TCT C, reverse CGTGTT CAT
CGG CCC ACT; Cpt-1β, forward ATT CTG TGC GGC
CCT TAT TGG AT, reverse TTT GCC TGG GAT GCC
TGT AGT GT; Cox4, forward ACT ACC CCT TGC CTG
ATGTG, reverse GCCCACAACTGTCTTCCATT;Vegf ,
forward AAGCCAGCACAT AGGAGAGATGA, reverse
TCT TTC TTT GGT CTG CAT TCA CA. Other primer
sequences and PCR conditions for the amplified genes
have been published previously (Puntschart et al. 1998;
Russell et al. 2003a; Cartoni et al. 2005; Leger et al. 2006b;
Lamon et al. 2009).
Protein extraction
Nuclear and cytosolic proteinswere extracted fromskeletal
muscle using the NE-PER Nuclear and Cytoplasmic
extraction kit (Pierce Biotechnology, Rockford, IL, USA)
as performed previously by our group (Lamon et al. 2009).
Exactly 2 μl of inhibitor cocktail, containing protease and
phosphatase inhibitors (Sigma, St Louis, MO, USA) at a
ratio of 1:1 per 20mg of muscle sample was added before
the extraction of both cytosolic and nuclear proteins.
In brief, the muscle samples were homogenised in the
C© 2011 The Authors. Journal compilation C© 2011 The Physiological Society
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CER I solution provided in the NE-PER kit using a Poly-
tronPT1200C (KinematicaAG, Luzern, Switzerland). The
following steps were performed in accordance with the
manufacturer’s protocol. For myotubes, total protein was
extracted using 1× RIPA buffer (Millipore, North Ryde,
NSW, Australia) with 1 μl ml−1 protease inhibitor cocktail
(Sigma, Castle Hill, NSW, Australia) and 10 μl ml−1
Halt Phosphatase Inhibitor Single-Use Cocktail (Thermo
Scientific, Rockford, IL, USA). Total protein content
was determined using the BCA protein assay kit (Pierce
Biotechnology, Rockford, IL, USA) according to the
manufacturer’s instructions.
Western blotting
Electrophoresis and protein transfer were performed
using the XCell Surelock Novex Mini-Cell (Invitrogen,
Carlsbad, CA, USA) system. Protein lysates were separated
by SDS-PAGE using pre-cast NuPAGE Novex 4 to 12%
Bis-Tris gels (Invitrogen) and transferred to a PVDF
membrane (Millipore, Billerica, MA, USA). Membranes
were then incubated at room temperature for 1 h
in blocking buffer (0.1% Tween 20–Tris-buffered saline
(TBST)) supplemented with 5% gelatin. After blocking,
membranes were incubated overnight at 4◦C with the
following primary antibodies diluted 1:1000 in 5%
gelatin–TBST: STARS (Institute ofMedical andVeterinary
Science, Adelaide, SA, Australia); SRF (Santa Cruz, sc-335;
CA, USA); MRTF-A (Santa Cruz, sc-32909). Following
washing themembraneswere incubated for1 hwithhorse-
radish peroxidase-conjugated secondary antibody diluted
1:2000 in 5% gelatin–TBST. After washing, the specific
proteins were revealed using ECL-Plus (GE Healthcare,
Buckinghamshire, UK) and exposed on a Kodak 2000mm
image station (Eastman Kodak, Rochester, NY, USA).
Individual protein band optical densities were determined
using ImageJ Software (National Institutes of Health,
Bethesda,MA, USA). Tubulin (cytoplasmic fractions) and
Lamin A (nuclear fractions) as well as Ponceau staining
(0.5% Ponceau-S (w/v), 1% acetic acid (v/v)) were used to
control for protein loading as published previously by our
group (Lamon et al. 2009). A representative blot is shown
in Supplementary Fig. S1. Validation of our STARS anti-
body using siRNA Knockdown of STARS and adenoviral
over-expression of STARS is shown in Supplementary
Fig. S2.
Immunofluorescence
Immunfluorescence experiments for identifying
fibre-specific protein levels of STARS were performed
as reported previously by our group (Russell et al.
2003b, 2004). The antibodies raised against STARS,
MHC type I and MHC type IIa were diluted 1:200, 1:10
and 1:10, and visualized using a goat anti-rabbit (IgG)
fluorescein isothiocyanate (FITC), donkey anti-mouse
(IgM)-TRITC and a goat anti-mouse (IgGγ1)-Alexaflour
320, respectively. Negative controls, using only the
secondary antibody, were also performed in parallel and
on the same glass slide as the experimental samples.
Sections were viewed and photographed using an
Olympus IX70 fluorescent microsope and a Magna Fire
camera with dedicated software. Due to freezing artifacts
only 6 of the 9 subjects were analysed. Between 80 and
120 fibres were visualized per subject.
C2C12 myotubes
C2C12 myoblasts (ATCC) were plated in 12-well or
6-well tissue culture plates in complete DMEM (10% fetal
bovine serum). As the cultures approached confluence
(∼90% confluent), media was changed to differentiation
medium (DMEM) supplemented with 2% horse serum.
Differentiation media was replaced on days 2, 4 and 6.
Adenoviral infections
For siERRα experiments, myotubes were infected with
multiplicity of infection of 200 (MOI 200) siERRα or
vector control adenovirus on day 4 of differentiation. On
day 6 of differentiation, myotubes were infected with an
additional doseofMOI200 siERRα (or vector control) and
MOI 50 of PGC-1α (tagged with a FLAG epitope) or LacZ
(control) expressing adenovirus. Twenty-four hours later,
RNA or DNAwas harvested for RT-qPCR gene expression
analysis or ChIP analyses, respectively. For expression of a
constitutively active ERRα (VP16-ERRα), day 6myotubes
were infected with MOI 50 of adenoviruses expressing
LacZ (control) orVP16-ERRα (Schreiber et al.2004).RNA
was harvested 24 h later.
siRNA knockdown of STARS combined
with PGC1α over-expression
STARS knockdown in C2C12 myotubes was achieved
using 100 pmol of Stealth RNAi siRNA (target
sequence: 5′-ACCAGAACGGTTGTCAGCAAGGCTT-3′;
Invitrogen) over a 72 h period. Stealth RNAiTM siRNA
Negative Control Hi GC (Invitrogen) was used as the
control siRNA, which contains the same GC content
as the target sequence. siRNA transfection of C2C12
myotubes was performed using 5 μl Lipofectamine 2000
(Invitrogen). Twenty-four hours after transfection, the
C2C12 myotubes were infected with either a green
fluorescent protein (GFP; control) or PGC-1α adenovirus
at a MOI of 25 for a further 48 h.
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Chromatin immunoprecipitation (ChIP)
ChIP was performed on adenovirus-transduced C2C12
myotubes as described previously (Cartoni et al.
2005). Briefly, C2C12 myotubes were crosslinked for
10min at 37◦C in 1% formaldehyde in PBS. After
quenching, sonication to ∼500 bp fragments and
pre-clearing by treatment with protein A/G sepharose,
soluble chromatin was immnuoprecipitated with the
following antibodies: anti-GFP (control), anti-FLAG
(clone M2) for the detection of FLAG-tagged PGC-1α,
or anti-ERRα (a generous gift of Dr V. Giguere
(Sladek et al. 1997)). Genomic DNA (gDNA) from
each immunoprecipitation was quantified by real-time
PCR, using primers (TCTCCTCCAAGTGCCAGAGT
and AGCTGTATTGAGGGCTACCG) to amplify an ERR
response element (ERRE) 272 bp upstream of Stars,
as well as primers specific to the ERR response
element-containing region of the Esrra gene (positive
control) and a region that lacks ERREs, distal to the
Esrra promoter (negative control) (primers described in
Villena et al. 2007). Data were normalized first against
total genomic input and then expressed relative to levels
of immunoprecipitated DNA from the ERRα negative
control region (Villena et al. 2007). Values shown are
the mean and standard deviation of three independent
experimental replicates.
Statistics
Differences between time were determined using
a one-way ANOVA. Experiments combining
over-expression and knockdown of targets were analysed
using a two-way ANOVA. The level of significance was
set at P < 0.05. Where required, a post hoc analysis was
Figure 1. Effect of acute endurance exercise on STARS mRNA, STARS protein, MRTF-A and SRF nuclear
protein
Effect of acute endurance exercise on the levels of: A, STARS mRNA; B, STARS protein; C, MRTF-A; and D,
SRF nuclear protein. Pre, before exercise; 3 h, 3 h post-exercise; 24 h, 24 h post-exercise. ∗P < 0.05, significantly
different from the other groups, ∗∗P < 0.01, significantly different from pre.
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performed using either paired or unpaired t tests with a
Bonferroni adjustment.
Results
STARS mRNA and protein levels were increased by
140% and 40%, respectively (P < 0.05), when measured
3 h post-exercise, with both returning to near-basal
levels 24 h post-exercise (Fig. 1). MRTF-A nuclear protein
content increased by 34% (P < 0.05) 3 h post-exercise
and returned to basal lines levels 24 h post-exercise.
SRF nuclear protein content also increased by 39%
when measured 3 h post-exercise (P < 0.05); however,
it remained elevated 24 h post-exercise (P < 0.01)
(Fig. 1).
Levels of the SRF targets genes, CPT-1β and JUNB
mRNA increased by 2.3- and 1.8-fold (P < 0.05),
respectively, 3 h post-exercise and returned to baseline
levels 24 h post-exercise (Fig. 2). No change in other
SRF target genes, α-actin or IGF-1 mRNA was observed.
PGC-1αmRNAandERRαmRNAwere also increased 4.5-
and 2.7-fold, respectively 3 h post-exercise and returned
to baseline levels 24 h post-exercise (Fig. 2), a response
mirroring that of STARS, CPT-1β and JUNB mRNA. As
PGC-1α is known to transcriptionally regulate CPT-1β
(Moore et al. 2003), it was of interest to determine
if STARS could also be regulated via a PGC-1α/ERRα
Figure 2. Effect of acute endurance exercise on CPT-1β, JUNB, α-actin, IGF-1, PGC-1α and ERRα mRNA
levels
Effect of acute endurance exercise on: A, CPT-1β; B, JUNB; C, α-actin; D, IGF-1; E, PGC-1α; and F, ERRα mRNA
levels. Pre, before exercise; 3 h, 3 h post-exercise; 24 h, 24 h post-exercise.. Significantly different from the other
groups; ∗P < 0.05; ∗∗P < 0.01.
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transcriptional program. Infection of C2C12 myotubes
with an adenovirus-expressing human PGC-1α resulted
in a 3-fold increase in Stars mRNA (P < 0.01). This was
abolished when the myotubes were infected with PGC-1α
as well as an adenovirus containing an siRNA sequence
against ERRα. Additionally, expression of a constitutively
active form of ERRα, VP16-ERRα, resulted in a 7-fold
increase in Stars mRNA (P < 0.01) (Fig. 3).
To test if ERRα and PGC-1α act directly at the Stars
gene to induce its expression, we asked whether ERRα
and PGC-1α interact physically with the Stars promoter.
Analysis of theStars genomic sequence indicated aputative
ERRα binding site matching the known 9 bp ERRE
consensus 5′-TNAAGGTCA-3′ (Sladek et al. 1997) and
was conserved across species (Fig. 4A). To determine
binding of endogenous ERRα and exogenous adenovirally
expressed PGC-1α at this region, we immunoprecipitated
crosslinked chromatin with antibodies against either GFP
(control antibody measuring background), FLAG-tagged
PGC-1α or ERRα, and measured the enrichment of the
Stars locus DNA in the immunoprecipitated material.
Both PGC-1α and ERRα were detected at the Stars ERRE
(Fig. 4B), as well as at the previously defined ERRE of
the Esrra gene that was used as positive control (Fig. 4C).
ERRα was detected at the Stars locus only when PGC-1α
was expressed, i.e. when endogenous ERRα levels were
induced (Cartoni et al. 2005). Knockdown of endogenous
ERRα expression by siERRα ablated binding of PGC-1α
to the Stars ERRE (Fig. 4B), demonstrating a critical role
for ERRα in recruitment of the PGC-1α co-activator to
the Stars promoter.
In human skeletal muscle we have previously shown
that PGC-1α protein levels are greater in oxidative type I
and oxidative-glycolytic type IIa fibres than in glycolytic
type IIx fibres (Russell et al. 2003a). Using immuno-
fluorescence staining we observed that STARS protein
levels are also predominately expressed in oxidative type I
and oxidative-glycolytic type IIa fibres when compared
with glycolytic type IIx fibres (Fig. 5A and B). STARS
was also expressed in the myonuclei as shown via its
co-localization with the 4,6-diamidino-2-phenylindole
(DAPI) stain (Fig. 5C–E). Due to limited nuclear protein
extracts STARS nuclear protein content could only be
measured in 6 of the 9 subjects. Following exercise, 5 of
6 subjects showed an increase in STARS nuclear protein
levels. Although the increase was by 60% this did not reach
statistical significance (Fig. 5F).
As PGC-1α is known to regulate genes involved in
mitochondrial biogenesis, angiogenesis and oxidative
phosphorylation, it was of interest to see if knockdown
of STARS could ablate this response. In C2C12 myotubes
PGC-1α over-expression resulted in a 2.0-fold increase
in Cox4 and Vegf mRNA, an effect not influenced by
the knockdown of STARS. PGC-1α over-expression also
increased Cpt-1β mRNA by 6.6-fold. However, the end-
ogenous knockdown of STARS significantly reduced the
basal levels ofCpt-1βmRNA levels by 8.2-fold and ablated
the PGC-1α-induced increase in Cpt-1β mRNA (Fig. 6).
Discussion
Identifying the molecular targets and intracellular signals
activated by endurance exercise will significantly enhance
our understanding of how skeletal muscle adapts to
increased contractile load and may identify potential
Figure 3. Stars is regulated via the PGC-1α/ERRα transcriptional program in C2C12 myotubes
A, Stars mRNA levels 24 h after expression of LacZ (control) or PGC-1α, in the absence or presence of siRNA against
ERRα (siERRα). N = 6 per group (duplicate samples from 3 separate experiments). B, Stars mRNA levels 24 h after
expression of LacZ (control) or the constitutively active VP16-ERRα. N = 4 per group. ∗∗P < 0.01, significantly
different from the other groups.
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therapeutic targets to combat diseases characterized
by perturbed skeletal muscle metabolism, growth and
regeneration. The present study demonstrates several new
and important findings, which are summarized in Fig. 7.
Firstly, we show for the first time that an acute bout of
single-leg endurance exercise is sufficient to induce an
increase in STARS mRNA and protein levels; secondly,
the response of STARS is paralleled by an increase in
the nuclear protein content of several key members of
the STARS signalling pathway, MRTF-A and SRF; thirdly,
in C2C12 myotubes the STARS gene is a target of the
PGC-1α/ERRα transcriptional complex; and finally, the
presence STARS appears to be required for the PGC-1α
regulation of the CPT-1β gene in C2C12 myotubes.
STARS, an actin-binding protein, is considered to
communicate mechanical stress signals to downstream
transcriptional regulators, such as MRTF-A and SRF,
via its influence on actin dynamics (Arai et al. 2002;
Kuwahara et al. 2005). SRF is known to regulate genes
involved in muscle structure, function and growth such
as α-actin, MHC, IGF and JUNB (Charvet et al. 2006;
Lindecke et al. 2006; Miano et al. 2007) as well as
fat metabolism, such as CPT-1β (Moore et al. 2001).
Therefore, STARSmay be an upstream regulator of signals
controlling the expression of genes which encode proteins
involved in muscle function, growth and metabolism. In
support of this notion, forced over-expression of STARS
in vivo (Kuwahara et al. 2007) and in vitro (Koekemoer
et al. 2009) results in hypertrophy of cardiac tissue and
protects against apoptosis. Additionally, we have recently
shown that the STARS signalling pathway is increased in
hypertrophied human skeletalmuscle following resistance
exercise (Lamon et al. 2009). In contrast, STARS and
several members of its signalling pathway are reduced in
skeletal muscle of sarcopenic mice (Sakuma et al. 2008)
and after 1 day of limb immobilization in rats (Giger
et al. 2009). However, after 20 days of limb immobilization
in humans there were no observed changes in STARS
Figure 4. PGC-1α and ERRα bind an ERRE upstream of Stars in C2C12 myotubes
A, a University of California, Santa Cruz (UCSC) genome browser screenshot depicting the presence of an ERRE (at
272 bp 5′ of the Stars transcription site and its conservation across species. Occupancy of PGC-1α and ERRα at the
Stars (B) and Esrra (positive control) (C) ERREs, as determined by ChIP assays in C2C12 myotubes expressing LacZ
(control) or PGC-1α, in the absence (Super) or presence of siRNA for ERRα (siErrα). Data are expressed relative to a
region devoid of ERREs and are the mean ± SD of triplicates. ∗∗P < 0.01, significantly different from all treatments
within the group.
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(Sakuma et al. 2009). The results from the present study
show that acute moderate-intensity exercise results not
only in increased levels of STARS mRNA but also the
STARSprotein.Combined, these observations suggest that
the regulation of STARS is rapid and transient which
is a logical regulatory response for a protein believed
to be responsible for the sensing and transmission of
extracellular stress signals. It should be noted that this is
the firstmeasurement of endogenous STARSprotein levels
and shows, at least in the present experimentalmodel, that
the regulation of STARS mRNA is closely mirrored by the
regulation of its protein.
In parallel with the increase in STARS, we show
for the first time that both MRTF-A and its trans-
criptional target SRF have enhanced nuclear abundance
following endurance exercise, a response consistent
with enhanced STARS activity (Kuwahara et al. 2005).
These results support our previous observation following
high-intensity resistance training (Lamon et al. 2009).
Along similar lines, endurance exercise training has also
Figure 5. The STARS protein is more
abundantly expressed in oxidative type I
and oxidative-glycolytic type IIa fibres,
than in glycolytic type IIx fibres and is also
found in the nucleus
Immunofluorescence staining of: A, the STARS
protein; and B, MHCI (red; oxidative type I),
MHCIIa (blue; oxidative-glycolytic type IIa) and
MHCIIx (not stained; glycolytic type IIx). The
same fibres to the marks of I, IIa or IIx in figures
A and B. C, DAPI stain; D, STARS stain; and E,
their co-localization, respectively, is shown in
the section. Arrows represent co-localization of
the nuclei and STARS. F, Western blot showing
the STARS protein levels in nuclear protein
fraction before, 3 h after and 24 h
post-exercise.
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been shown to increase SRF activity, as shownby enhanced
phosphorylation levels, in human skeletal muscle (Rose
et al. 2007). In the present study, we also observed an
increase in the SRF target genes CPT-1β, a regulator of
Figure 6. Regulation of: A, Cox4; B, Cpt-1β; and C, Vegf mRNA
by PGC-1α with and without STARS knockdown in C2C12
myotubes
N = 6 per group. ∗∗P < 0.01, significantly different from the other
groups.
long-chain fatty acid β-oxidation, and JUNB, a cell-cycle
and growth regulator, but not the expression levels of
α-actin and IGF-1, genes involved in structure and growth.
While these results suggest that bothmoderate and intense
exercise elicits stress signals that can be detected by STARS
and transmitted downstream to its effector targets, such
as MRTF-A and SRF, their transcriptional control might
be dependent on the exercise intensity. For example, SRF
is known to regulate over 200 genes, many of which
are involved in muscle structure, function, growth and
regeneration (Charvet et al. 2006; Miano et al. 2007)
but not all are regulated at the same time. The selective
regulation of certain SRF target genes might be attributed
to their sensitivity to the stress signals initiated by the acute
nature of the endurance exercise protocol.
While we show here that endurance exercise, and
previously that resistance exercise (Lamon et al. 2009),
regulates STARS transcription and translation, the exact
stress signals initiating this are unknown. During exercise,
numerous stress signals are initiated by changes in motor
nerve activation and calcium concentrations mechanical
and contractile stress, increased muscle blood flow
and shear stress, hormonal and metabolic stress which
are known to activate intracellular signalling pathways
controlling skeletal muscle gene transcription and trans-
lation (Bassel-Duby & Olson, 2006; Koulmann & Bigard,
2006; Park et al. 2007; Favier et al. 2008; Russell, 2010).
Identifying the primary stressor/s activated by endurance
exercise which regulate STARS, and consequently its
Figure 7. A diagram summarizing the main findings from the
study
STARS is transcriptional target of PGC-1α/ERRα signalling. Acute
endurance exercise increases STARS mRNA and protein levels as well
as the nuclear translocation of the transcriptional co-activator
MRTF-A and its target transcription factor SRF. Increased nuclear
abundance of MRTF-A and SRF should increase the potential for SRF
target transcription.
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downstream signalling pathway, is beyond the scope of
this study; however, this should be an area investigated in
the future.
Our observation that STARS is increased in response
to moderate-intensity endurance exercise suggests that
the STARS signalling pathway may also play a role in
skeletal muscle adaptations associated with endurance
exercise such as substrate oxidation, capillary function
and mitochondrial biogenesis, factors often perturbed
in metabolic diseases (Schrauwen & Hesselink, 2004).
Indeed SRF, a downstream target of STARS signalling, has
also been shown to control the transcription of CPT-1β
(Moore et al. 2001), a regulator of fat metabolism, as
well as vascular endothelial growth factor (VEGF), a
regulator of angiogenesis (Franco et al. 2008). Another
commonalty between CPT-1β and VEGF is that they
can also be regulated by the transcriptional co-activator
PGC-1α (Moore et al. 2003; Zhang et al. 2011). PGC-1α
is upregulated in human skeletal muscle in response to
both moderate- and high-intensity endurance exercise
(Russell et al. 2003a, 2005; Cartoni et al. 2005). PGC-1α
co-activates several transcription factors that regulate
genes involved in skeletal muscle substrate oxidation and
mitochondrial biogenesis (Knutti & Kralli, 2001; Hock &
Kralli, 2009). We identified that one of these transcription
factors, ERRα, has a binding site on the STARS promoter.
Therefore, we performed in vitro experiments using
C2C12 myotubes whereby we manipulated PGC-1α and
ERRα levels using adenoviral infection. Our results
demonstrate that STARS is a transcriptional target of the
PGC-1α/ERRα transcriptional program.
Previous work by our group has shown that in human
skeletal muscle, PGC-1α protein levels are greater in
oxidative type I and oxidative-glycolytic type IIa fibres
than in glycolytic type IIx fibres (Russell et al. 2003a). In
the present study, we also observed a similar fibre type
expression for the STARS protein. In addition to this, we
observed that the STARS protein was also localized to the
nucleus, which supports observations made in transiently
transfected COS cells (Arai et al. 2002) and in rat end-
othelial cells (Troidl et al. 2009). The PGC-1α regulation
of STARS, their similar fibre type expression profile, as
well as the localization of STARS in the nucleus, suggested
to us that a PGC-1α/STARS transcriptional relationship
may exist. Our observation that the knockdown of end-
ogenous STARS reduces CPT-1β mRNA and attenuates
the PGC-1α upregulation of CPT-1β mRNA supports
this possibility. However, it remains to be determined
whether STARS has the capacity to directly bind DNA or
whether its downregulation impacts indirectly on trans-
criptional signalling pathways, potentially through SRF.
These in vitro results, combined with our observation of
increases in PGC-1α and ERRα mRNA following acute
endurance exercise, suggest that a possible feed-forward
loop involving SRF, PGC-1α, ERRα and STARS may
exist duringmoderate-intensitymuscle contractionwhich
controls oxidative metabolism and muscle function. In
contrast to the increase in these genes following exercise,
skeletal muscle SRF, PGC-1α and STARS are all reduced
in conditions such as ageing (Ling et al. 2004; Lahoute
et al. 2008; Sakuma et al. 2008) and limb immobilization
(Oishi et al. 2008; Giger et al. 2009), situations that present
reduced skeletal muscle mass, function and attenuated
metabolism. The possible existence of this novel trans-
criptional pathway requires further investigation.
In conclusion, we show for the first time that STARS
mRNA and protein as well as MRTF-A and SRF nuclear
content are increased following endurance exercise.
Additionally, we have identified the STARS gene as a
PGC-1α/ERRα transcriptional target and a gene that may
be involved in the regulation of oxidative metabolism.
Future investigations should focus on STARS and its
downstream signalling pathway on the regulation of
skeletal muscle oxidative function, potentially via its
influence on actin polymerization.
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Healthy living throughout the lifespan requires continual growth and repair of cardiac,
smooth, and skeletal muscle. To effectively maintain these processes muscle cells detect
extracellular stress signals and efficiently transmit them to activate appropriate intracellular
transcriptional programs. The striated muscle activator of Rho signaling (STARS) protein,
also known as Myocyte Stress-1 (MS1) protein and Actin-binding Rho-activating protein
(ABRA) is highly enriched in cardiac, skeletal, and smooth muscle. STARS binds actin,
co-localizes to the sarcomere and is able to stabilize the actin cytoskeleton. By regulating
actin polymerization, STARS also controls an intracellular signaling cascade that stimulates
the serum response factor (SRF) transcriptional pathway; a pathway controlling genes
involved in muscle cell proliferation, differentiation, and growth. Understanding the
activation, transcriptional control and biological roles of STARS in cardiac, smooth, and
skeletal muscle, will improve our understanding of physiological and pathophysiological
muscle development and function.
Keywords: ABRA, MS-1, sarcomere, exercise, disuse, cardiac muscle, skeletal muscle, smooth muscle
IDENTIFICATION OF STARS
The striated muscle activator of Rho signaling (STARS) protein,
also known as Myocyte Stress-1 (MS1) and Actin-binding Rho-
activating protein (ABRA), is a 43 kD protein, highly enriched in
cardiac, skeletal, and smooth muscle (Arai et al., 2002; Mahadeva
et al., 2002; Peng et al., 2008; Troidl et al., 2009). STARS was inde-
pendently identified in 2002 using differential cDNA screening
for novel genes expressed in the hearts of mouse embryos (Arai
et al., 2002) and using molecular indexing to identify regulated
genes following left ventricle (LV) pressure overload in the rat
(Mahadeva et al., 2002). It is highly responsive to stress condi-
tions and its ability to stimulate the serum response factor (SRF)
(Arai et al., 2002; Kuwahara et al., 2005) transcriptional pathway
makes this protein an interesting target for understanding physi-
ological and pathophysiological muscle development. This review
highlights our current understanding of STARS with a focus on its
activation, transcriptional control, identifying physiological and
pathophysiological conditions resulting in its regulation and the
biological processes it influences. A schematic overview is shown
in Figure 1.
LOCALIZATION AND ACTIVATION OF STARS
In primary cardiomyocytes STARS locates to the sarcomere where
it associates with the I-band, predominantly around the Z-disk
and to a smaller extent in the M-line (Arai et al., 2002). When
overexpressed, STARS binds actin in rat cardiomyocytes and non-
muscle COS (monkey kidney cells) cells (Arai et al., 2002). Its
function as an actin-binding protein has important consequences
for intracellular signaling that may influence numerous cellu-
lar processes within muscle tissue. STARS, in conjunction with
Rho, enhances actin polymerization by increasing the binding of
G-actin to F-actin (Arai et al., 2002). The reduction in G-actin
removes its inhibitory effect on the transcriptional co-activator,
myocardin-related transcription factor-A (MRTFA), allowing its
translocation to the nucleus (Arai et al., 2002; Kuwahara et al.,
2005). Once in the nucleus, MRTF-A associates with SRF to
promote transcription of its target genes (Kuwahara et al., 2005).
STARS protein activity is regulated by two actin-binding
LIM (ABLIM) protein family members, ABLIM-2 and ABLIM-3
(Barrientos et al., 2007). Both ABLIM proteins co-precipitate
with STARS in transfected COS cells, strongly bind to F-actin in
C2C12 cells and localize to the sarcomere in mouse skeletal mus-
cle (Barrientos et al., 2007). The ABLIM proteins can also enhance
STARS-dependent SRF-activation. It has been suggested that the
ABLIM proteins regulate STARS activity by assisting its binding
to the sarcomere (Barrientos et al., 2007). As the sarcomere plays
a critical role in sensing biomechanical stress and activating sig-
naling pathways in skeletal muscle, STARS could possibly act as
a link between contractile function and intracellular signaling in
muscle cells.
The actin binding of STARS requires two separate but
co-dependent regions in the C-terminal end of the protein,
located between the amino acid sequences 234–279 and 346–375
(Arai et al., 2002). These regions contain two independent F-actin
binding domains, actin binding domain 1 and 2 (ABD1/ABD2)
(Fogl et al., 2011). ABD1 (fragment 193–296) binds with higher
affinity to F-actin when compared to ABD2. ABD1 does not
adopt a well-folded structure until it is bound to F-actin (Fogl
et al., 2011), while ABD2 (fragment 294–375), the most C-
terminal fragment, is independently folded (Fogl et al., 2011).
It has been hypothesized that ABD1 could completely fulfill
the actin-binding function of STARS in muscle, therefore, leav-
ing ABD2 available for other potential functions within muscle
(Fogl et al., 2011). While STARS is predominantly cytosolic, we
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FIGURE 1 | A schematic outline highlighting the physiological and pathophysiological conditions that show a regulation of STARS, the transcription
factors known to upregulate STARS, the downstream signaling events controlled by STARS, and the biological roles of STARS.
(Wallace et al., 2011) and others (Arai et al., 2002) have observed
its location in the nucleus. It is possible that the nuclear role or
function of STARS is controlled by ABD2, however, this remains
to be determined. The functional significance of STARS within
the nucleus is currently unclear but leaves the possibility that
STARS itself may act as a transcriptional co-activator or transcrip-
tion factor. Future studies are required to determine if STARS can
bind DNA.
TRANSCRIPTIONAL REGULATION OF STARS
The STARS promoter contains binding sites for several muscle-
enriched transcription factors (Figure 2). Gene expression of
STARS is diminished in the heart of Mef2c null mouse embryos.
This suggests that Mef2c may be involved in the transcriptional
regulation of STARS gene expression, at least in cardiac muscle
(Kuwahara et al., 2007). Further analysis confirmed the existence
of two regions that synergistically mediate MEF2C activation
of STARS transcription (Kuwahara et al., 2007). Two conserved
E-boxes have also been identified within the proximal 1.5 kbp
of the 5′ upstream STARS promoter sequence (Ounzain et al.,
2008). These two sites are required for recruiting MyoD and sub-
sequently activating the STARS promoter during myogenic dif-
ferentiation in C2C12 muscle cells. Recent work from our group
identified a putative estrogen-related response element (ERRE)
binding site on the STARS promoter (Wallace et al., 2011). Over
expression of constitutively active estrogen-related receptor-α
(ERRα) in C2C12 myotubes increased STARS mRNA levels.
FIGURE 2 | The known transcriptional activators of STARS, their target
sequences, and location on the STARS promoter.
Over expressing peroxisome proliferator-activated receptor-γ
coactivator-1α (PGC-1α), with and without the shRNA knock-
down of ERRα in C2C12 myotubes, demonstrated that STARS is
under the control of a PGC-1α/ERRα transcriptional program.
STARS can also regulate its own transcription via a feed-forward
mechanism that requires SRF binding to the serum response
element (SRE) on the STARS promoter (Chong et al., 2012).
Conversely, STARS is repressed in embryonic, neonatal, and adult
hearts by GATA4 (Ounzain et al., 2012). Depletion of GATA4
allows the pathological up regulation of STARS (Ounzain et al.,
2012).
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PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS THAT
INFLUENCE STARS EXPRESSION
CARDIAC MUSCLE HYPERTROPHY
Cardiac hypertrophy is an adaptation of the heart in response
to an increased workload, stress, or injury. This adaptation is
initially beneficial but sustained cardiac hypertrophy eventu-
ally results in impaired cardiac function, partially due to cell
death caused by apoptosis (Dorn, 2009). STARS is increased in
several models of cardiac hypertrophy and myopathy. Left ven-
tricle hypertrophy (LVH) in rats, stimulated by pressure overload
by aortic banding, caused a pronounced early up-regulation of
STARS within 1 h and a considerable 3-fold increase in STARS
at 4 h post banding (Mahadeva et al., 2002). This elevation of
STARS mRNA had returned to control levels before 24 h post
banding. The transient increase in STARS gene expression was
observed prior to any detectable increase in LV mass which did
not occur until at least 4 days post banding. This suggests that
STARS may detect the initial mechanical stress and its activa-
tion would signal to mechanisms that directly cause the cardiac
remodeling response to LVH. Transgenic (Tg) mice expressing
constitutively active calcineurin, under the control of a cardiac-
specific α-myosin heavy chain (α-MHC) promoter (Cn-Tg mice),
also develop cardiac hypertrophy and cardiomyopathy (Kuwahara
et al., 2007). In this model STARS is also 8–9-fold higher in the
hearts of Cn-Tg mice when compared to wild type littermates
(Kuwahara et al., 2007). However, this cardiac hypertrophy only
occurswhen themice are subjected to pressure overload.A similar
observation has been made in humans with STARS mRNA signif-
icantly higher in human hearts with idiopathic cardiomyopathy
when compared to normal control hearts (Kuwahara et al., 2007).
In vitro it has been shown that overexpressing STARS increases the
size of H2c9 rat myocardial cells (Koekemoer et al., 2009). While
the mechanism behind this cardiomyocyte hypertrophy was not
established, STARS overexpression did not affect proliferation,
but it did reduce chemically induced apoptosis (Koekemoer et al.,
2009). STARS may also regulate muscle cell hypertrophy by influ-
encing protein synthesis and degradation, however, this has not
been experimentally determined. These observations suggest that
STARS is an early marker of cardiac remodeling in response to
increased mechanical stress. The fact that endogenous STARS is
rapidly and transiently increased in response to external stress
signals suggests that it may have a protective and a physiological
adaptive role in muscle cells. However, forced and uncontrolled
up-regulation of STARS may result in maladaptation.
EXERCISE, DISUSE, AND AGING
The adaptation of skeletal muscle to changes in mechanical
stress, such as muscle contraction or immobilization, requires
the sensing and the transduction of the extracellular stress sig-
nals into the cell in order to generate the appropriate physio-
logical response. Our group first observed that STARS mRNA
levels significantly increased in the vastus lateralis muscle follow-
ing 8 weeks of hypertrophy-inducing resistance exercise train-
ing in humans (Lamon et al., 2009). Similarly skeletal muscle
STARS gene expression is increased (Pollanen et al., 2010) in
post-menauposal women following 12 months of hypertrophy-
inducing plyometric power training (Sipila et al., 2001). Whether
STARS directly causes skeletal muscle hypertrophy has not been
established. With respect to acute single-bout exercise, STARS
gene expression increases 10-fold when measured 3 h after eccen-
tric exercise (MacNeil et al., 2010). Work from our group has
also shown that STARS mRNA and protein levels are increased
3 h following an acute bout of single-leg endurance exercise; both
returning to basal levels 24 h post-exercise (Wallace et al., 2011).
This transient increase in STARS following contraction-induced
mechanical stress may provide a protective mechanism to reduce
the risk of contractile damage to the sarcomere or be required to
activate intracellular signals responsible for muscle adaptation to
exercise.
Limb immobilization drastically reduces the exposure of skele-
tal muscle to mechanical stress factors. Hind limb suspension
decreased STARS mRNA expression in rat soleus muscle within
the first 24 h and remains elevated for 48 h. However, a reduction
in muscle weight was not observed until 48 h post intervention
(Giger et al., 2009). Whether the decrease in STARS is a cause or
a consequence of muscle wasting is yet to be established. In con-
trast, 20 days of hind limb suspension in humans, resulting in
a 10% loss in muscle mass, did not reduce STARS mRNA levels
(Sakuma et al., 2009). We have observed that reducing mechani-
cal stress due to cessation of exercise training for 8 weeks results in
a loss of muscle mass and a reduction in STARS mRNA (Lamon
et al., 2009).
STARS is reduced in skeletal muscle from of aged mice
(Sakuma et al., 2008) and pigs (Peng et al., 2008). As STARS binds
and stabilizes actin and the sarcomere, it has been suggested that
it protects against contraction-induced damage (Arai et al., 2002).
Muscle from older animals is more susceptible to contraction-
induced damage, partially due to a mechanically compromised
sarcomeric structure that is less able to withstand stretch (Lynch
et al., 2008). Older muscle also repairs less efficiently which is
attributed to its reduced capacity to promote satellite cell acti-
vation, proliferation, and differentiation, thereby contributing
to its impaired regenerative capacity and reduced muscle mass
(Grounds, 1998; Welle, 2002). The reduction in STARS in older
muscle may be a factor contributing to the increased susceptibil-
ity of contraction-induced muscle damage aswell as its attenuated
muscle cell proliferation and repair.
INSULIN RESISTANCE
STARS gene expression is upregulated in skeletal muscle of
patients with type 2 diabetes when compared with healthy fam-
ily members (Jin et al., 2011). In rodents, STARS expression is
also increased in mice made insulin resistant by high-fat feeding
(Jin et al., 2011) as well as in the heart of streptozotocin (STZ)-
induced type I diabetic mice and in db/db type II diabetic mice
(Ounzain et al., 2012). Knock-down of STARS in L6 myotubes
enhances insulin signaling, as measured by increased insulin
stimulated Akt phosphorylation as well as basal and insulin-
stimulated glucose uptake (Jin et al., 2011). Additionally, the
reduction in STARS increases plasma membrane GLUT4 local-
ization in basal and insulin stimulated conditions. Presently, it
is difficult to determine if the increase in STARS in diabetic
muscle is a consequence of or directly contributes to insulin
resistance.
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OTHER BIOLOGICAL ROLES OF STARS
ANGIOGENESIS
Fluid shear stress (FSS)-induced collateral growth during arteri-
ogenesis is associated with an increase in STARS gene expression
(Troidl et al., 2009). This induction of STARS is abolished with
the nitric oxide (NO) inhibitor L-NAME, suggesting that STARS
transcription may be controlled by NO. The local intracollateral
over expression of STARS ameliorates collateral conductance in
rabbits following femoral artery ligature. In contrast, mice with
an ablation of STARS have impaired arteriogenesis (Troidl et al.,
2009). These observations extend the role of STARS to arterial
structure and function.
SMOOTH MUSCLE CELL PROLIFERATION
Overexpression of STARS in porcine smooth muscle cells (SMCs)
increases proliferation (Troidl et al., 2009). The ability of STARS
to enhance SMC proliferation was also observed in the A10
rat vascular SMC line, but not in porcine aortic endothelial
cells (Troidl et al., 2009) or in the H9c2 rat cardiac cell line
(Koekemoer et al., 2009). At present the effect of STARS on
skeletal muscle cell proliferation has not been investigated. The
potential of STARS to promote muscle cell proliferation requires
further validation in vivo. Furthermore, identification of the
downstream molecules activated by STARS that regulate pro-
liferation is required. STARS may play an important role in
sensing mechanical stress and up-regulating important pathways
controlling muscle growth and regeneration. It also appears that
the biological role/s of STARS may depend on the muscle cell type
investigated.
CONCLUSION
Continual adaptations such as growth, repair, and maintenance
of cardiac, smooth, and skeletal muscle are required through-
out the lifespan for the maintenance of healthy living and
longevity. For healthy adaptation to occur the muscle cells must
be able to detect the extracellular stress signals and efficiently
transmit them to appropriate intracellular transcriptional pro-
grams. The STARS protein appears to be a key player in the
detection and transmission of adaptive stress signals in muscle
cells. However, forced chronic overexpression of STARS appears
to make the muscle cells hypersensitive to adaptive external
stress and may result in a maladaptive response. These obser-
vations suggest that if STARS was to be considered a ther-
apeutic target to enhance muscle growth and repair then it
would require a precise and conditional method of induction or
suppression.
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